clvs_Current_Folio

0001558370-17-005797.txt : 20170803 0001558370-17-005797.hdr.sgml : 20170803 20170803122307 ACCESSION NUMBER: 0001558370-17-005797 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170803 DATE AS OF CHANGE: 20170803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Clovis Oncology, Inc. CENTRAL INDEX KEY: 0001466301 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900475355 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35347 FILM NUMBER: 171003975 BUSINESS ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-5000 MAIL ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 10-Q 1 clvs-20170630x10q.htm 10-Q clvs_Current_Folio_10Q

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended June 30, 2017.

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the transition period from to .

Commission file number: 001-35347

Clovis Oncology, Inc.

(Exact name of Registrant as specified in its charter)


Delaware	90-0475355
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

5500 Flatiron Parkway, Suite 100
Boulder, Colorado	80301
(Address of principal executive offices)	(Zip Code)

(303) 625-5000

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐		Accelerated filer	☒
Non-accelerated filer	☐	(Do not check if a smaller reporting company)	Smaller reporting company	☐
			Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, as of July 28, 2017 was 48,879,354.

Table of Contents

CLOVIS ONCOLOGY, INC.

FORM 10-Q

TABLE OF CONTENTS


PART I. Financial Information		3

ITEM 1.	Financial Statements (unaudited)	3

	Consolidated Statements of Operations and Comprehensive Loss — for the three and six months ended June 30, 2017 and 2016	3

	Consolidated Balance Sheets — as of June 30, 2017 and December 31, 2016	4

	Consolidated Statements of Cash Flows — for the six months ended June 30, 2017 and 2016	5

	Notes to Unaudited Consolidated Financial Statements	6

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21

ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	33

ITEM 4.	Controls and Procedures	33

PART II. Other Information		35

ITEM 1.	Legal Proceedings	35

ITEM 1A.	Risk Factors	37

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	38

ITEM 3.	Defaults Upon Senior Securities	38

ITEM 4.	Mine Safety Disclosures	38

ITEM 5.	Other Information	38

ITEM 6.	Exhibits	38

SIGNATURES		42

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1.FINANCIAL STATEMENTS

CLOVIS ONCOLOGY, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In thousands, except per share amounts)


	Three months ended June 30,				Six months ended June 30,
	2017		2016		2017		2016
	(in thousands, except per share amounts)

Product revenue, net	$	14,620	$	—	$	21,665	$	—
Operating expenses:
Cost of sales - product		2,730		—		3,893		—
Cost of sales - intangible asset amortization		372		—		743		—
Research and development		33,108		67,729		65,555		142,337
Selling, general and administrative		36,149		9,552		65,373		19,379
Acquired in-process research and development		—		300		—		300
Impairment of intangible asset		—		104,517		—		104,517
Change in fair value of contingent purchase consideration		—		(25,452)		—		(24,936)
Total expenses		72,359		156,646		135,564		241,597
Operating loss		(57,739)		(156,646)		(113,899)		(241,597)
Other income (expense):
Interest expense		(2,598)		(2,106)		(5,178)		(4,210)
Foreign currency gain (loss)		76		183		(83)		(368)
Legal settlement loss, net of insurance receivable		(117,000)		—		(117,000)		—
Other income		594		196		946		221
Other income (expense), net		(118,928)		(1,727)		(121,315)		(4,357)
Loss before income taxes		(176,667)		(158,373)		(235,214)		(245,954)
Income tax benefit		1,281		29,059		1,365		33,240
Net loss	$	(175,386)	$	(129,314)	$	(233,849)	$	(212,714)
Other comprehensive income:
Foreign currency translation adjustments, net of tax		2,812		(1,381)		3,279		2,132
Net unrealized gain (loss) on available-for-sale securities, net of tax		—		48		(5)		278
Other comprehensive income (loss)		2,812		(1,333)		3,274		2,410
Comprehensive loss	$	(172,574)	$	(130,647)	$	(230,575)	$	(210,304)

Loss per basic and diluted common share:
Basic and diluted net loss per common share	$	(3.88)	$	(3.37)	$	(5.24)	$	(5.54)
Basic and diluted weighted average common shares outstanding		45,176		38,389		44,610		38,375

See accompanying Notes to Unaudited Consolidated Financial Statements.

Table of Contents

CLOVIS ONCOLOGY, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except for share amounts)


	June 30,		December 31,
	2017		2016

ASSETS
Current assets:
Cash and cash equivalents	$	491,786	$	216,186
Accounts receivable, net		1,143		121
Insurance receivable		25,000		—
Inventories		6,478		—
Available-for-sale securities		179,744		49,997
Prepaid research and development expenses		4,854		6,427
Other current assets		6,766		6,679
Total current assets		715,771		279,410
Property and equipment, net		4,155		4,440
Intangible assets, net		20,304		21,047
Goodwill		62,018		57,192
Other assets		47,648		2,468
Total assets	$	849,896	$	364,557
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Accounts payable	$	13,360	$	10,912
Accrued research and development expenses		21,158		35,198
Milestone liability		21,011		20,062
Accrued liability for legal settlement		142,000		—
Other accrued expenses		21,848		19,487
Total current liabilities		219,377		85,659
Deferred income taxes, net		632		—
Convertible senior notes		281,761		281,126
Deferred rent, long-term		4,333		1,406
Total liabilities		506,103		368,191
Commitments and contingencies (Note 14)
Stockholders' equity (deficit):
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at June 30, 2017 and December 31, 2016		—		—
Common stock, $0.001 par value per share, 100,000,000 shares authorized at June 30, 2017 and December 31, 2016; 48,843,131 and 38,724,090 shares issued and outstanding at June 30, 2017 and December 31, 2016 respectively		49		39
Additional paid-in capital		1,752,943		1,174,950
Accumulated other comprehensive loss		(44,306)		(47,580)
Accumulated deficit		(1,364,893)		(1,131,043)
Total stockholders' equity (deficit)		343,793		(3,634)
Total liabilities and stockholders' equity (deficit)	$	849,896	$	364,557

See accompanying Notes to Unaudited Consolidated Financial Statements.

Table of Contents

CLOVIS ONCOLOGY, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)


	Six months ended June 30,
	2017		2016

Operating activities
Net loss	$	(233,849)	$	(212,714)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense		19,563		20,542
Depreciation and amortization		1,281		550
Amortization of premiums and discounts on available-for-sale securities		245		151
Amortization of debt issuance costs		635		616
Legal settlement loss, net of insurance receivable		117,000		—
Impairment of intangible asset		—		104,517
Change in fair value of contingent purchase consideration		—		(24,661)
Loss on disposal of property and equipment		—		170
Deferred income taxes		(1,266)		(33,207)
Changes in operating assets and liabilities:
Accounts receivable		(1,023)		—
Inventory		(6,478)		—
Prepaid and accrued research and development expenses		(15,162)		(12,772)
Other operating assets		(36,855)		1,260
Accounts payable		3,202		3,608
Other accrued expenses		3,166		270
Net cash used in operating activities		(149,541)		(151,670)
Investing activities
Purchases of property and equipment		(249)		(756)
Deposits for purchases of property and equipment		(2,515)		—
Purchases of available-for-sale securities		(180,000)		—
Maturities of available-for-sale securities		50,000		100,000
Acquired in-process research and development - milestone payment		(1,100)		—
Net cash (used in) provided by investing activities		(133,864)		99,244
Financing activities
Proceeds from the sale of common stock, net of issuance costs		546,170		—
Proceeds from the exercise of stock options and employee stock purchases		12,270		1,943
Net cash provided by financing activities		558,440		1,943
Effect of exchange rate changes on cash and cash equivalents		565		106
Increase (decrease) in cash and cash equivalents		275,600		(50,377)
Cash and cash equivalents at beginning of period		216,186		278,756
Cash and cash equivalents at end of period	$	491,786	$	228,379
Supplemental disclosure of cash flow information:
Cash paid for interest	$	3,594	$	3,594
Non-cash investing and financing activities:
Vesting of restricted stock units	$	2,627	$	34

See accompanying Notes to Unaudited Consolidated Financial Statements.

Table of Contents

CLOVIS ONCOLOGY, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

1. Nature of Business and Basis of Presentation

Clovis Oncology, Inc. (together with its consolidated subsidiaries, the “Company”, “Clovis”, “we”, “our”, “us”) is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and other international markets. We have and intend to continue to license or acquire rights to oncology compounds in all stages of development. In exchange for the right to develop and commercialize these compounds, we generally expect to provide the licensor with a combination of upfront payments, milestone payments and royalties on future sales. In addition, we generally expect to assume the responsibility for future drug development and commercialization costs. We currently operate in one segment. Since inception, our operations have consisted primarily of developing in-licensed compounds, evaluating new product acquisition candidates and general corporate activities.

During the second quarter of 2016, we completed the submission of our New Drug Application (“NDA”) with the U.S. Food and Drug Administration (“FDA”) for approval of rucaparib in the U.S. On December 19, 2016, the FDA approved Rubraca® (rucaparib) tablets as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. We began selling Rubraca in the U.S. in the fourth quarter of 2016. Our Marketing Authorization Application (MAA) for rucaparib that was submitted to the European Medicines Agency (“EMA”) for an ovarian cancer treatment indication comparable to what was approved by the FDA is currently under review. We anticipate an opinion from the Committee for Medicinal Products for Human Use (CHMP) in late 2017, and, pending a favorable opinion from the CHMP, a potential approval would follow during the first quarter of 2018. Following a potential approval for the treatment indication, we intend to submit a supplemental application for the second-line or later maintenance treatment indication, for which we anticipate a potential approval during the third quarter of 2018.

Basis of Presentation

All financial information presented includes the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments, consisting only of normal recurring adjustments that, in the opinion of management, are necessary to fairly state our financial position, results of operations and cash flows for the periods presented herein. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2016 (“2016 Form 10-K”) for a broader discussion of our business and the opportunities and risks inherent in such business.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates, including estimates related to revenue deductions, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.

Table of Contents

Liquidity

We have incurred significant net losses since inception and have relied on our ability to fund our operations through debt and equity financings. We expect operating losses and negative cash flows to continue for the foreseeable future. As we continue to incur losses, transition to profitability is dependent upon achieving a level of revenues from Rubraca adequate to support our cost structure. We may never achieve profitability, and unless or until we do, we will continue to need to raise additional cash.

In January 2017, we sold 5,750,000 shares of our common stock in a public offering at $41.00 per share. The net proceeds from the offering were $221.2 million, after deducting underwriting discounts and commissions and offering expenses. In June 2017, we sold 3,920,454 shares of our common stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.9 million, after deducting underwriting discounts and commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including sales and marketing expenses associated with Rubraca in the United States and, if approved by the EMA, in Europe, funding of our development programs, selling, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on current estimates, we believe that our existing cash, cash equivalents and available-for-sale securities will allow us to fund our operating plan through at least the next 12 months.

2. Summary of Significant Accounting Policies

Revenue Recognition

Revenues from product sales are recognized when persuasive evidence of an arrangement exists, delivery has occurred and title of the product and associated risk of loss has passed to the customer, the price is fixed or determinable, collection from the customer has been reasonably assured and all performance obligations have been met and returns and allowances can be reasonably estimated. Revenue is recorded net of estimated rebates, chargebacks, discounts and other deductions as well as estimated product returns (collectively, “sales deductions”). We only recognize revenue on product sales once the product is resold to the patient or healthcare provider by the specialty distributor or specialty pharmacy provider, therefore reducing the significance of estimates made for product returns. To date, we have not had any product returns and, we currently do not have an accrual for product returns. We will continue to assess our estimate for product returns as we gain additional historical experience.

Cost of Sales – Product

Product cost of sales consists primarily of materials, third-party manufacturing costs as well as freight and royalties owed to our licensing partners for Rubraca sales. Based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, certain of the manufacturing costs of Rubraca units recognized as revenue during the three and six months ended June 30, 2017 were expensed prior to the December 19, 2016 FDA approval, and therefore are not included in costs of sales during the current period. We expect cost of sales to increase in relation to product revenues as we deplete these inventories and we expect to use the remaining pre-commercialization inventory for product sales through the third quarter of 2017.

Cost of Sales – Intangible Asset Amortization

Cost of sales for intangible asset amortization consists of the amortization of capitalized milestone payments made to our licensing partners upon FDA approval of Rubraca. Milestone payments are amortized on a straight-line basis over the estimated remaining patent life of Rubraca.

Table of Contents

Inventory

Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. We began capitalizing incurred inventory related costs upon the regulatory approval of Rubraca. Prior to the regulatory approval of Rubraca, we incurred costs for the manufacture of the drug that could potentially be available to support the commercial launch of Rubraca and all such costs were recognized as research and development expense. We periodically analyze our inventory levels, and write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and/or inventory in excess of expected sales requirements as cost of product revenues. Expired inventory would be disposed of and the related costs would be written off as cost of product revenues.

The active pharmaceutical ingredient (“API”) in Rubraca is currently produced by a single supplier. As the API has undergone significant manufacturing specific to its intended purpose at the point it is purchased by us, we classify the API as work-in-process inventory.

Our other significant accounting policies are described in Note 2, Summary of Significant Accounting Policies of the Notes to the Consolidated Financial Statements included in our 2016 Form 10-K.

From time to time, the Financial Accounting Standards Board (“FASB”) or other standards setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification (“ASC”) are communicated through issuance of an Accounting Standards Update (“ASU”).

Recently Issued Accounting Standards

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” and has subsequently issued several supplemental and/or clarifying ASUs (collectively, “ASC 606”). ASC 606 prescribes a single common revenue standard that replaces most existing U.S. GAAP revenue recognition guidance. ASC 606 is intended to provide a more consistent interpretation and application of the principles outlined in the standard across filers in multiple industries and within the same industries compared to current practices, which should improve comparability. Adoption of ASC 606 is required for annual and interim periods beginning after December 15, 2017. Upon adoption, we must elect to adopt either retrospectively to each prior reporting period presented or use the modified retrospective transition method with the cumulative effect of initial adoption recognized at the date of initial application. We expect to apply the new standard using the modified retrospective method upon its adoption date on January 1, 2018.

We have begun a comprehensive scoping process to identify and disaggregate all revenue streams that may be impacted by the adoption of ASC 606. To date, we have examined our revenue recognition policy specific to revenue streams from representative contracts governing product sales from Rubraca and have come to preliminary conclusions on the impact of the new standard using the 5-step process prescribed by ASC 606. However, a detailed analysis of individual contracts representative of each of the revenue streams planned for the assessment phase of our implementation plan may impact these preliminary conclusions. We are continuing to assess ASC 606’s impact on our financial statements.

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. ASU 2016-02 requires modified retrospective adoption for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures.

In January 2017, the FASB issued ASU No. 2017-01, “Clarifying the Definition of a Business,” which clarifies the definition of a business in ASC 805. The guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is permitted. Currently, there is no impact to our consolidated financial statements and related disclosures, but we will adopt on January 1, 2018 for any business combinations and will consider adopting early for any acquisitions prior to January 1, 2018.

In May 2017, the FASB issued ASU 2017-09, “Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting”, which amends the scope of modification accounting for share-based payment arrangements.

Table of Contents

The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which we would be required to apply modification accounting under ASC 718. Specifically, we would not apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. The guidance is effective for annual reporting periods, including interim period within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures should we have a modification to our share-based payment awards in the future.

3. Financial Instruments and Fair Value Measurements

Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

The three levels of inputs that may be used to measure fair value include:

Level 1:	Quoted prices in active markets for identical assets or liabilities. Our Level 1 assets consist of money market investments. We do not have Level 1 liabilities.

Level 2:	Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Our Level 2 assets consist of U.S. treasury securities. We do not have Level 2 liabilities.

Level 3:	Unobservable inputs that are supported by little or no market activity. We do not have Level 3 assets or liabilities that are measured at fair value on a recurring basis.

The following table identifies our assets and liabilities that were measured at fair value on a recurring basis (in thousands):


	Balance		Level 1		Level 2		Level 3
June 30, 2017
Assets:
Money market	$	450,588	$	450,588	$	—	$	—
U.S. treasury securities		179,744		—		179,744		—
Total assets at fair value	$	630,332	$	450,588	$	179,744	$	—
December 31, 2016
Assets:
Money market	$	202,361	$	202,361	$	—	$	—
U.S. treasury securities		49,997		—		49,997		—
Total assets at fair value	$	252,358	$	202,361	$	49,997	$	—

There were no transfers between the Level 1 and Level 2 categories or into or out of the Level 3 category during the three and six months ended June 30, 2017.

Financial instruments not recorded at fair value include our convertible senior notes. At June 30, 2017, the carrying amount of the convertible senior notes was $281.8 million, which represents the aggregate principal amount net of remaining debt issuance costs, and the fair value was $487.0 million. The fair value was determined using Level 2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system. See Note 9, Convertible Senior Notes for discussion of the convertible senior notes.

Table of Contents

4. Available-for-Sale Securities

As of June 30, 2017, available-for-sale securities consisted of the following (in thousands):


			Gross		Gross		Aggregate
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. treasury securities	$	179,758	$	—	$	(14)	$	179,744

As of December 31, 2016, available-for-sale securities consisted of the following (in thousands):


			Gross		Gross		Aggregate
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. treasury securities	$	50,004	$	—	$	(7)	$	49,997

As of June 30, 2017, the fair value and gross unrealized losses of available-for-sale securities that have been in a continuous unrealized loss position for less than 12 months were as follows (in thousands):


	Aggregate		Gross
	Fair		Unrealized
	Value		Losses
U.S. treasury securities	$	179,744	$	(14)

We have concluded that decline in the market value of the available-for-sales securities is temporary. A decline in the market value of a security below its cost that is deemed to be other than temporary is charged to earnings and results in the establishment of a new cost basis for the security. Factors evaluated to determine if an investment is other-than-temporarily impaired include significant deterioration in earnings performance, credit rating, asset quality or business prospects of the issuer; adverse changes in the general market conditions in which the issuer operates; and our intent and ability to hold the security until an anticipated recovery in value occurs.

As of June 30, 2017, the amortized cost and fair value of available-for-sale securities by contractual maturity were (in thousands):


	Amortized		Fair
	Cost		Value
Due in one year or less	$	179,758	$	179,744
Due in one year to two years		—		—
Total	$	179,758	$	179,744

5. Inventories

We generally have two categories of inventory: work-in-process and finished goods. As of June 30, 2017, the carrying value of all of our product inventory, which consisted only of the Rubraca API, was categorized as work-in-process. The costs related to our finished goods on-hand as of June 30, 2017 were expensed as incurred prior to the commercialization of Rubraca on December 19, 2016. The carrying value of our inventory as of December 31, 2016 was zero.

At June 30, 2017, other assets on the Consolidated Balance Sheets includes a cash deposit of $31.8 million made to a manufacturer for the purchase of inventory which we do not expect to be commercially consumed within the next twelve months.

Table of Contents

6. Other Current Assets

Other current assets were comprised of the following (in thousands):


	June 30,		December 31,
	2017		2016
Receivable from partners	$	52	$	2,882
Prepaid insurance		817		1,234
Prepaid expenses - other		3,012		2,109
Receivable - other		2,750		364
Other		135		90
Total	$	6,766	$	6,679

7. Intangible Assets and Goodwill

Intangible assets related to capitalized milestones under license agreements consisted of the following (in thousands):


	June 30,		December 31,
	2017		2016
Intangible asset - milestones	$	21,100	$	21,100
Accumulated amortization		(796)		(53)
Total intangible asset, net	$	20,304	$	21,047

The estimated useful lives of these intangible assets are based on the estimated remaining patent life of Rubraca and extend through 2031.

We recorded amortization expense of $0.4 million and $0.8 million related to capitalized milestone payments during the three and six months ended June 30, 2017, respectively, included in cost of sales – intangible asset amortization at the Consolidated Statements of Operations and Comprehensive Loss. There was no amortization expense during the three and six months ended June 30, 2016.

Estimated future amortization expense associated with intangibles is expected to be as follows (in thousands):


2017 (remaining)	$	743
2018		1,486
2019		1,486
2020		1,486
2021		1,486
Thereafter		13,617
	$	20,304

The change in goodwill established as part of the purchase accounting of EOS in November 2013 consisted of the following (in thousands):


Balance at December 31, 2016	$	57,192
Change in foreign currency gains and losses		4,826
Balance at June 30, 2017	$	62,018

Table of Contents

8. Other Accrued Expenses

Other accrued expenses were comprised of the following (in thousands):


	June 30,		December 31,
	2017		2016
Accrued personnel costs	$	11,928	$	15,850
Accrued interest payable		2,097		2,096
Income tax payable		662		556
Accrued corporate legal fees and professional services		1,072		589
Accrued royalties		2,551		—
Accrued sales deductions		1,003		—
Accrued expenses - other		2,535		396
Total	$	21,848	$	19,487

9. Convertible Senior Notes

On September 9, 2014, we completed a private placement of $287.5 million aggregate principal amount of 2.5% convertible senior notes due 2021 (the “Notes”) resulting in net proceeds of $278.3 million after deducting offering expenses. In accordance with the accounting guidance, the conversion feature did not meet the criteria for bifurcation, and the entire principal amount was recorded as a long-term liability on the Consolidated Balance Sheets.

The Notes are governed by the terms of the indenture between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee. The Notes are senior unsecured obligations and bear interest at a rate of 2.5% per year, payable semi-annually in arrears on March 15 and September 15 of each year. The Notes will mature on September 15, 2021, unless earlier converted, redeemed or repurchased.

Holders may convert all or any portion of the Notes at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the holders will receive shares of our common stock at an initial conversion rate of 16.1616 shares per $1,000 in principal amount of Notes, equivalent to a conversion price of approximately $61.88 per share. The conversion rate is subject to adjustment upon the occurrence of certain events described in the indenture, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date or upon our issuance of a notice of redemption, we will increase the conversion rate for holders who elect to convert the Notes in connection with such a corporate event or during the related redemption period in certain circumstances.

On or after September 15, 2018, we may redeem the Notes, at our option, in whole or in part, if the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending not more than two trading days preceding the date on which we provide written notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Notes.

If we undergo a fundamental change, as defined in the indenture, prior to the maturity date of the Notes, holders may require us to repurchase for cash all or any portion of the Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

The Notes rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the Notes; equal in right of payment to all of our liabilities that are not so subordinated; effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries.

Table of Contents

life of the debt was equal to the seven-year term of the Notes. As of June 30, 2017 and December 31, 2016, the balance of unamortized debt issuance costs was $5.7 million and $6.4 million, respectively.

The following table sets forth total interest expense recognized during the three and six months ended June 30, 2017 and 2016 (in thousands):


	Three months ended June 30,				Six months ended June 30,
	2017		2016		2017		2016
Contractual interest expense	$	1,797	$	1,797	$	3,594	$	3,594
Accretion of interest on milestone liability		483		—		949		—
Amortization of debt issuance costs		318		309		635		616
Total interest expense	$	2,598	$	2,106	$	5,178	$	4,210

10. Stockholders’ Equity

Common Stock

The holders of common stock are entitled to one vote per share on all matters to be voted upon by our stockholders. Subject to the preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by our Board of Directors.

Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss consists of changes in foreign currency translation adjustments, which includes changes in a subsidiary’s functional currency, and unrealized gains and losses on available-for-sale securities.

The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the three months ended June 30, 2017 and 2016 as follows (in thousands):


	Foreign Currency				Unrealized				Total Accumulated
	Translation Adjustments				(Losses) Gains				Other Comprehensive Loss
	2017		2016		2017		2016		2017		2016
Balance at April 1,	$	(46,967)	$	(43,564)	$	(151)	$	(153)	$	(47,118)	$	(43,717)
Other comprehensive income (loss)		4,451		(2,170)		(3)		76		4,448		(2,094)
Total before tax		(42,516)		(45,734)		(154)		(77)		(42,670)		(45,811)
Tax effect		(1,639)		789		3		(28)		(1,636)		761
Balance at June 30,	$	(44,155)	$	(44,945)	$	(151)	$	(105)	$	(44,306)	$	(45,050)

The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the six months ended June 30, 2017 and 2016 as follows (in thousands):


	Foreign Currency				Unrealized				Total Accumulated
	Translation Adjustments				(Losses) Gains				Other Comprehensive Loss
	2017		2016		2017		2016		2017		2016
Balance at December 31,	$	(47,434)	$	(47,077)	$	(146)	$	(383)	$	(47,580)	$	(47,460)
Other comprehensive income (loss)		5,186		3,410		(8)		441		5,178		3,851
Total before tax		(42,248)		(43,667)		(154)		58		(42,402)		(43,609)
Tax effect		(1,907)		(1,278)		3		(163)		(1,904)		(1,441)
Balance at June 30,	$	(44,155)	$	(44,945)	$	(151)	$	(105)	$	(44,306)	$	(45,050)

Table of Contents

The period change in each of the periods presented was primarily due to the currency translation of the goodwill and deferred income taxes associated with the acquisition of EOS in November 2013. There were no reclassifications out of accumulated other comprehensive loss in each of the three and six months ended June 30, 2017 and 2016.

11. Share-Based Compensation

Share-based compensation expense for all equity based programs, including stock options, restricted stock units and the employee stock purchase plan, for the three and six months ended June 30, 2017 and 2016 was recognized in the accompanying Consolidated Statements of Operations as follows (in thousands):


	Three months ended June 30,				Six months ended June 30,
	2017		2016		2017		2016
Research and development	$	4,825	$	6,615	$	8,991	$	13,924
Selling, general and administrative		5,792		2,962		10,572		6,618
Total share-based compensation expense	$	10,617	$	9,577	$	19,563	$	20,542

We did not recognize a tax benefit related to share-based compensation expense during the three and six months ended June 30, 2017 and 2016, respectively, as we maintain net operating loss carryforwards and have established a valuation allowance against the entire net deferred tax asset as of June 30, 2017.

Stock Options

The following table summarizes the activity relating to our options to purchase common stock for the six months ended June 30, 2017:


				Weighted
		Weighted		Average	Aggregate
		Average		Remaining	Intrinsic
	Number of	Exercise		Contractual	Value
	Options	Price		Term (Years)	(Thousands)
Outstanding at December 31, 2016	5,520,482	$	42.00
Granted	778,700
Exercised	(372,464)
Forfeited	(199,985)
Outstanding at June 30, 2017	5,726,733	$	45.43	7.6	$	276,451
Vested and expected to vest at June 30, 2017	5,364,276	$	45.30	7.4	$	259,650
Vested and exercisable at June 30, 2017	2,935,211	$	44.63	6.2	$	143,983

The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of $93.63 as of June 30, 2017, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date.

The following table summarizes information about our stock options as of and for the three and six months ended June 30, 2017 and 2016 (in thousands):


	Three months ended June 30,				Six months ended June 30,
	2017		2016		2017		2016
Weighted-average grant date fair value per share	$	44.94	$	11.01	$	46.53	$	14.65
Intrinsic value of options exercised	$	4,759	$	578,525	$	14,284	$	624,925
Cash received from stock option exercises	$	5,439	$	352,423	$	11,113	$	407,523

As of June 30, 2017, the unrecognized share-based compensation expense related to unvested options, adjusted for expected forfeitures, was $83.4 million and the estimated weighted-average remaining vesting period was 2.6 years.

Table of Contents

Restricted Stock

During 2016, we issued restricted stock units (“RSUs”) to certain employees under the 2011 Stock Incentive Plan. The RSUs vest either (i) over two years, with 50% vesting one year from the date of grant and the remaining 50% vesting two years from the date of grant or (ii) 25% vest one year from the date of grant with the remaining RSUs vesting ratably each subsequent quarter over the following three years, as defined in the grant agreement. Vested RSUs are payable in shares of our common stock at the end of the vesting period. RSUs are measured based on the fair value of the underlying stock on the grant date. The minimum statutory tax on the value of common stock shares issued to employees upon vesting are paid by us through the sale of registered shares of our common stock.

The following table summarizes the activity relating to our unvested RSUs for the six months ended June 30, 2017:



		Weighted
		Average
	Number of	Grant Date
	Units	Fair Value
Unvested at December 31, 2016	562,458	$	24.70
Granted	214,984		61.67
Vested	(44,443)		19.37
Forfeited	(27,177)		24.08
Unvested as of June 30, 2017	705,822	$	36.32
Expected to vest after June 30, 2017	604,394	$	35.81

As of June 30, 2017, the unrecognized share-based compensation expense related to unvested RSUs, adjusted for expected forfeitures, was $18.5 million and the estimated weighted-average remaining vesting period was 3.4 years.

12. License Agreements

In June 2011, we entered into a worldwide license agreement with Pfizer, Inc. to obtain exclusive global rights to develop and commercialize rucaparib, a small molecule inhibitor of poly (ADP-ribose) polymerase (“PARP”), used for the treatment of selected solid tumors. The exclusive rights are exclusive even as to Pfizer and include the right to grant sublicenses. Pursuant to the terms of the license agreement, we made a $7.0 million upfront payment to Pfizer and are required to make additional payments to Pfizer for the achievement of certain development and regulatory and sales milestones and royalties on sales as required by the license agreement. Prior to the FDA approval of rucaparib, discussed below, we made milestone payments of $1.4 million, which were recognized as acquired in-process research and development expense.

On August 30, 2016, we entered into a first amendment to the worldwide license agreement with Pfizer, which amends the June 2011 existing worldwide license agreement to permit us to defer payment of the milestone payments payable upon (i) FDA approval of an NDA for 1st Indication in US and (ii) EMA approval of an MAA for 1st Indication in EU, to a date that is 18 months after the date of achievement of such milestones. In the event that we defer such milestone payments, we have agreed to certain higher payments related to the achievement of such milestones.

On December 19, 2016, the FDA approved Rubraca (rucaparib) tablets as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. The FDA approval resulted in a $0.75 million milestone payment to Pfizer as required by the license agreement, which was made in the first quarter of 2017. The FDA approval also resulted in the obligation to pay a $20.0 million milestone payment, for which we have exercised the option to defer payment by agreeing to pay $23.0 million within 18 months after the date of the FDA approval. These payments were recognized as intangible assets and will be amortized over the estimated remaining useful life of Rubraca.

Table of Contents

met, the majority of which relate to annual sales targets of $500.0 million and above, which, in the aggregate, could amount to total milestone payments of $170.0 million, and tiered royalty payments at a mid-teen percentage rate on our net sales, with standard provisions for royalty offsets to the extent we need to obtain any rights from third parties to commercialize rucaparib.

In April 2012, we entered into a license agreement with AstraZeneca UK Limited to acquire exclusive rights associated with rucaparib under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of rucaparib for the uses claimed by these patents. The FDA approval of rucaparib on December 19, 2016 resulted in a $0.35 million milestone obligation to AstraZeneca as required by the license agreement, which was paid in the first quarter of 2017. This payment was recognized in intangible assets and will be amortized over the estimated remaining useful life of rucaparib. AstraZeneca will also receive royalties on any net sales of rucaparib.

We are party to other product license agreements for our other drug candidates, lucitanib and rociletinib (see our 2016 Form 10-K for additional details). We and Les Laboratories Servier (“Servier”) are developing lucitanib pursuant to a global development plan agreed to between the parties. Servier is responsible for all of the global development costs for lucitanib up to €80.0 million. Cumulative global development costs in excess of €80.0 million, if any, will be shared equally between us and Servier. We recorded a $0.1 million and $1.3 million receivable at June 30, 2017 and December 31, 2016, respectively, for the reimbursable development costs incurred under the global development plan, which is included in other current assets on the Consolidated Balance Sheets. For the three months ending June 30, 2017 and 2016, we incurred $0.0 million and $2.6 million, respectively, in research and development costs and recorded reductions in research and development expense of $0.1 million and $2.8 million, respectively, for reimbursable development costs due from Servier. For the six months ending June 30, 2017 and 2016, we incurred $0.9 million and $6.2 million, respectively, in research and development costs and recorded reductions in research and development expense of $1.0 million and $6.4 million, respectively, for reimbursable development costs due from Servier.

During the second quarter of 2016, we and Servier agreed to discontinue the development of lucitanib for breast cancer and lung cancer and are continuing to evaluate, what, if any, further development of lucitanib will be pursued. Based on current estimates, we expect to complete the committed on-going development activities in 2017 and expect full reimbursement of our development costs from Servier. Reimbursements are recorded as a reduction to research and development expense on the Consolidated Statements of Operations.

13. Net Loss Per Common Share

Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury-stock method for the stock options and RSUs and the if-converted method for the Notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share.

The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):


	Three and Six months ended June 30,
	2017	2016
Common shares under option	6,373	455
Convertible senior notes	4,646	4,646
Total potential dilutive shares	11,019	5,101

14. Commitments and Contingencies

Royalty and License Fee Commitments

We have entered into certain license agreements, as identified in Note 12, License Agreements, with third parties that include the payment of development and regulatory milestones, as well as royalty payments, upon the achievement of pre-established development, regulatory and commercial targets. Our payment obligation related to these license

Table of Contents

agreements is contingent upon the successful development, regulatory approval and commercialization of the licensed products. Due to the nature of these arrangements, the future potential payments are inherently uncertain, and accordingly, we only recognize payment obligations which are probable and estimable as of the balance sheet date. Milestone liabilities of $21.0 million and $20.1 million are recorded on our Consolidated Balance Sheets at June 30, 2017 and December 31, 2016, respectively, and relate to milestone payments for the licensing of our rucaparib product, which was approved by the FDA on December 19, 2016.

Manufacture and Services Agreement Commitments

On October 3, 2016, we entered into a Manufacturing and Services Agreement (the “Agreement”) with a non-exclusive third-party supplier for the production of the active ingredient for Rubraca. Under the terms of the Agreement, we will provide the third-party supplier a rolling forecast for the supply of the active ingredient in Rubraca that will be updated by us on a quarterly basis. We are obligated to order material sufficient to satisfy an initial quantity specified in any forecast. In addition, the third-party supplier will construct, in its existing facility, a production train that will be exclusively dedicated to the manufacture of the Rubraca active ingredient. We are obligated to make scheduled capital program fee payments toward capital equipment and other costs associated with the construction of the dedicated production train. Further, once the facility is operational, we are obligated to pay a fixed facility fee each quarter for the duration of the Agreement, which expires on December 31, 2025, unless extended by mutual consent of the parties. As of June 30, 2017, $183.6 million of purchase commitments exist under the Agreement.

Legal Proceedings

We and certain of our officers were named as defendants in several lawsuits, as described below. We cannot reasonably predict the outcome of these legal proceedings, nor can we estimate the amount of loss or range of loss, if any, that may result. An adverse outcome in these proceedings could have a material adverse effect on our results of operations, cash flows or financial condition.

On November 19, 2015, Sonny P. Medina, a purported Clovis shareholder, filed a purported shareholder class action complaint in the United States District Court for the District of Colorado (the “Medina Complaint”). The Medina Complaint purported to be asserted on behalf of a class of persons who purchased Clovis stock between May 20, 2014 and November 13, 2015, and it generally alleged that Clovis and certain of its officers violated federal securities laws by making allegedly false and misleading statements regarding the progress toward FDA approval and the potential for market success of rociletinib.

Throughout November and December 2015, three other purported shareholders filed similar purported class actions concerning alleged misstatements about rociletinib. On January 19, 2016, a number of motions were filed seeking to consolidate the shareholder class actions into one matter and for appointment of a lead plaintiff. On February 18, 2016, the Medina Court consolidated the various actions into a single proceeding and appointed M. Arkin (1999) LTD and Arkin Communications LTD (the “Arkin Plaintiffs”) as the lead plaintiffs and Bernstein Litowitz Berger & Grossmann LLP as lead counsel for the putative class.

The Arkin Plaintiffs filed a consolidated complaint on May 6, 2016 (the “Consolidated Complaint”). The Consolidated Complaint named as defendants the Company and certain of its current and former officers (the “Clovis Defendants”), certain underwriters (the “Underwriter Defendants”) for a Company follow-on offering conducted in July 2015 (the “July 2015 Offering”), and certain Company venture capital investors (the “Venture Capital Defendants”). The Consolidated Complaint alleged that defendants violated particular sections of the Securities Exchange Act of 1934 (the “Exchange Act”) and the Securities Act of 1933 (the “Securities Act”). The purported misrepresentations and omissions concerned allegedly misleading statements about rociletinib. The consolidated action was purportedly brought on behalf of investors who purchased the Company’s securities between May 31, 2014 and April 7, 2016 (with respect to the Exchange Act claims) and investors who purchased the Company’s securities pursuant or traceable to the July 2015 Offering (with respect to the Securities Act claims). The Consolidated Complaint sought unspecified compensatory and recessionary damages.

The Clovis Defendants, the Underwriter Defendants and the Venture Capital Defendants filed motions to dismiss on July 27, 2016. On February 9, 2017, the Medina Court issued an opinion and order granting in part and denying in part the Clovis Defendants’ motion to dismiss, granting in part and denying in part the Underwriter Defendants’ motion to dismiss, and granting the Venture Capital Defendants’ motion to dismiss. On February 22, 2017, the Arkin Plaintiffs

Table of Contents

filed an amended consolidated class action complaint, directed solely at repleading its Section 12(a) claims against the Underwriter Defendants.

On March 14, 2017, the Clovis Defendants and the Arkin Plaintiffs participated in a mediation, which did not result in a settlement.

On June 18, 2017, the Clovis Defendants entered into a stipulation and agreement of settlement with the Arkin Plaintiffs whereby Clovis will issue to the plaintiffs and participating class members a total consideration comprised of $25.0 million in cash and the issuance of a to be determined number of shares of Clovis common stock (the “Settlement Shares”) equal to $117.0 million divided by the volume weighted average price of Clovis common stock over the 10 trading days immediately preceding the date of the hearing set by the Medina Court to consider the final approval of the settlement. The cash portion of the consideration is expected to be funded by Clovis’ insurance carriers. At June 30, 2017, the liability for the issuance of the shares and cash, including the amount to be reimbursed through insurance proceeds, was recorded to accrued liability for legal settlement on the Consolidated Balance Sheets in the amount of approximately $142.0 million and a receivable of approximately $25.0 million from the insurance carriers on the Consolidated Balance Sheets. Clovis will issue the Settlement Shares no later than 5 business days after the date the judgment is entered by the Medina Court approving the settlement whereby the issuance of the shares will be recorded in common stock and additional paid-in capital and the accrued liability for legal settlement will be cleared.

As the settlement agreement is in response to the alleged violation of securities laws by certain of our officers, we have determined that the resulting loss does not relate to activities that are in the normal course of our operations and therefore, should not be recognized in operating losses for the period. Accordingly, we have recognized the entire expense associated to the settlement agreement in legal settlement loss within the other income (expense), net of insurance receivable on the Consolidated Statements of Operations and Comprehensive Loss.

On July 14, 2017, the Medina Court issued an order preliminarily approving the settlement. A final hearing to determine whether the settlement should be approved is scheduled for October 26, 2017.

On January 22, 2016, the Electrical Workers Local #357 Pension and Health & Welfare Trusts, a purported shareholder of Clovis, filed a purported class action complaint (the “Electrical Workers Complaint”) against Clovis and certain of its officers, directors, investors and underwriters in the Superior Court of the State of California, County of San Mateo. The Electrical Workers Complaint purports to be asserted on behalf of a class of persons who purchased stock in the July 2015 Offering. The Electrical Workers Complaint generally alleges that the defendants violated the Securities Act because the offering documents for the July 2015 Offering contained allegedly false and misleading statements regarding the progress toward FDA approval and the potential for market success of rociletinib. The Electrical Workers Complaint seeks unspecified damages. On June 30, 2016, the Electrical Workers Plaintiffs filed an amended complaint asserting substantially similar claims (the “Electrical Workers Amended Complaint”).

On September 23, 2016, following briefing and after hearing oral argument, the Electrical Workers Court granted defendants’ motion to stay proceedings pending resolution of the Medina action. Per the order to stay proceedings, the parties’ first status report as to the progress of the Medina action was filed on March 23, 2017. The parties’ second status report is due on September 21, 2017.

The Company intends to vigorously defend against the allegations in the Electrical Workers Amended Complaint, but there can be no assurance that the defense will be successful.

On November 10, 2016, Antipodean Domestic Partners (“Antipodean”) filed a complaint (the “Antipodean Complaint”) against Clovis and certain of its officers, directors and underwriters in New York Supreme Court, County of New York. The Antipodean Complaint alleges that the defendants violated certain sections of the Securities Act by making allegedly false statements to Antipodean and in the Offering Materials for the July 2015 Offering relating to the efficacy of rociletinib, its safety profile, and its prospects for market success. In addition to the Securities Act claims, the Antipodean Complaint also asserts Colorado state law claims and common law claims. Both the state law and common law claims are based on allegedly false and misleading statements regarding rociletinib’s progress toward FDA approval. The Antipodean Complaint seeks compensatory, recessionary, and punitive damages.

Table of Contents

On December 15, 2016, the Antipodean Plaintiffs filed an amended complaint (the “Antipodean Amended Complaint”) asserting substantially the same claims against the same defendants and purporting to correct certain details in the original Antipodean Complaint.

On January 31, 2017, Defendants filed a motion to stay the Antipodean action pending resolution of the Medina action in the District of Colorado. Defendants also filed a motion to dismiss the Antipodean Amended Complaint on March 29, 2017. A hearing on both motions is scheduled for August 8, 2017.

On March 14, 2017, the Clovis Defendants and Antipodean participated in a mediation, which did not result in a settlement. The Company intends to vigorously defend against the allegations in the Antipodean Amended Complaint. However, there can be no assurance that the defense will be successful.

Clovis received a letter dated May 31, 2016 from an alleged owner of its common stock, which purports to set forth a demand for inspection of certain of our books and records pursuant to 8 Del. C. § 220 (the “Macalinao Demand Letter”). Clovis also received a letter dated December 15, 2016 from a second alleged owner of Clovis common stock, which purports to set forth a similar demand for inspection of the Company’s books and records pursuant to 8 Del. C. § 220 (the “McKenry Demand Letter”). Both the Macalinao and McKenry Demand Letters were purportedly made for the purposes of investigating alleged misconduct at the Company relating to rociletinib. Clovis submitted a response to the Macalinao Demand Letter on June 24, 2016, and likewise submitted a response to the McKenry Demand Letter on January 4, 2017. The Company produced certain books and records in response to the Macalinao and McKenry Demand Letters in January and February 2017, respectively.

In March 2017, Macalinao and McKenry (the “Derivative Plaintiffs”) filed shareholder derivative complaints against certain directors and officers of the Company in the Court of Chancery of the State of Delaware. On May 4, 2017, the Macalinao and McKenry actions were consolidated for all purposes in a single proceeding under the caption In re Clovis Oncology, Inc. Derivative Litigation, Case No, 2017-0222 (the “Consolidated Derivative Action”).

On May 18, 2017, the Derivative Plaintiffs filed the Consolidated Verified Shareholder Derivative Complaint (the “Consolidated Derivative Complaint”). The Consolidated Derivative Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by allegedly causing or allowing misrepresentations of the Company’s business operations and prospects, failing to ensure that the TIGER-X clinical trial was being conducted in accordance with applicable rules, regulations and protocols, and engaging in insider trading. The Consolidated Derivative Complaint purported to rely on documents produced by the Company in response to the Macalinao and McKenry Demand Letters. The Consolidated Derivative Complaint sought, among other things, an award of money damages.

On July 13, 2017, the court ordered the following briefing schedule with respect to the defendants’ forthcoming motion to dismiss the Consolidated Derivative Complaint: Defendants’ motion to dismiss was due, and was filed, on July 31, 2017; Plaintiffs’ opposition is due on August 30, 2017; and Defendants’ reply is due on September 14, 2017.

The Company intends to vigorously defend against the allegations in the Consolidated Derivative Complaint, but there can be no assurance that the defense will be successful.

On May 10, 2017, John Solak, a purported shareholder of the Company, filed a shareholder derivative complaint in the Court of Chancery of the State of Delaware (the “Solak Complaint”) against certain directors and an officer of the Company. The Solak Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by adopting a compensation plan that overcompensated the non-employee director defendants, in relation to companies of comparable market capitalization and size. The Solak Complaint also alleged claims of waste of corporate assets and unjust enrichment due to this allegedly wrongful compensation plan. The Solak Complaint sought, among other things, an award of money damages and the imposition of corporate governance reforms.

On June 12, 2017, the parties in the Solak action entered into a stipulation extending the defendants’ time to respond to the Solak Complaint until August 11, 2017, which was entered by the Court on June 20, 2017.

The Company intends to vigorously defend against the allegations in the Solak Complaint, but there can be no assurance that the defense will be successful.

Table of Contents

On March 20, 2017, a purported shareholder of the Company, filed a shareholder derivative complaint (the “Guo Complaint”) against certain officers and directors of the Company in the United States District Court for the District of Colorado. The Guo Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by either recklessly or with gross negligence approving or permitting misrepresentations of the Company’s business operations and prospects. The Guo Complaint also alleged claims for waste of corporate assets and unjust enrichment. Finally, the Guo Complaint alleged that certain of the individual defendants violated Section 14(a) of the Securities Exchange Act, by allegedly negligently issuing, causing to be issued, and participating in the issuance of materially misleading statements to stockholders in the Company’s Proxy Statement on Schedule DEF 14A in connection with the 2015 Annual Meeting of Stockholders, held on June 11, 2015. The Guo Complaint sought, among other things, an award of money damages.

On June 19, 2017, the parties filed a joint motion to stay the Guo action pending resolution of the motion to dismiss the Consolidated Derivative Complaint. On June 20, 2017, the court granted the motion to stay.

The Company intends to vigorously defend against the allegations in the Guo Complaint, but there can be no assurance that the defense will be successful.

In addition, the Company has received inquiries and requests for information from governmental agencies, including the U.S. Securities and Exchange Commission and the U.S. Department of Justice, relating to the Company’s regulatory update announcement in November 2015 that the FDA requested additional clinical data on the efficacy and safety of rociletinib. The Company is continuing to cooperate with these agencies with respect to their investigations. The proposed settlement of the Medina action does not resolve these inquiries and the Company cannot predict their timing or outcome.

Table of Contents

ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Information

This Quarterly Report on Form 10-Q and the information incorporated herein by reference includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this Quarterly Report on Form 10-Q and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned non-clinical studies and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, the degree of clinical utility of our products, particularly in specific patient populations, expectations regarding clinical trial data, our results of operations, financial condition, liquidity, prospects, growth and strategies, the industry in which we operate and the trends that may affect the industry or us.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity and the development of the industry in which we operate may differ materially from the forward-looking statements contained herein.

Any forward-looking statements that we make in this Quarterly Report on Form 10-Q speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events.

You should also read carefully the factors described in the “Risk Factors” in Part I, Item 1A in our most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”), as updated from time to time in our subsequent SEC filings, to better understand the risks and uncertainties inherent in our business and underlying any forward-looking statements.

Overview

We are a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use.

Our commercial product Rubraca® (rucaparib) is the first and only oral, small molecule poly ADP-ribose polymerase, or PARP, inhibitor of PARP1, PARP2 and PARP3 approved in the United States by the FDA as monotherapy for the treatment of patients with deleterious BRCA (human genes associated with the repair of damaged DNA) mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca.

Our MAA for rucaparib that was submitted to the EMA for an ovarian cancer treatment indication comparable to what was approved by the FDA is currently under review. We anticipate an opinion from the CHMP in late 2017, and, pending a favorable opinion from the CHMP, a potential approval would follow during the first quarter of 2018. Following a potential approval for the treatment indication, we intend to submit a supplemental application for the second-line or later maintenance treatment indication, for which we anticipate a potential approval during the third quarter of 2018. Additionally, rucaparib is being studied as a potential maintenance therapy for ovarian cancer patients in the ARIEL3 trial. On June 19, 2017, we announced that the ARIEL3 trial successfully achieved the primary endpoint of improved progression-free survival (PFS) by investigator review in each of the three populations studied. PFS was also improved in the rucaparib group compared with placebo by blinded independent central review (BICR), a key secondary endpoint. Based on these findings, we plan to submit a supplemental New Drug Application (sNDA) before the end of

Table of Contents

October 2017 for a second-line and later maintenance treatment indication for all women with platinum-sensitive ovarian cancer who have responded to their most recent platinum therapy. Rucaparib is also being developed in patients with mutant BRCA tumors and other DNA repair deficiencies beyond BRCA – commonly referred to as homologous recombination deficiencies. Studies open for enrollment or under consideration include prostate, breast, pancreatic, gastroesophageal, bladder and lung cancers.

We hold worldwide rights for rucaparib. In June 2011, we obtained an exclusive, worldwide license from Pfizer to develop and commercialize rucaparib. U.S. Patent 6,495,541, and its equivalent counterparts issued in dozens of countries, directed to the rucaparib composition of matter, expire in 2020 and are potentially eligible for up to five years patent term extension in various jurisdictions. We believe that patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Act, could be available to extend our patent exclusivity for rucaparib to the fourth quarter of 2023 in the United States. In Europe, we believe that patent term extension under a supplementary protection certificate could be available for an additional five years to at least 2025. In April 2012, we obtained an exclusive license from AstraZeneca under a family of patents and patent applications to permit the development and commercialization of rucaparib for certain methods of treating patients with PARP inhibitors. Additionally, other patents and patent applications are directed to methods of making, methods of using, dosing regimens, various salt and polymorphic forms and formulations and have expiration dates ranging from 2020 through potentially 2035, including the camsylate salt/polymorph patent family licensed from Pfizer, which expires in 2031 and a patent application directed to high dosage strength rucaparib tablets that, if issued, will expire in 2035. We are aware of a number of cases where salt and polymorph patents have been challenged. Two oppositions were filed in the granted European counterpart of the rucaparib camsylate salt/polymorph patent on June 20, 2017. European oppositions are commonly filed against patents related to pharmaceutical products. The grounds of opposition related to Rubraca were lack of novelty and lack of inventive step. The novelty and inventive step challenges are based on prior art references (or closely related disclosures) that were previously raised by the European patent examiner during prosecution of the application. The claims of the granted patent were found to be patentable over this prior art. While the ultimate results of patent challenges can be difficult to predict, we believe a number of factors, including a constellation of unexpected properties, support the novelty and non-obviousness of our rucaparib camsylate salt/polymorph composition of matter patent. Based on these factors, we believe a successful challenge of that patent would be difficult.

In addition, we have two other product candidates: lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3, and rociletinib, an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR). While we have stopped enrollment in ongoing trials for each of these candidates, we continue to provide drugs to patients whose clinicians recommend continuing therapy. We maintain certain development and commercialization rights for lucitanib and global development and commercialization rights for rociletinib.

We commenced operations in April 2009. To date, we have devoted substantially all of our resources to identifying and in-licensing product candidates, performing development activities with respect to those product candidates and the general and administrative support of these operations. Through June 30, 2017, we have generated $13.6 million in license and milestone revenue related to our collaboration and license agreement with Servier and have generated $21.7 million net product revenue related to sales of Rubraca, which we began to commercialize on December 19, 2016. We have principally funded our operations using the net proceeds from the sale of convertible preferred stock, the issuance of convertible promissory notes, public offerings of our common stock and our convertible senior notes offering.

We have never been profitable and, as of June 30, 2017, we had an accumulated deficit of $1,364.9 million. We incurred net losses of $233.8 million and $212.7 million for the six months ended June 30, 2017 and 2016, respectively. The net loss for the six months ended June 30, 2017 included a charge of $117.0 million related to a legal settlement. The net loss for the six months ended June 30, 2016 included a charge of $104.5 million for the impairment of intangible asset and a gain of $24.9 million from a reduction in fair value of contingent purchase consideration. We had cash, cash equivalents and available-for-sale securities totaling $671.5 million at June 30, 2017.

We expect to incur significant losses for the foreseeable future, as we incur costs related to commercial activities associated with Rubraca. In January 2017, we sold 5,750,000 shares of our common stock in a public offering at $41.00 per share. The net proceeds from the offering were $221.2 million, after deducting underwriting discounts and commissions and offering expenses. In June 2017, we sold 3,920,454 shares of our common stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.9 million, after deducting underwriting discounts and

Table of Contents

commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including sales and marketing expenses associated with Rubraca in the United States and, if approved by the EMA, in Europe, funding of our development programs, selling, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on our current estimates, we believe that our cash, cash equivalents and available-for-sale securities will allow us to fund activities through at least the next 12 months. Until we can generate a sufficient amount of revenue from Rubraca, we expect to finance our operations in part through additional public or private equity or debt offerings and may seek additional capital through arrangements with strategic partners or from other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenues to achieve profitability, and we may never do so.

Product License Agreements

We are obligated under the license agreement to use commercially reasonable efforts to develop and commercialize rucaparib and we are responsible for all remaining development and commercialization costs for rucaparib. We are required to make regulatory milestone payments to Pfizer of up to an additional $69.75 million in aggregate if specified clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are obligated to make sales milestone payments to Pfizer if specified annual sales targets for rucaparib are met, the majority of which relate to annual sales targets of $500.0 million and above, which, in the aggregate, could amount to total milestone payments of $170.0 million, and tiered royalty payments at a mid-teen percentage rate on our net sales, with standard provisions for royalty offsets to the extent we need to obtain any rights from third parties to commercialize rucaparib.

Table of Contents

We are party to other product license agreements for our other drug candidates, lucitanib and rociletinib (see our 2016 Form 10-K for additional details).

Financial Operations Overview

Revenue

Product revenue is derived from sales of our product, Rubraca, in the United States. We distribute our product in the U.S. principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers. Our customers subsequently resell our products to patients and healthcare providers. Separately, we have arrangements with certain payors and other third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and other discounts. Revenue is recorded net of estimated rebates, chargebacks, discounts and other deductions as well as estimated product returns (collectively, “sales deductions”). We only recognize revenue on product sales once the product is resold to the patient or healthcare provider by the specialty distributor or specialty pharmacy provider, therefore reducing the significance of estimates made for product returns.

Sales Deductions

Estimating sales deductions requires significant judgments about future events and uncertainties, and requires us to rely heavily on assumptions, as well as historical experience. Estimated sales deductions are provided for the following:

Rebates. Rebates include mandated discounts under the Medicaid Drug Rebate Program and the Medicare coverage gap program. Rebates are amounts owed after the final dispensing of products to a benefit plan participant and are based upon contractual agreements or legal requirements with the public sector benefit providers. The accrual for rebates is based on statutory discount rates and known sales to specialty pharmacy patients, or expected utilization for specialty distributor sales to healthcare providers. As we gain more historical experience, the accrual will be based solely on the expected utilization from historical data we have accumulated since Rubraca product launch. Rebates are generally invoiced and paid quarterly in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for known or estimated prior quarters’ unpaid rebates. If actual future rebates vary from estimates, we may need to adjust balances of such rebates to reflect our actual expenditures with respect to these programs, which would affect revenue in the period of adjustment.

Chargebacks. Chargebacks are discounts that occur when contracted customers, which currently consist primarily of group purchasing organizations, Public Health Service organizations and federal government entities purchasing via the Federal Supply Schedule, purchase directly from our specialty distributors at a discounted price. The specialty distributor, in turn, charges back the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the healthcare provider. The accrual for specialty distributor chargebacks is estimated based on known chargeback rates and known sales to specialty distributors adjusted for the estimated utilization by healthcare providers.

Discounts. Specialty distributors and specialty pharmacies are offered various forms of consideration, including service fees and prompt pay discounts for payment within a specified period. We expect these customers will earn prompt pay discounts and therefore, we deduct the full amount of these discounts from product sales when revenue is recognized. Service fees are recorded as a selling expense when product sales occur.

Co-pay assistance. Patients who have commercial insurance and meet certain eligibility requirements may receive co-pay assistance. The intent of this program is to reduce the patient’s out of pocket costs. Liabilities for co-pay assistance are based on actual program participation and estimates of program redemption using data provided by third-party administrators.

Returns. Sales of our products are not subject to a general right of return at the point we recognize revenue, which is the point the product is sold to the patient or healthcare provider. To date, we have not had any product returns and, we currently do not have an accrual for product returns. We will continue to assess our estimate for product returns as we gain additional historical experience.

Table of Contents

In the three and six months ended June 30, 2017, we recorded net product revenue of $14.6 million and $21.7 million, respectively, related to sales of Rubraca, which we began to commercialize on December 19, 2016. Our ability to generate revenue and become profitable depends upon our ability to successfully commercialize products. Any inability on our part to successfully commercialize Rubraca in the United States and any foreign territories where it may be approved, or any significant delay in such approvals, could have a material adverse impact on our ability to execute upon our business strategy and, ultimately, to generate sufficient revenues from Rubraca to reach or maintain profitability or sustain our anticipated levels of operations.

Cost of Sales – Product

We recorded product cost of sales from sales of Rubraca in the three and six months ended June 30, 2017. Product cost of sales consists primarily of materials, third-party manufacturing costs as well as freight and royalties owed to our licensing partners for Rubraca sales. Based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, certain of the manufacturing costs of Rubraca units recognized as revenue during the three and six months ended June 30, 2017 were expensed prior to the December 19, 2016 FDA approval, and therefore are not included in costs of sales during the current period. We expect cost of sales to increase in relation to product revenues as we deplete these inventories and we expect to use the remaining pre-commercialization inventory for product sales through the third quarter of 2017.

Cost of Sales – Intangible Asset Amortization

Research and Development Expenses

Research and development expenses consist of costs incurred for the development of our product candidates and companion diagnostics, which include:

license fees and milestone payments related to the acquisition of in-licensed products, which are reported on our Consolidated Statements of Operations as acquired in-process research and development;

employee-related expenses, including salaries, benefits, travel and share-based compensation expense;

expenses incurred under agreements with contract research organizations and investigative sites that conduct our clinical trials;

the cost of acquiring, developing and manufacturing clinical trial materials;

costs associated with non-clinical activities and regulatory operations;

market research, disease education and other commercial product planning activities, including the hiring of a U.S. sales and marketing and medical affairs organization in preparation for the commercial launch of rucaparib; and

activities associated with the development of companion diagnostics for our product candidates.

Research and development costs are expensed as incurred. License fees and milestone payments related to in-licensed products and technology are expensed if it is determined that they have no alternative future use. Costs for certain development activities, such as clinical trials and manufacturing of clinical supply, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors. As a result of the FDA approval of Rubraca and the discontinuation of enrollment in rociletinib, our research and development expenses decreased in both the three and six months ended June 30, 2017 compared to the same periods in the prior year and are expected to decrease for the remainder of 2017 compared to prior year as we continue to commercialize Rubraca and commercialization related expenses are classified as selling, general and administrative expenses and not research and development costs.

Table of Contents

The following table identifies research and development and acquired in-process research and development costs on a program-specific basis for our products under development. Personnel-related costs, depreciation and share-based compensation are not allocated to specific programs, as they are deployed across multiple projects under development and, as such, are separately classified as personnel and other expenses in the table below (in thousands):


	Three months ended June 30,				Six months ended June 30,
	2017		2016		2017		2016
	(in thousands)
Rucaparib Expenses
Research and development	$	16,980	$	24,379	$	31,490	$	48,936
Acquired in-process research and development				300		—		300
Rucaparib Total		16,980		24,679		31,490		49,236
Lucitanib Expenses
Research and development (a)		(13)		(194)		(99)		(214)
Lucitanib Total		(13)		(194)		(99)		(214)
Rociletinib Expenses
Research and development	$	1,528	$	16,821		4,719		37,415
Rociletinib Total		1,528		16,821		4,719		37,415
Personnel and other expenses		14,613		26,723		29,445		56,200
Total	$	33,108	$	68,029	$	65,555	$	142,637

(a)This amount reflects actual costs incurred less amounts due from Servier for reimbursable development expenses pursuant to the collaboration and license agreement described in Note 12, License Agreements to our unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q.

Selling, General and Administrative Expenses

Selling, general and administrative expenses consist principally of salaries and related costs for personnel in executive, commercial, finance, legal, investor relations, human resources, and information technology functions. Other selling, general and administrative expenses include facilities expenses, communication expenses, information technology costs, corporate insurance and professional fees for legal, consulting and accounting services. With the FDA approval of Rubraca on December 19, 2016, all sales and marketing expenses associated with Rubraca are included in selling, general and administrative expenses. We anticipate that our selling, general and administrative expenses will continue to increase in the future in support of our commercial activities related to Rubraca.

Acquired In-Process Research and Development Expenses

Acquired in-process research and development expenses consist of upfront payments to acquire a new drug compound, as well as subsequent milestone payments. Acquired in-process research and development payments are immediately expensed provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no alternative future use. Once regulatory approval is received, payments to acquire rights, and the related milestone payments, are capitalized and the amortization of such assets recorded to intangible asset amortization cost of sales.

Change in Fair Value of Contingent Purchase Consideration

In connection with the acquisition of EOS in November 2013, we also recorded a purchase consideration liability equal to the estimated fair value of future payments that are contingent upon the achievement of various regulatory and sales milestones. Subsequent to the acquisition date, we re-measure contingent consideration arrangements at fair value each reporting period and record changes in fair value of contingent purchase consideration and foreign currency gains (losses) for changes in the foreign currency translation rate on the Consolidated Statements of Operations. Changes in fair value are primarily attributed to new information about the likelihood of achieving such milestones and the passage of time. In the absence of new information, changes in fair value reflect only the passage of time as we progress towards the achievement of future milestones. During the second quarter of 2016, we recorded a $25.5 million reduction in the fair value of the contingent purchase consideration liability due to our and our development partner’s decision to discontinue the development of lucitanib for breast cancer. At June 30, 2017, the contingent purchase consideration

Table of Contents

liability recorded on the Consolidated Balance Sheets was zero due to the uncertainty of achieving any of the lucitanib regulatory milestones.

Other Income and Expense

Other income and expense is primarily comprised of foreign currency gains and losses resulting from transactions with contract research organizations (“CROs”), investigational sites and contract manufacturers where payments are made in currencies other than the U.S. dollar. Other expense also includes interest expense recognized related to our convertible senior notes.

Critical Accounting Policies and Significant Judgments and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates and judgments, including those related to contingent purchase consideration, the allocation of purchase consideration, intangible asset impairment, clinical trial accruals and share-based compensation. We base our estimates on historical experience, known trends and events and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

For a description of our critical accounting policies, please see Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016. There have not been any material changes to our critical accounting policies since December 31, 2016.

New Accounting Standards

From time to time, the Financial Accounting Standards Board (“FASB”) or other standards-setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification are communicated through the issuance of an Accounting Standards Update. Unless otherwise discussed, we believe that the impact of recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on our Consolidated Financial Statements upon adoption.

To understand the impact of recently issued guidance, whether adopted or to be adopted, please review the information provided in Note 2, Summary of Significant Accounting Policies, in the Notes to the Unaudited Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

Table of Contents

Results of Operations

Comparison of Three Months Ended June 30, 2017 and 2016:

The following table summarizes the results of our operations for the three months ended June 30, 2017 and 2016 (in thousands):


					Change
	Three months ended June 30,				Favorable/(Unfavorable)
	2017		2016		$		%

Product revenue, net	$	14,620	$	—	$	14,620		n/a
Operating expenses:
Cost of sales - product		2,730		—		(2,730)		n/a
Cost of sales - intangible asset amortization		372		—		(372)		n/a
Research and development		33,108		67,729		34,621		51	%
Selling, general and administrative		36,149		9,552		(26,597)		(278)	%
Acquired in-process research and development		—		300		300		n/a
Impairment of intangible asset		—		104,517		104,517		n/a
Change in fair value of contingent purchase consideration		—		(25,452)		(25,452)		n/a
Total expenses		72,359		156,646		84,287		54	%
Operating loss		(57,739)		(156,646)		98,907		63	%
Other income (expense):
Interest expense		(2,598)		(2,106)		(492)		(23)	%
Foreign currencygains (losses)		76		183		(107)		58	%
Legal settlement loss		(117,000)		—		(117,000)		n/a
Other income		594		196		398		(203)	%
Other income (expense), net		(118,928)		(1,727)		(117,201)		(6,786)	%
Loss before income taxes		(176,667)		(158,373)		(18,294)		(12)	%
Income tax benefit		1,281		29,059		(27,778)		96	%
Net loss	$	(175,386)	$	(129,314)	$	(46,072)		(36)	%

Product Revenue, Net. Product revenue for the three months ended June 30, 2017 was due to the recognition of $14.6 million of net product revenue from the sale of our first commercial product, Rubraca, which was approved for sale in the United States markets and we began shipping on December 19, 2016. Revenue is recorded net of sales deductions comprised of rebates, chargebacks and other discounts. Sales deductions represented approximately 7.9% of the gross product revenue recognized in the three months ended June 30, 2017 and are summarized as follows:


	Three months ended
	June 30, 2017
	$		% of Gross Sales
	(in thousands)

Gross product revenue	$	15,876		100.0%
Sales deductions:
Government rebates and chargebacks		635		4.0%
Discounts and fees		621		3.9%
Total sales deductions		1,256		7.9%
Product revenue, net	$	14,620		92.1%

Cost of Sales – Product. Product cost of sales for the three months ended June 30, 2017 of $2.7 million relate to freight and royalties costs associated with Rubraca sales in the period. Manufacturing costs associated with sales in the quarter were expensed as incurred based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, and therefore, were not included in product cost of sales for the three months ended June

Table of Contents

30, 2017. We expect cost of sales to increase in relation to product revenues once we deplete these inventories in the third quarter 2017.

Cost of Sales – Intangible Asset Amortization. In the three months ended June 30, 2017, we recognized cost of sales of $0.4 million associated with the amortization of capitalized milestone payments related to the FDA approval of Rubraca. Prior to the FDA approval on December 16, 2016, all acquired license and milestone payments were expensed as incurred.

Research and Development Expenses. Research and development expenses decreased during the three months ended June 30, 2017 compared to the same period in the prior year primarily due to lower research and development costs for rucaparib and rociletinib and classification of commercialization related expenses associated with Rubraca in selling, general and administrative expenses rather than research and development expenses. In the three months ended June 30, 2017, Rubraca commercialization costs included in selling, general and administrative expenses were $26.9 million.

Clinical trial costs for rucaparib were relatively flat compared to the same quarter a year ago as higher costs from enrollment in ARIEL4, our confirmatory ovarian cancer trials, and enrollment in our TRITON2 and TRITON3 studies for prostate cancer were largely offset by lower costs for the ARIEL2 and ARIEL3 studies, which have completed enrollment. Clinical supply and related manufacturing development costs were $3.5 million lower than the second quarter of 2016 due to the capitalization of these costs subsequent to the FDA approval of rucaparib.

Clinical trial costs for rociletinib were $8.2 million lower than the second quarter of 2016 primarily due to the completion of patient enrollment for all of the TIGER studies in non-small cell lung cancer. Clinical supply and related manufacturing development costs were $4.3 million lower than the second quarter of 2016 driven by timing of production to support our clinical studies.

Selling, General and Administrative Expenses. Selling, general and administrative expenses increased during the three months ended June 30, 2017 compared to the same period in the prior year primarily due to classification of commercialization related expenses associated with Rubraca in selling, general and administrative expenses rather than research and development expenses.

Table of Contents

Comparison of Six Months Ended June 30, 2017 and 2016:

The following table summarizes the results of our operations for the six months ended June 30, 2017 and 2016 (in thousands):


					Change
	Six months ended June 30,				Favorable/(Unfavorable)
	2017		2016		$		%

Product revenue, net	$	21,665	$	—	$	21,665		n/a
Operating expenses:
Cost of sales - product		3,893		—		(3,893)		n/a
Cost of sales - intangible asset amortization		743		—		(743)		n/a	%
Research and development		65,555		142,337		76,782		54	%
Selling, general and administrative		65,373		19,379		(45,994)		(237)	%
Acquired in-process research and development		—		300		300		n/a
Impairment of intangible asset		—		104,517		104,517		n/a
Change in fair value of contingent purchase consideration		—		(24,936)		(24,936)		n/a
Total expenses		135,564		241,597		106,033		44	%
Operating loss		(113,899)		(241,597)		127,698		52.86	%
Other income (expense):
Interest expense		(5,178)		(4,210)		(968)		(22.99)	%
Foreign currency gains (losses)		(83)		(368)		285		77.45	%
Legal settlement loss		(117,000)		—		(117,000)		n/a
Other income		946		221		725		328	%
Other income (expense), net		(121,315)		(4,357)		(116,958)		(2,684.37)	%
Loss before income taxes		(235,214)		(245,954)		10,740		4.37	%
Income tax benefit		1,365		33,240		(31,875)		(96)	%
Net loss	$	(233,849)	$	(212,714)	$	(21,135)		(10)	%

Product Revenue, Net. Product revenue for the six months ended June 30, 2017 was due to the recognition of $21.7 million of net product revenue from the sale of our first commercial product, Rubraca, which was approved for sale in the United States markets and we began shipping on December 19, 2016. Revenue is recorded net of sales deductions comprised of rebates, chargebacks and other discounts. Sales deductions represented approximately 8.9% of the gross product revenue recognized in the six months ended June 30, 2017 and are summarized as follows:


	Six months ended
	June 30, 2017
	$		% of Gross Sales
	(in thousands)

Gross product revenue	$	23,778		100.0%
Sales deductions:
Government rebates and chargebacks		1,072		4.5%
Discounts and fees		1,041		4.4%
Total sales deductions		2,113		8.9%
Product revenue, net	$	21,665		91.1%

Cost of Sales – Product. Product cost of sales for the six months ended June 30, 2017 of $3.9 million relate to freight and royalties costs associated with Rubraca sales in the period. Manufacturing costs associated with sales in the quarter were expensed as incurred based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, and therefore, were not included in product cost of sales for the six months ended June 30, 2017. We expect cost of sales to increase in relation to product revenues once we deplete these inventories in the third quarter of 2017.

Table of Contents

Cost of Sales – Intangible Asset Amortization. In the six months ended June 30, 2017, we recognized cost of sales of $0.7 million associated with the amortization of capitalized milestone payments related to the FDA approval of Rubraca. Prior to the FDA approval on December 19, 2016, all acquired license and milestone payments were expensed as incurred.

Research and Development Expenses. Research and development expenses decreased during the six months ended June 30, 2017 compared to the same period in the prior year primarily due to lower research and development costs for rucaparib and rociletinib and classification of commercialization related expenses associated with Rubraca in selling, general and administrative expenses rather than research and development expenses. In the six months ended June 30, 2017, Rubraca commercialization costs included in selling, general and administrative expenses were $47.0 million.

Clinical trial costs for rucaparib were relatively flat compared to the same period a year ago as higher costs from enrollment in ARIEL4, our confirmatory ovarian cancer trials, and enrollment in our TRITON2 and TRITON3 studies for prostate cancer were largely offset by lower costs for the ARIEL2 and ARIEL3 studies, which have completed enrollment. Diagnostic development costs were $6.1 million lower compared to the prior year as the prior year included the costs associated with our collaboration with Foundation Medicine, Inc. to develop a novel companion diagnostic test to identify patients most likely to respond to rucaparib. Finally, clinical supply and related manufacturing development costs were $7.0 million lower than 2016 due to the capitalization of these costs subsequent to the FDA approval of rucaparib.

Clinical trial costs for rociletinib were $18.5 million lower than 2016 primarily due to the completion of patient enrollment for all of the TIGER studies in non-small cell lung cancer. Clinical supply and related manufacturing development costs were $7.2 million lower than 2016 driven by timing of production to support our clinical studies.

Selling, General and Administrative Expenses. Selling, general and administrative expenses increased during the six months ended June 30, 2017 compared to the same period in the prior year primarily due mainly to classification of commercialization related expenses associated with Rubraca in selling, general and administrative expenses rather than research and development expenses.

Liquidity and Capital Resources

To date, we have funded our operations through the public offering of our common stock and the private placement of convertible debt securities and preferred stock. In January 2017, we sold 5,750,000 shares of our common stock in a public offering at $41.00 per share. The net proceeds from the offering were $221.2 million, after deducting underwriting discounts and commissions and offering expenses. In June 2017, we sold 3,920,454 shares of our common stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.9 million, after deducting underwriting discounts and commissions and offering expenses. At June 30, 2017, we had cash, cash equivalents and available-for-sale securities totaling $671.5 million.

The following table sets forth the primary sources and uses of cash for the six months ended March 31, 2017 and 2016 (in thousands):


	Six months ended June 30,
	2017		2016

Net cash used in operating activities	$	(149,541)	$	(151,670)
Net cash (used in) provided by investing activities		(133,864)		99,244
Net cash provided by financing activities		558,440		1,943
Effect of exchange rate changes on cash and cash equivalents		565		106
Net increase (decrease) in cash and cash equivalents	$	275,600	$	(50,377)

Operating Activities

Net cash used in operating activities for all periods resulted primarily from our net losses adjusted for non-cash items and changes in components of working capital. Net cash used in operating activities was lower during the six months ended June 30, 2017 compared to the same period in the prior year due to a lower net loss as adjusted for non-

Table of Contents

cash items, partially offset by increases in the operating assets needed to support the commercialization of Rubraca, most notably related to inventory.

Investing Activities

Net cash used in investing activities for the six months ended June 30, 2017 includes purchases of available-for-sale securities of $180.0 million offset by cash from maturities of available-for-sale securities of $50.0 million. Net cash provided by investing activities in the same period in the prior year was mainly the result of maturities of available-for-sale securities of $100.0 million in that period.

Financing Activities

Net cash provided by financing activities for the six months ended June 30, 2017 and 2016 includes $12.3 million and $1.9 million, respectively, received from employee stock option exercises. In addition, we completed the sale of $546.2 million of common stock, net of issuance costs, during the six months ended June 30, 2017.

Operating Capital Requirements

We expect to incur significant losses for the foreseeable future, as we commercialize Rubraca and expand our selling, general and administrative functions to support the growth in our commercial organization. Additionally, our operating plan for the next 12 months includes a significant investment in inventory to meet the projected commercial requirements for Rubraca. We receive the active pharmaceutical ingredient in Rubraca from one supplier and we experience long lead times associated with its production. Accordingly, we expect to experience a decrease in our liquidity at the beginning of a production cycle and an increase as the inventory produced is sold through.

As of June 30, 2017, we had cash, cash equivalents and available-for-sale securities totaling $671.5 million and total current liabilities of $219.4 million. In January 2017, we sold 5,750,000 shares of our common stock in a public offering at $41.00 per share. The net proceeds from the offering were $221.2 million, after deducting underwriting discounts and commissions and offering expenses. In June 2017, we sold 3,920,454 shares of our common stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.9 million, after deducting underwriting discounts and commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including commercial planning and sales and marketing expenses associated with the launch of Rubraca in the United States and, if approved by the EMA, in Europe, funding of our development programs, selling, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on current estimates, we believe that our existing cash, cash equivalents and available-for-sale securities will allow us to fund our operating plan through at least the next 12 months.

Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amounts of our working capital requirements. Our future funding requirements will depend on many factors, including but not limited to:

the number and characteristics of the product candidates, companion diagnostics and indications we pursue;

the achievement of various development, regulatory and commercial milestones resulting in required payments to partners pursuant to the terms of our license agreements;

the scope, progress, results and costs of researching and developing our product candidates and related companion diagnostics and conducting clinical and non-clinical trials;

the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates and companion diagnostics;

the cost of commercialization activities, including marketing and distribution costs;

the cost of manufacturing any of our product candidates we successfully commercialize;

the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and outcome of such litigation; and

the timing, receipt and amount of sales, if any, of our product candidates.

Table of Contents

Contractual Obligations and Commitments

For a discussion of our contractual obligations, see “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2016 Annual Report on Form 10-K. There have not been any material changes to such contractual obligations or potential milestone payments since December 31, 2016. For further information regarding our contractual obligations and commitments, see Note 14, Commitments and Contingencies to our unaudited consolidated financial statements included elsewhere in this report.

ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk related to changes in interest rates. As of June 30, 2017, we had cash, cash equivalents and available-for-sale securities of $671.5 million, consisting of bank demand deposits, money market funds and U.S. treasury securities. The primary objectives of our investment policy are to preserve principal and maintain proper liquidity to meet operating needs. Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are in short-term securities. Our available-for-sale securities are subject to interest rate risk and will decline in value if market interest rates increase. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair value of our portfolio.

We contract with contract research organizations, investigational sites and contract manufacturers globally where payments are made in currencies other than the U.S. dollar. In addition, on October 3, 2016, we entered into a Manufacturing and Services Agreement with a Swiss company for the production and supply of the active ingredient for Rubraca. Under the terms of this agreement, payments for the supply of the active ingredient in Rubraca as well as scheduled capital program fee payment toward capital equipment and other costs associated with the construction of a dedicated production train will be made in Swiss francs. Once the production facility is operational, we are obligated to pay a fixed facility fee each quarter for the duration of the agreement, which expires on December 31, 2025.

As of June 30, 2017, $183.6 million of purchase commitments exist under the Swiss Manufacturing and Services Agreement and we are required to remit amounts due in Swiss francs. Due to other variables that may exist, it is difficult to quantify the impact of a particular change in exchange rates. However, we estimate that if the value of the US dollar was to strengthen by 10% compared to the value of Swiss franc as of June 30, 2017, it would decrease the total US dollar purchase commitment under the Swiss Manufacturing and Services Agreement by approximately $16.7 million. Similarly, a 10% weakening of the US dollar compared to the Swiss franc would increase the total US dollar purchase commitment by approximately $20.4 million.

While we periodically hold foreign currencies, primarily Euro and Pound Sterling, we do not use other financial instruments to hedge our foreign exchange risk. Transactions denominated in currencies other than the functional currency are recorded based on exchange rates at the time such transactions arise. As of both June 30, 2017 and December 31, 2016, approximately 1% of our total liabilities were denominated in currencies other than the functional currency.

ITEM 4.CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended (“Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Principal Financial and Accounting Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective. With the participation of our Chief Executive Officer and Principal Financial and Accounting Officer, management performed an evaluation as of June 30, 2017 of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on this evaluation, our Chief Executive Officer and Principal Financial and Accounting Officer

Table of Contents

concluded that, as of June 30, 2017, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended June 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

ITEM 1.LEGAL PROCEEDINGS

On March 14, 2017, the Clovis Defendants and the Arkin Plaintiffs participated in a mediation, which did not result in a settlement.

On June 18, 2017, the Clovis Defendants entered into a stipulation and agreement of settlement with the Arkin Plaintiffs whereby Clovis will issue to the plaintiffs and participating class members total consideration comprised of $25.0 million in cash and the issuance of a to be determined number of shares of Clovis common stock (the “Settlement Shares”) equal to $117.0 million divided by the volume weighted average price of Clovis common stock over the 10 trading days immediately preceding the date of the hearing set by the Medina Court to consider the final approval of the settlement. The cash portion of the consideration is expected to be funded by Clovis’ insurance carriers. At June 30, 2017, the liability for the issuance of the shares and cash, including the amount to be reimbursed through insurance proceeds, was recorded to accrued liability for legal settlement on the Consolidated Balance Sheets in the amount of approximately $142.0 million and a receivable of approximately $25.0 million from the insurance carriers on the Consolidated Balance Sheets. Clovis will issue the Settlement Shares no later than 5 business days after the date the judgment is entered by the Medina Court approving the settlement whereby the issuance of the shares will be recorded in common stock and additional paid-in capital and the accrued liability for legal settlement will be cleared.

On July 14, 2017, the Medina Court issued an order preliminarily approving the settlement. A final hearing to determine whether the settlement should be approved is scheduled for October 26, 2017.

Table of Contents

The Company intends to vigorously defend against the allegations in the Electrical Workers Amended Complaint, but there can be no assurance that the defense will be successful.

Table of Contents

Company’s business operations and prospects, failing to ensure that the TIGER-X clinical trial was being conducted in accordance with applicable rules, regulations and protocols, and engaging in insider trading. The Consolidated Derivative Complaint purported to rely on documents produced by the Company in response to the Macalinao and McKenry Demand Letters. The Consolidated Derivative Complaint sought, among other things, an award of money damages.

The Company intends to vigorously defend against the allegations in the Consolidated Derivative Complaint, but there can be no assurance that the defense will be successful.

The Company intends to vigorously defend against the allegations in the Solak Complaint, but there can be no assurance that the defense will be successful.

The Company intends to vigorously defend against the allegations in the Guo Complaint, but there can be no assurance that the defense will be successful.

ITEM 1A.RISK FACTORS

Our business faces significant risks and uncertainties. Certain factors may have a material adverse effect on our business prospects, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the risk factors described under the heading “Risk Factors” in Part I, Item 1A of our most recent Annual Report on Form 10-K, in addition to other information contained in or

Table of Contents

incorporated by reference into this Quarterly Report on Form 10-Q and our other public filings with the SEC. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.

There have been no material changes to the risk factors included in our previously filed Annual Report on Form 10-K for the year ended December 31, 2016. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial also may negatively impact our business.

ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3.DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5.OTHER INFORMATION

None.

ITEM 6.EXHIBITS

INDEX TO EXHIBITS

o
Exhibit
Number	Exhibit Description

3.1(5)	Amended and Restated Certificate of Incorporation of Clovis Oncology, Inc.

3.2(5)	Amended and Restated Bylaws of Clovis Oncology, Inc.

4.1(3)	Form of Common Stock Certificate of Clovis Oncology, Inc.

4.2(8)	Indenture dated as of September 9, 2014, by and between Clovis Oncology, Inc. and The Bank of New York Mellon Trust Company, N.A.

10.1*(4)	Amended and Restated Strategic License Agreement, dated as of June 16, 2011, by and between Clovis Oncology, Inc. and Avila Therapeutics, Inc.

10.2*(4)	License Agreement, dated as of June 2, 2011, by and between Clovis Oncology, Inc. and Pfizer Inc.

10.3+(1)	Clovis Oncology, Inc. 2009 Equity Incentive Plan.

10.4+(4)	Clovis Oncology, Inc. 2011 Stock Incentive Plan.

10.5+(1)	Form of Clovis Oncology, Inc. 2009 Equity Incentive Plan Stock Option Agreement.

10.6+(4)	Form of Clovis Oncology, Inc. 2011 Stock Incentive Plan Stock Option Agreement.

10.7+(3)	Employment Agreement, dated as of August 24, 2011, between Clovis Oncology, Inc. and Patrick J. Mahaffy.

10.8+(3)	Employment Agreement, dated as of August 24, 2011, between Clovis Oncology, Inc. and Erle T. Mast.

Table of Contents

10.9+(3)	Employment Agreement, dated as of August 24, 2011, between Clovis Oncology, Inc. and Gillian C. Ivers-Read.

10.10+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Paul Klingenstein.

10.11+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and James C. Blair.

10.12+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Edward J. McKinley.

10.13+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Thorlef Spickschen.

10.14+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and M. James Barrett.

10.15+(1)	Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Brian G. Atwood.

10.16+(1)	Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Patrick J. Mahaffy.

10.17+(1)	Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Erle T. Mast.

10.18+(1)	Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Gillian C. Ivers-Read.

10.19+(1)	Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Andrew R. Allen.

10.20+(4)	Clovis Oncology, Inc. 2011 Employee Stock Purchase Plan.

10.21+(4)	Clovis Oncology, Inc. 2011 Cash Bonus Plan.

10.22+(6)	Indemnification Agreement, dated as of March 22, 2012, between Clovis Oncology, Inc. and Steven L. Hoerter.

10.23+(2)	Indemnification Agreement, dated as of June 13, 2013, between Clovis Oncology, Inc. and Ginger L. Graham.

10.24+(2)	Indemnification Agreement, dated as of June 13, 2013, between Clovis Oncology, Inc. and Keith Flaherty.

10.25(7)	Stock Purchase Agreement, dated as of November 19, 2013, by and among the Company, EOS, the Sellers listed on Exhibit A thereto and Sofinnova Capital V FCPR, acting in its capacity as the Sellers’ Representative.

10.26*(7)	Development and Commercialization Agreement, dated as of October 24, 2008, by and between Advenchen Laboratories LLC and Ethical Oncology Science S.p.A., as amended by the First Amendment, dated as of April 13, 2010 and the Second Amendment, dated as of July 30, 2012.

10.27*(7)	Collaboration and License Agreement, dated as of September 28, 2012, by and between Ethical Oncology Science S.p.A. and Les Laboratoires Servier and Institut de Recherches Internationales Servier.

Table of Contents

10.28+(12)	Indemnification Agreement, dated as of January 29, 2016, by and between Clovis Oncology, Inc. and Lindsey Rolfe.

10.29+(12)	Employment Agreement, dated as of February 25, 2016, by and between Clovis Oncology, Inc. and Lindsey Rolfe.

10.30+(12)	Indemnification Agreement, dated as of January 26, 2016, by and between Clovis Oncology, Inc. and Dale Hooks.

10.31+(12)	Employment Agreement, dated as of January 26, 2016, by and between Clovis Oncology, Inc. and Dale Hooks.

10.32+(9)	Indemnification Agreement, dated as of February 17, 2016, by and between Clovis Oncology, Inc. and Daniel W. Muehl.

10.33+(15)	Employment Agreement, dated as of July 6, 2017, by and between Clovis Oncology, Inc. and Daniel W. Muehl.

10.34+(10)	Salary Waiver Letter, dated as of May 9, 2016, by and between Clovis Oncology, Inc. and Patrick J. Mahaffy.

10.35*(11)	First Amendment to License Agreement, by and between Clovis Oncology, Inc. and Pfizer Inc., dated as of August 30, 2016.

10.36+(13)	Form of Clovis Oncology, Inc. 2011 Stock Incentive Plan RSU Agreement.

10.37*(13)	Manufacturing Services Agreement, by and between Clovis Oncology, Inc. and Lonza Ltd, dated as of October 3, 2016.

10.38*(14)	Strata Trial Collaboration Agreement, by and between Clovis Oncology, Inc. and Strata Oncology, Inc., dated as of January 30, 2017

21.1	List of Subsidiaries of Clovis Oncology, Inc.

31.1	Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

31.2	Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

32.1	Certification of principal executive officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2	Certification of principal financial officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101	The following materials from Clovis Oncology, Inc.’s Quarterly Report on Form 10-Q for the period ended June 30, 2017, formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Statements of Operations and Comprehensive Loss, (ii) the Consolidated Balance Sheets, (iii) the Consolidated Statements of Cash Flows and (iv) Notes to Unaudited Consolidated Financial Statements.

(1)

Filed as an exhibit with the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on June 23, 2011.

(2)

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on June 14, 2013.

Table of Contents

(3)

Filed as an exhibit with Amendment No. 2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on August 31, 2011.

(4)

Filed as an exhibit with Amendment No. 3 to the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on October 31, 2011.

(5)

Filed as an exhibit with the Registrant’s Annual Report on Form 10-K on March 15, 2012.

(6)

Filed as an exhibit with the Registrant’s Registration Statement on Form S-1 (File No. 333-180293) on March 23, 2012.

(7)

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on November 19, 2013.

(8)

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on September 9, 2014.

(9)

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on April 1, 2016.

(10)

Filed as an exhibit with the Registrant’s Quarterly Report on Form 10-Q on May 9, 2016.

(11)

Filed as an exhibit with the Registrant’s Quarterly Report on Form 10-Q on November 4, 2016.

(12)

Filed as an exhibit with the Registrant’s Annual Report on Form 10-K on February 29, 2016.

(13)

Filed as an exhibit with the Registrant’s Annual Report on Form 10-K on February 23, 2017.

(14)

Filed as an exhibit with the Registrant’s Quarterly Report on Form 10-Q on May 4, 2017.

(15)

Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on July 7, 2017.

+ Indicates management contract or compensatory plan.

* Confidential treatment has been granted with respect to portions of this exhibit, which portions have been omitted and filed separately with the Securities and Exchange Commission.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: August 3, 2017	CLOVIS ONCOLOGY, INC.

	By:	/s/ PATRICK J. MAHAFFY
		Patrick J. Mahaffy
		President and Chief Executive Officer; Director

	By:	/s/ DANIEL W. MUEHL
		Daniel W. Muehl
		Senior Vice President of Finance and Principal Financial and Accounting Officer

EX-21.1 2 clvs-20170630ex2111bd900.htm EX-21.1 clvs_Ex21_1


		Exhibit 21.1
List of Subsidiaries of Clovis Oncology, Inc.

Name:		Jurisdiction of Organization:
Clovis Oncology UK Limited		United Kingdom
Clovis Oncology Italy Srl		Italy
Clovis Oncology IT Srl		Italy
Clovis Oncology Switzerland GmbH		Switzerland
Clovis Oncology France SAS		France
Clovis Oncology Spain SL		Spain
Clovis Oncology Germany GmbH		Germany
Clovis Oncology Denmark ApS		Denmark

EX-31.1 3 clvs-20170630ex3115bf7ef.htm EX-31.1 clvs_Ex31_1

Exhibit 31.1

I, Patrick J. Mahaffy, certify that:

I have reviewed this quarterly report on Form 10-Q of Clovis Oncology, Inc. for the quarter ended June 30, 2017;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 3, 2017

/s/ PATRICK J. MAHAFFY
Patrick J. Mahaffy
President and Chief Executive Officer

EX-31.2 4 clvs-20170630ex3120382e1.htm EX-31.2 clvs_Ex31_2

Exhibit 31.2

I, Daniel W. Muehl, certify that:

I have reviewed this quarterly report on Form 10-Q of Clovis Oncology, Inc. for the quarter ended June 30, 2017;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 3, 2017

/s/ DANIEL W. MUEHL

Daniel W. Muehl

Senior Vice President of Finance and

Principal Financial and Accounting Officer

EX-32.1 5 clvs-20170630ex32101b0f8.htm EX-32.1 clvs_Ex32_1

Exhibit 32.1

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Clovis Oncology, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended June 30, 2017, as filed with the Securities and Exchange Commission (the “Report”), Patrick J. Mahaffy, as Chief Executive Officer of the Company, does hereby certify, pursuant to §906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. §1350), that to his knowledge:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 3, 2017

/s/ PATRICK J. MAHAFFY
Patrick J. Mahaffy
President and Chief Executive Officer

EX-32.2 6 clvs-20170630ex3222599d6.htm EX-32.2 clvs_Ex32_2

Exhibit 32.2

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Clovis Oncology, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended June 30, 2017, as filed with the Securities and Exchange Commission (the “Report”), Daniel W. Muehl, as Senior Vice President of Finance and Principal Financial and Accounting Officer of the Company, does hereby certify, pursuant to §906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. §1350), that to his knowledge:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 3, 2017

/s/ DANIEL W. MUEHL

Daniel W. Muehl

Senior Vice President of Finance and

Principal Financial and Accounting Officer

EX-101.INS 7 clvs-20170630.xml EX-101.INS 0001466301 us-gaap:ConvertibleDebtMember 2016-12-31 0001466301 2017-01-31 0001466301 us-gaap:RestrictedStockUnitsRSUMember 2016-12-31 0001466301 clvs:StockIncentivePlanTwentyElevenMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-01-01 2017-06-30 0001466301 clvs:StockIncentivePlanTwentyElevenMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2017-01-01 2017-06-30 0001466301 clvs:StockIncentivePlanTwentyElevenMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-01-01 2017-06-30 0001466301 clvs:StockIncentivePlanTwentyElevenMember clvs:ShareBasedCompensationAwardTrancheFourMember 2017-01-01 2017-06-30 0001466301 2017-06-01 2017-06-30 0001466301 2017-01-01 2017-01-31 0001466301 us-gaap:EmployeeStockOptionMember 2017-06-30 0001466301 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-06-30 0001466301 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0001466301 us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2017-06-30 0001466301 us-gaap:ConvertibleDebtMember 2014-09-09 2014-09-09 0001466301 us-gaap:ConvertibleDebtMember 2014-09-09 0001466301 us-gaap:ConvertibleDebtMember 2017-06-30 0001466301 us-gaap:USTreasurySecuritiesMember 2017-01-01 2017-06-30 0001466301 us-gaap:USTreasurySecuritiesMember 2017-06-30 0001466301 us-gaap:USTreasurySecuritiesMember 2016-12-31 0001466301 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member 2017-06-30 0001466301 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2017-06-30 0001466301 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2017-06-30 0001466301 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2017-06-30 0001466301 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2017-06-30 0001466301 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2017-06-30 0001466301 us-gaap:USTreasurySecuritiesMember 2017-06-30 0001466301 us-gaap:MoneyMarketFundsMember 2017-06-30 0001466301 us-gaap:FairValueInputsLevel3Member 2017-06-30 0001466301 us-gaap:FairValueInputsLevel2Member 2017-06-30 0001466301 us-gaap:FairValueInputsLevel1Member 2017-06-30 0001466301 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member 2016-12-31 0001466301 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2016-12-31 0001466301 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2016-12-31 0001466301 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2016-12-31 0001466301 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2016-12-31 0001466301 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2016-12-31 0001466301 us-gaap:USTreasurySecuritiesMember 2016-12-31 0001466301 us-gaap:MoneyMarketFundsMember 2016-12-31 0001466301 us-gaap:FairValueInputsLevel3Member 2016-12-31 0001466301 us-gaap:FairValueInputsLevel2Member 2016-12-31 0001466301 us-gaap:FairValueInputsLevel1Member 2016-12-31 0001466301 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0001466301 us-gaap:ConvertibleDebtSecuritiesMember 2017-01-01 2017-06-30 0001466301 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-06-30 0001466301 us-gaap:ConvertibleDebtSecuritiesMember 2016-01-01 2016-06-30 0001466301 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-04-01 2017-06-30 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2017-04-01 2017-06-30 0001466301 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-06-30 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-06-30 0001466301 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-04-01 2016-06-30 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2016-04-01 2016-06-30 0001466301 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-06-30 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-06-30 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2017-06-30 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-06-30 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2017-03-31 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-03-31 0001466301 2017-03-31 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-12-31 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2016-06-30 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-06-30 0001466301 2016-06-30 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2016-03-31 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-03-31 0001466301 2016-03-31 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2015-12-31 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-12-31 0001466301 2015-12-31 0001466301 clvs:LicenseAgreementsLucitanibMember 2017-06-30 0001466301 clvs:LicenseAgreementsLucitanibMember 2016-12-31 0001466301 2017-07-28 0001466301 us-gaap:RestrictedStockUnitsRSUMember 2017-06-30 0001466301 clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember 2016-12-19 2016-12-19 0001466301 clvs:LicenseAgreementsLicensorAstraZenecaUKLtdMember clvs:LicenseAgreementsRucaparibMember 2016-12-19 2016-12-19 0001466301 clvs:LicenseAgreementsLucitanibMember 2017-04-01 2017-06-30 0001466301 clvs:LicenseAgreementsLucitanibMember 2017-01-01 2017-06-30 0001466301 clvs:LicenseAgreementsLucitanibMember 2016-04-01 2016-06-30 0001466301 clvs:LicenseAgreementsLucitanibMember 2016-01-01 2016-06-30 0001466301 2015-11-01 2015-12-31 0001466301 clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember us-gaap:LicenseAgreementTermsMember 2017-01-01 2017-06-30 0001466301 clvs:LicenseAgreementsLucitanibMember 2012-09-01 2012-09-30 0001466301 2017-06-18 2017-06-18 0001466301 clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember us-gaap:LicenseAgreementTermsMember 2011-06-01 2011-06-30 0001466301 clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0001466301 clvs:SemiAnnualPaymentSecondPaymentMember us-gaap:ConvertibleDebtMember 2017-01-01 2017-06-30 0001466301 clvs:SemiAnnualPaymentFirstPaymentMember us-gaap:ConvertibleDebtMember 2017-01-01 2017-06-30 0001466301 us-gaap:ConvertibleDebtMember 2017-01-01 2017-06-30 0001466301 clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember 2017-06-30 0001466301 clvs:LicenseAgreementsLicensorPfizerMember clvs:LicenseAgreementsRucaparibMember 2017-01-01 2017-06-30 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2017-04-01 2017-06-30 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-04-01 2017-06-30 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-06-30 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-06-30 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2016-04-01 2016-06-30 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-04-01 2016-06-30 0001466301 2016-04-01 2016-06-30 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2016-01-01 2016-06-30 0001466301 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-01-01 2016-06-30 0001466301 2017-06-30 0001466301 2016-12-31 0001466301 2017-04-01 2017-06-30 0001466301 2017-01-01 2017-06-30 0001466301 2016-01-01 2016-06-30 clvs:segment iso4217:USD xbrli:shares xbrli:shares clvs:Vote clvs:shareholder iso4217:EUR xbrli:pure clvs:item iso4217:USD 0 949000 483000 589000 1072000 35198000 21158000 1003000 -43609000 58000 -43667000 -45811000 -77000 -45734000 -42402000 -154000 -42248000 -42670000 -154000 -42516000 0 1100000 20000000 170000000 0 0 24936000 25452000 0 0 3893000 2730000 2 --03-15 --09-15 1.00 23000000 31800000 69750000 500000000 12772000 15162000 7000000 <div> <div> 12. License Agreements   In June 2011, we entered into a worldwide license agreement with Pfizer, Inc. to obtain exclusive global rights to develop and commercialize rucaparib, a small molecule inhibitor of poly (ADP-ribose) polymerase (“PARP”), used for the treatment of selected solid tumors. The exclusive rights are exclusive even as to Pfizer and include the right to grant sublicenses. Pursuant to the terms of the license agreement, we made a $7.0 million upfront payment to Pfizer and are required to make additional payments to Pfizer for the achievement of certain development and regulatory and sales milestones and royalties on sales as required by the license agreement. Prior to the FDA approval of rucaparib, discussed below, we made milestone payments of $1.4 million, which were recognized as acquired in-process research and development expense.   On August 30, 2016, we entered into a first amendment to the worldwide license agreement with Pfizer, which amends the June 2011 existing worldwide license agreement to permit us to defer payment of the milestone payments payable upon (i) FDA approval of an NDA for 1st Indication in US and (ii) EMA approval of an MAA for 1st Indication in EU, to a date that is 18 months after the date of achievement of such milestones. In the event that we defer such milestone payments, we have agreed to certain higher payments related to the achievement of such milestones.   On December 19, 2016, the FDA approved Rubraca (rucaparib) tablets as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. The FDA approval resulted in a $0.75 million milestone payment to Pfizer as required by the license agreement, which was made in the first quarter of 2017. The FDA approval also resulted in the obligation to pay a $20.0 million milestone payment, for which we have exercised the option to defer payment by agreeing to pay $23.0 million within 18 months after the date of the FDA approval. These payments were recognized as intangible assets and will be amortized over the estimated remaining useful life of Rubraca.   We are obligated under the license agreement to use commercially reasonable efforts to develop and commercialize rucaparib and we are responsible for all remaining development and commercialization costs for rucaparib. We are required to make regulatory milestone payments to Pfizer of up to an additional $69.75 million in aggregate if specified clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are obligated to make sales milestone payments to Pfizer if specified annual sales targets for rucaparib are met, the majority of which relate to annual sales targets of $500.0 million and above, which, in the aggregate, could amount to total milestone payments of $170.0 million, and tiered royalty payments at a mid-teen percentage rate on our net sales, with standard provisions for royalty offsets to the extent we need to obtain any rights from third parties to commercialize rucaparib.   In April 2012, we entered into a license agreement with AstraZeneca UK Limited to acquire exclusive rights associated with rucaparib under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of rucaparib for the uses claimed by these patents. The FDA approval of rucaparib on December 19, 2016 resulted in a $0.35 million milestone obligation to AstraZeneca as required by the license agreement, which was paid in the first quarter of 2017. This payment was recognized in intangible assets and will be amortized over the estimated remaining useful life of rucaparib. AstraZeneca will also receive royalties on any net sales of rucaparib.   We are party to other product license agreements for our other drug candidates, lucitanib and rociletinib (see our 2016 Form 10-K for additional details). We and Les Laboratories Servier (“Servier”) are developing lucitanib pursuant to a global development plan agreed to between the parties. Servier is responsible for all of the global development costs for lucitanib up to €80.0 million. Cumulative global development costs in excess of €80.0 million, if any, will be shared equally between us and Servier. We recorded a $0.1 million and $1.3 million receivable at June 30, 2017 and December 31, 2016, respectively, for the reimbursable development costs incurred under the global development plan, which is included in other current assets on the Consolidated Balance Sheets. For the three months ending June 30, 2017 and 2016, we incurred $0.0 million and $2.6 million, respectively, in research and development costs and recorded reductions in research and development expense of $0.1 million and $2.8 million, respectively, for reimbursable development costs due from Servier. For the six months ending June 30, 2017 and 2016, we incurred $0.9 million and $6.2 million, respectively, in research and development costs and recorded reductions in research and development expense of $1.0 million and $6.4 million, respectively, for reimbursable development costs due from Servier.   During the second quarter of 2016, we and Servier agreed to discontinue the development of lucitanib for breast cancer and lung cancer and are continuing to evaluate, what, if any, further development of lucitanib will be pursued. Based on current estimates, we expect to complete the committed on-going development activities in 2017 and expect full reimbursement of our development costs from Servier. Reimbursements are recorded as a reduction to research and development expense on the Consolidated Statements of Operations.   <div /></div> </div> 117000000 25000000 P5D P10D 80000000 1400000 3 1 0 2515000 6400000 2800000 1000000 100000 <div> <div> Reimbursements are recorded as a reduction to research and development expense on the Consolidated Statements of Operations. <div /></div> </div> 350000 750000 604394 35.81 34000 2627000 93.63 false --12-31 Q2 2017 2017-06-30 10-Q 0001466301 48879354 Yes Accelerated Filer Clovis Oncology, Inc. CLVS

1300000

100000

<div> <div> 8. Other Accrued Expenses   Other accrued expenses were comprised of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:73.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued personnel costs </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11,928 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 15,850 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued interest payable </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,097 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,096 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Income tax payable </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 662 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 556 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued corporate legal fees and professional services </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,072 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 589 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued royalties </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,551 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued sales deductions </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,003 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued expenses - other </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,535 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 396 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 21,848 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 19,487 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

10912000

13360000

121000

1143000

-151000

-245000

19487000

21848000

2551000

-47460000

-383000

-47077000

-43717000

-153000

-43564000

-45050000

-105000

-44945000

-47580000

-146000

-47434000

-47118000

-151000

-46967000

-44306000

-151000

-44155000

1174950000

1752943000

20542000

13924000

6618000

9577000

6615000

2962000

19563000

8991000

10572000

10617000

4825000

5792000

616000

309000

635000

318000

800000

400000

5101000

4646000

455000

11019000

4646000

6373000

364557000

849896000

279410000

715771000

252358000

202361000

49997000

202361000

49997000

202361000

49997000

630332000

450588000

179744000

450588000

179744000

450588000

179744000

7000

14000

50004000

179758000

<div> <div> As of June 30, 2017, the fair value and gross unrealized losses of available-for-sale securities that have been in a continuous unrealized loss position for less than 12 months were as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:72.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:00.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:00.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Losses </td> <td valign="bottom" style="width:00.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> U.S. treasury securities </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 179,744 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (14) </td> <td valign="bottom" style="width:00.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

14000

179744000

49997000

179744000

179758000

179744000

49997000

179744000

<div> <div> As of June 30, 2017, the amortized cost and fair value of available-for-sale securities by contractual maturity were (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Due in one year or less </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 179,758 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 179,744 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Due in one year to two years </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 179,758 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 179,744 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div>     Basis of Presentation   All financial information presented includes the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.   The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments, consisting only of normal recurring adjustments that, in the opinion of management, are necessary to fairly state our financial position, results of operations and cash flows for the periods presented herein. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2016 (“2016 Form 10-K”) for a broader discussion of our business and the opportunities and risks inherent in such business. <div /></div> </div>

-24661000

<div> <div> 1. Nature of Business and Basis of Presentation   Clovis Oncology, Inc. (together with its consolidated subsidiaries, the “Company”, “Clovis”, “we”, “our”, “us”) is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and other international markets. We have and intend to continue to license or acquire rights to oncology compounds in all stages of development. In exchange for the right to develop and commercialize these compounds, we generally expect to provide the licensor with a combination of upfront payments, milestone payments and royalties on future sales. In addition, we generally expect to assume the responsibility for future drug development and commercialization costs. We currently operate in one segment. Since inception, our operations have consisted primarily of developing in-licensed compounds, evaluating new product acquisition candidates and general corporate activities.   During the second quarter of 2016, we completed the submission of our New Drug Application (“NDA”) with the U.S. Food and Drug Administration (“FDA”) for approval of rucaparib in the U.S. On December 19, 2016, the FDA approved Rubraca® (rucaparib) tablets as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. We began selling Rubraca in the U.S. in the fourth quarter of 2016. Our Marketing Authorization Application (MAA) for rucaparib that was submitted to the European Medicines Agency (“EMA”) for an ovarian cancer treatment indication comparable to what was approved by the FDA is currently under review. We anticipate an opinion from the Committee for Medicinal Products for Human Use (CHMP) in late 2017, and, pending a favorable opinion from the CHMP, a potential approval would follow during the first quarter of 2018.  Following a potential approval for the treatment indication, we intend to submit a supplemental application for the second-line or later maintenance treatment indication, for which we anticipate a potential approval during the third quarter of 2018.   Basis of Presentation   All financial information presented includes the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.   The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments, consisting only of normal recurring adjustments that, in the opinion of management, are necessary to fairly state our financial position, results of operations and cash flows for the periods presented herein. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2016 (“2016 Form 10-K”) for a broader discussion of our business and the opportunities and risks inherent in such business.   Use of Estimates   The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates, including estimates related to revenue deductions, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.   Liquidity   We have incurred significant net losses since inception and have relied on our ability to fund our operations through debt and equity financings. We expect operating losses and negative cash flows to continue for the foreseeable future. As we continue to incur losses, transition to profitability is dependent upon achieving a level of revenues from Rubraca adequate to support our cost structure. We may never achieve profitability, and unless or until we do, we will continue to need to raise additional cash.   In January 2017, we sold 5,750,000 shares of our common stock in a public offering at $41.00 per share. The net proceeds from the offering were $221.2 million, after deducting underwriting discounts and commissions and offering expenses. In June 2017, we sold 3,920,454 shares of our common stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.9 million, after deducting underwriting discounts and commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including sales and marketing expenses associated with Rubraca in the United States and, if approved by the EMA, in Europe, funding of our development programs, selling, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on current estimates, we believe that our existing cash, cash equivalents and available-for-sale securities will allow us to fund our operating plan through at least the next 12 months. <div /></div> </div>

278756000

228379000

216186000

491786000

-50377000

275600000

<div> <div> <a name="_AEIOULastRenderedPageBreakAEIOU33"></a><a name="_AEIOULastRenderedPageBreakAEIOU32"></a>14. Commitments and Contingencies   Royalty and License Fee Commitments   We have entered into certain license agreements, as identified in Note 12, License Agreements, with third parties that include the payment of development and regulatory milestones, as well as royalty payments, upon the achievement of pre-established development, regulatory and commercial targets. Our payment obligation related to these license agreements is contingent upon the successful development, regulatory approval and commercialization of the licensed products. Due to the nature of these arrangements, the future potential payments are inherently uncertain, and accordingly, we only recognize payment obligations which are probable and estimable as of the balance sheet date. Milestone liabilities of $21.0 million and $20.1 million are recorded on our Consolidated Balance Sheets at June 30, 2017 and December 31, 2016, respectively, and relate to milestone payments for the licensing of our rucaparib product, which was approved by the FDA on December 19, 2016.   Manufacture and Services Agreement Commitments   On October 3, 2016, we entered into a Manufacturing and Services Agreement (the “Agreement”) with a non-exclusive third-party supplier for the production of the active ingredient for Rubraca. Under the terms of the Agreement, we will provide the third-party supplier a rolling forecast for the supply of the active ingredient in Rubraca that will be updated by us on a quarterly basis. We are obligated to order material sufficient to satisfy an initial quantity specified in any forecast. In addition, the third-party supplier will construct, in its existing facility, a production train that will be exclusively dedicated to the manufacture of the Rubraca active ingredient.  We are obligated to make scheduled capital program fee payments toward capital equipment and other costs associated with the construction of the dedicated production train. Further, once the facility is operational, we are obligated to pay a fixed facility fee each quarter for the duration of the Agreement, which expires on December 31, 2025, unless extended by mutual consent of the parties. As of June 30, 2017, $183.6  million of purchase commitments exist under the Agreement.    Legal Proceedings   We and certain of our officers were named as defendants in several lawsuits, as described below. We cannot reasonably predict the outcome of these legal proceedings, nor can we estimate the amount of loss or range of loss, if any, that may result. An adverse outcome in these proceedings could have a material adverse effect on our results of operations, cash flows or financial condition.   On November 19, 2015, Sonny P. Medina, a purported Clovis shareholder, filed a purported shareholder class action complaint in the United States District Court for the District of Colorado (the “Medina Complaint”). The Medina Complaint purported to be asserted on behalf of a class of persons who purchased Clovis stock between May 20, 2014 and November 13, 2015, and it generally alleged that Clovis and certain of its officers violated federal securities laws by making allegedly false and misleading statements regarding the progress toward FDA approval and the potential for market success of rociletinib.   Throughout November and December 2015, three other purported shareholders filed similar purported class actions concerning alleged misstatements about rociletinib. On January 19, 2016, a number of motions were filed seeking to consolidate the shareholder class actions into one matter and for appointment of a lead plaintiff. On February 18, 2016, the Medina Court consolidated the various actions into a single proceeding and appointed M. Arkin (1999) LTD and Arkin Communications LTD (the “Arkin Plaintiffs”) as the lead plaintiffs and Bernstein Litowitz Berger & Grossmann LLP as lead counsel for the putative class.   The Arkin Plaintiffs filed a consolidated complaint on May 6, 2016 (the “Consolidated Complaint”). The Consolidated Complaint named as defendants the Company and certain of its current and former officers (the “Clovis Defendants”), certain underwriters (the “Underwriter Defendants”) for a Company follow-on offering conducted in July 2015 (the “July 2015 Offering”), and certain Company venture capital investors (the “Venture Capital Defendants”). The Consolidated Complaint alleged that defendants violated particular sections of the Securities Exchange Act of 1934 (the “Exchange Act”) and the Securities Act of 1933 (the “Securities Act”). The purported misrepresentations and omissions concerned allegedly misleading statements about rociletinib. The consolidated action was purportedly brought on behalf of investors who purchased the Company’s securities between May 31, 2014 and April 7, 2016 (with respect to the Exchange Act claims) and investors who purchased the Company’s securities pursuant or traceable to the July 2015 Offering (with respect to the Securities Act claims). The Consolidated Complaint sought unspecified compensatory and recessionary damages.   The Clovis Defendants, the Underwriter Defendants and the Venture Capital Defendants filed motions to dismiss on July 27, 2016. On February 9, 2017, the Medina Court issued an opinion and order granting in part and denying in part the Clovis Defendants’ motion to dismiss, granting in part and denying in part the Underwriter Defendants’ motion to dismiss, and granting the Venture Capital Defendants’ motion to dismiss. On February 22, 2017, the Arkin Plaintiffs filed an amended consolidated class action complaint, directed solely at repleading its Section 12(a) claims against the Underwriter Defendants.   On March 14, 2017, the Clovis Defendants and the Arkin Plaintiffs participated in a mediation, which did not result in a settlement.   On June 18, 2017, the Clovis Defendants entered into a stipulation and agreement of settlement with the Arkin Plaintiffs whereby Clovis will issue to the plaintiffs and participating class members  a total consideration comprised of $25.0 million in cash and the issuance of a to be determined number of shares of Clovis common stock (the “Settlement Shares”) equal to $117.0 million divided by the volume weighted average price of Clovis common stock over the 10 trading days immediately preceding the date of the hearing set by the Medina Court to consider the final approval of the settlement. The cash portion of the consideration is expected to be funded by Clovis’ insurance carriers. At June 30, 2017, the liability for the issuance of the shares and cash, including the amount to be reimbursed through insurance proceeds, was recorded to accrued liability for legal settlement on the Consolidated Balance Sheets in the amount of approximately $142.0 million and a receivable of approximately $25.0 million from the insurance carriers on the Consolidated Balance Sheets. Clovis will issue the Settlement Shares no later than 5 business days after the date the judgment is entered by the Medina Court approving the settlement whereby the issuance of the shares will be recorded in common stock and additional paid-in capital and the accrued liability for legal settlement will be cleared.   As the settlement agreement is in response to the alleged violation of securities laws by certain of our officers, we have determined that the resulting loss does not relate to activities that are in the normal course of our operations and therefore, should not be recognized in operating losses for the period. Accordingly, we have recognized the entire expense associated to the settlement agreement in legal settlement loss within the other income (expense), net of insurance receivable on the Consolidated Statements of Operations and Comprehensive Loss.   On July 14, 2017, the Medina Court issued an order preliminarily approving the settlement. A final hearing to determine whether the settlement should be approved is scheduled for October 26, 2017.   On January 22, 2016, the Electrical Workers Local #357 Pension and Health & Welfare Trusts, a purported shareholder of Clovis, filed a purported class action complaint (the “Electrical Workers Complaint”) against Clovis and certain of its officers, directors, investors and underwriters in the Superior Court of the State of California, County of San Mateo. The Electrical Workers Complaint purports to be asserted on behalf of a class of persons who purchased stock in the July 2015 Offering. The Electrical Workers Complaint generally alleges that the defendants violated the Securities Act because the offering documents for the July 2015 Offering contained allegedly false and misleading statements regarding the progress toward FDA approval and the potential for market success of rociletinib. The Electrical Workers Complaint seeks unspecified damages. On June 30, 2016, the Electrical Workers Plaintiffs filed an amended complaint asserting substantially similar claims (the “Electrical Workers Amended Complaint”).   On September 23, 2016, following briefing and after hearing oral argument, the Electrical Workers Court granted defendants’ motion to stay proceedings pending resolution of the Medina action. Per the order to stay proceedings, the parties’ first status report as to the progress of the Medina action was filed on March 23, 2017. The parties’ second status report is due on September 21, 2017.   The Company intends to vigorously defend against the allegations in the Electrical Workers Amended Complaint, but there can be no assurance that the defense will be successful.   On November 10, 2016, Antipodean Domestic Partners (“Antipodean”) filed a complaint (the “Antipodean Complaint”) against Clovis and certain of its officers, directors and underwriters in New York Supreme Court, County of New York. The Antipodean Complaint alleges that the defendants violated certain sections of the Securities Act by making allegedly false statements to Antipodean and in the Offering Materials for the July 2015 Offering relating to the efficacy of rociletinib, its safety profile, and its prospects for market success. In addition to the Securities Act claims, the Antipodean Complaint also asserts Colorado state law claims and common law claims. Both the state law and common law claims are based on allegedly false and misleading statements regarding rociletinib’s progress toward FDA approval. The Antipodean Complaint seeks compensatory, recessionary, and punitive damages.   On December 15, 2016, the Antipodean Plaintiffs filed an amended complaint (the “Antipodean Amended Complaint”) asserting substantially the same claims against the same defendants and purporting to correct certain details in the original Antipodean Complaint.   On January 31, 2017, Defendants filed a motion to stay the Antipodean action pending resolution of the Medina action in the District of Colorado. Defendants also filed a motion to dismiss the Antipodean Amended Complaint on March 29, 2017. A hearing on both motions is scheduled for August 8, 2017.   On March 14, 2017, the Clovis Defendants and Antipodean participated in a mediation, which did not result in a settlement. The Company intends to vigorously defend against the allegations in the Antipodean Amended Complaint.  However, there can be no assurance that the defense will be successful.   Clovis received a letter dated May 31, 2016 from an alleged owner of its common stock, which purports to set forth a demand for inspection of certain of our books and records pursuant to 8 Del. C. § 220 (the “Macalinao Demand Letter”). Clovis also received a letter dated December 15, 2016 from a second alleged owner of Clovis common stock, which purports to set forth a similar demand for inspection of the Company’s books and records pursuant to 8 Del. C. § 220 (the “McKenry Demand Letter”). Both the Macalinao and McKenry Demand Letters were purportedly made for the purposes of investigating alleged misconduct at the Company relating to rociletinib. Clovis submitted a response to the Macalinao Demand Letter on June 24, 2016, and likewise submitted a response to the McKenry Demand Letter on January 4, 2017. The Company produced certain books and records in response to the Macalinao and McKenry Demand Letters in January and February 2017, respectively.   In March 2017, Macalinao and McKenry (the “Derivative Plaintiffs”) filed shareholder derivative complaints against certain directors and officers of the Company in the Court of Chancery of the State of Delaware. On May 4, 2017, the Macalinao and McKenry actions were consolidated for all purposes in a single proceeding under the caption In re Clovis Oncology, Inc. Derivative Litigation, Case No, 2017-0222 (the “Consolidated Derivative Action”).   On May 18, 2017, the Derivative Plaintiffs filed the Consolidated Verified Shareholder Derivative Complaint (the “Consolidated Derivative Complaint”). The Consolidated Derivative Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by allegedly causing or allowing misrepresentations of the Company’s business operations and prospects, failing to ensure that the TIGER-X clinical trial was being conducted in accordance with applicable rules, regulations and protocols, and engaging in insider trading. The Consolidated Derivative Complaint purported to rely on documents produced by the Company in response to the Macalinao and McKenry Demand Letters. The Consolidated Derivative Complaint sought, among other things, an award of money damages.   On July 13, 2017, the court ordered the following briefing schedule with respect to the defendants’ forthcoming motion to dismiss the Consolidated Derivative Complaint: Defendants’ motion to dismiss was due, and was filed, on July 31, 2017; Plaintiffs’ opposition is due on August 30, 2017; and Defendants’ reply is due on September 14, 2017.   The Company intends to vigorously defend against the allegations in the Consolidated Derivative Complaint, but there can be no assurance that the defense will be successful.   On May 10, 2017, John Solak, a purported shareholder of the Company, filed a shareholder derivative complaint in the Court of Chancery of the State of Delaware (the “Solak Complaint”) against certain directors and an officer of the Company. The Solak Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by adopting a compensation plan that overcompensated the non-employee director defendants, in relation to companies of comparable market capitalization and size. The Solak Complaint also alleged claims of waste of corporate assets and unjust enrichment due to this allegedly wrongful compensation plan. The Solak Complaint sought, among other things, an award of money damages and the imposition of corporate governance reforms.   On June 12, 2017, the parties in the Solak action entered into a stipulation extending the defendants’ time to respond to the Solak Complaint until August 11, 2017, which was entered by the Court on June 20, 2017.     The Company intends to vigorously defend against the allegations in the Solak Complaint, but there can be no assurance that the defense will be successful.   On March 20, 2017, a purported shareholder of the Company, filed a shareholder derivative complaint (the “Guo Complaint”) against certain officers and directors of the Company in the United States District Court for the District of Colorado. The Guo Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by either recklessly or with gross negligence approving or permitting misrepresentations of the Company’s business operations and prospects. The Guo Complaint also alleged claims for waste of corporate assets and unjust enrichment. Finally, the Guo Complaint alleged that certain of the individual defendants violated Section 14(a) of the Securities Exchange Act, by allegedly negligently issuing, causing to be issued, and participating in the issuance of materially misleading statements to stockholders in the Company’s Proxy Statement on Schedule DEF 14A in connection with the 2015 Annual Meeting of Stockholders, held on June 11, 2015. The Guo Complaint sought, among other things, an award of money damages.   On June 19, 2017, the parties filed a joint motion to stay the Guo action pending resolution of the motion to dismiss the Consolidated Derivative Complaint. On June 20, 2017, the court granted the motion to stay.   The Company intends to vigorously defend against the allegations in the Guo Complaint, but there can be no assurance that the defense will be successful.   In addition, the Company has received inquiries and requests for information from governmental agencies, including the U.S. Securities and Exchange Commission and the U.S. Department of Justice, relating to the Company’s regulatory update announcement in November 2015 that the FDA requested additional clinical data on the efficacy and safety of rociletinib. The Company is continuing to cooperate with these agencies with respect to their investigations. The proposed settlement of the Medina action does not resolve these inquiries and the Company cannot predict their timing or outcome. <div /></div> </div>

0.001

100000000

38724090

48843131

38724090

48843131

39000

49000

-210304000

-130647000

-230575000

-172574000

281126000

281761000

281800000

743000

372000

<div> <div> Cost of Sales – Product   Product cost of sales consists primarily of materials, third-party manufacturing costs as well as freight and royalties owed to our licensing partners for Rubraca sales. Based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, certain of the manufacturing costs of Rubraca units recognized as revenue during the three and six months ended June 30, 2017 were expensed prior to the December 19, 2016 FDA approval, and therefore are not included in costs of sales during the current period. We expect cost of sales to increase in relation to product revenues as we deplete these inventories and we expect to use the remaining pre-commercialization inventory for product sales through the third quarter of 2017.   Cost of Sales – Intangible Asset Amortization   Cost of sales for intangible asset amortization consists of the amortization of capitalized milestone payments made to our licensing partners upon FDA approval of Rubraca. Milestone payments are amortized on a straight-line basis over the estimated remaining patent life of Rubraca.  <div /></div> </div>

61.88

16.1616

P30D

1.50

287500000

487000000

0.025

2021-09-15

2018-09-15

1.00

P7Y

<div> <div> The debt issuance costs are presented as a deduction from convertible senior notes on the Consolidated Balance Sheets and are amortized as interest expense over the expected life of the Notes using the effective interest method. We determined the expected life of the debt was equal to the seven-year term of the Notes. <div /></div> </div>

9200000

-33207000

-1266000

20062000

21011000

1406000

4333000

632000

550000

1281000

<div> <div> 11. Share-Based Compensation   Share-based compensation expense for all equity based programs, including stock options, restricted stock units and the employee stock purchase plan, for the three and six months ended June 30, 2017 and 2016 was recognized in the accompanying Consolidated Statements of Operations as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:26.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months ended June 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:23.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six months ended June 30,  </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,825 </td> <td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,615 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8,991 </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13,924 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Selling, general and administrative </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,792 </td> <td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,962 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 10,572 </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,618 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total share-based compensation expense </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10,617 </td> <td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 9,577 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 19,563 </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,542 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   We did not recognize a tax benefit related to share-based compensation expense during the three and six months ended June 30, 2017 and 2016, respectively, as we maintain net operating loss carryforwards and have established a valuation allowance against the entire net deferred tax asset as of June 30, 2017.   Stock Options   The following table summarizes the activity relating to our options to purchase common stock for the six months ended June 30, 2017:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Term (Years) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Thousands) </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at December 31, 2016 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,520,482 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 42.00 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 778,700 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (372,464) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (199,985) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at June 30, 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,726,733 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 45.43 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.6 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 276,451 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested and expected to vest at June 30, 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,364,276 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 45.30 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7.4 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 259,650 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Vested and exercisable at June 30, 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,935,211 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 44.63 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.2 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 143,983 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of $93.63 as of June 30, 2017, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date.   The following table summarizes information about our stock options as of and for the three and six months ended June 30, 2017 and 2016 (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:45.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:26.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months ended June 30,  </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:23.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six months ended June 30,  </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td colspan="2" valign="bottom" style="width:12.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td colspan="2" valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td colspan="2" valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Weighted-average grant date fair value per share </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 44.94 </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11.01 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 46.53 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14.65 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Intrinsic value of options exercised </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,759 </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 578,525 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 14,284 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 624,925 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash received from stock option exercises </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,439 </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 352,423 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11,113 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 407,523 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   As of June 30, 2017, the unrecognized share-based compensation expense related to unvested options, adjusted for expected forfeitures, was $83.4 million and the estimated weighted-average remaining vesting period was 2.6 years.   Restricted Stock   During 2016, we issued restricted stock units (“RSUs”) to certain employees under the 2011 Stock Incentive Plan. The RSUs vest either (i) over two years, with 50% vesting one year from the date of grant and the remaining 50% vesting two years from the date of grant or (ii) 25% vest one year from the date of grant with the remaining RSUs vesting ratably each subsequent quarter over the following three years, as defined in the grant agreement. Vested RSUs are payable in shares of our common stock at the end of the vesting period. RSUs are measured based on the fair value of the underlying stock on the grant date. The minimum statutory tax on the value of common stock shares issued to employees upon vesting are paid by us through the sale of registered shares of our common stock.   The following table summarizes the activity relating to our unvested RSUs for the six months ended June 30, 2017: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Grant Date </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Units </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested at December 31, 2016 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 562,458 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 24.70 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 214,984 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 61.67 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Vested </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,443) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 19.37 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (27,177) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24.08 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Unvested as of June 30, 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 705,822 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 36.32 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected to vest after June 30, 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 604,394 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 35.81 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   As of June 30, 2017, the unrecognized share-based compensation expense related to unvested RSUs, adjusted for expected forfeitures, was $18.5 million and the estimated weighted-average remaining vesting period was 3.4 years. <div /></div> </div>

<div> <div> The following table summarizes information about our stock options as of and for the three and six months ended June 30, 2017 and 2016 (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:45.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:26.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months ended June 30,  </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:23.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six months ended June 30,  </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td colspan="2" valign="bottom" style="width:12.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td colspan="2" valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">     </td> <td colspan="2" valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Weighted-average grant date fair value per share </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 44.94 </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11.01 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 46.53 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14.65 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Intrinsic value of options exercised </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,759 </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 578,525 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 14,284 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 624,925 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash received from stock option exercises </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,439 </td> <td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 352,423 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11,113 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 407,523 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

2882000

52000

-5.54

-3.37

-5.24

-3.88

<div> <div> Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury-stock method for the stock options and RSUs and the if-converted method for the Notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share. <div /></div> </div>

<div> <div> 13. Net Loss Per Common Share   Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury-stock method for the stock options and RSUs and the if-converted method for the Notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share.   The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:63.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:33.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three and Six months ended June 30,  </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:15.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Common shares under option </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,373 </td> <td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 455 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Convertible senior notes </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,646 </td> <td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,646 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total potential dilutive shares </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11,019 </td> <td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,101 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

106000

565000

15850000

11928000

407523

352423

11113

5439

P2Y7M6D

P3Y4M24D

18500000

83400000

<div> <div> 3. Financial Instruments and Fair Value Measurements   Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.   The three levels of inputs that may be used to measure fair value include:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 95.00%;margin-left:24.5pt;"> <tr> <td valign="top" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Level 1: </td> <td valign="top" style="width:91.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Quoted prices in active markets for identical assets or liabilities. Our Level 1 assets consist of money market investments. We do not have Level 1 liabilities. </td> </tr> <tr> <td valign="top" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:91.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Level 2: </td> <td valign="top" style="width:91.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Our Level 2 assets consist of U.S. treasury securities. We do not have Level 2 liabilities. </td> </tr> <tr> <td valign="top" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="top" style="width:91.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Level 3: </td> <td valign="top" style="width:91.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Unobservable inputs that are supported by little or no market activity. We do not have Level 3 assets or liabilities that are measured at fair value on a recurring basis. </td> </tr> </table></div>   The following table identifies our assets and liabilities that were measured at fair value on a recurring basis (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 1 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 2 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 3 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> June 30, 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Assets: </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Money market </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 450,588 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 450,588 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> U.S. treasury securities </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 179,744 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 179,744 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total assets at fair value </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 630,332 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 450,588 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 179,744 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2016 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Assets: </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Money market </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 202,361 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 202,361 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> U.S. treasury securities </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 49,997 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 49,997 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total assets at fair value </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 252,358 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 202,361 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 49,997 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   There were no transfers between the Level 1 and Level 2 categories or into or out of the Level 3 category during the three and six months ended June 30, 2017.   Financial instruments not recorded at fair value include our convertible senior notes. At June 30, 2017, the carrying amount of the convertible senior notes was $281.8 million, which represents the aggregate principal amount net of remaining debt issuance costs, and the fair value was $487.0 million. The fair value was determined using Level 2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system. See Note 9, Convertible Senior Notes for discussion of the convertible senior notes. <div /></div> </div>

-53000

-796000

13617000

743000

1486000

21100000

21047000

20304000

-368000

183000

-83000

76000

-170000

-117000000

57192000

62018000

<div> <div> 7. Intangible Assets and Goodwill   Intangible assets related to capitalized milestones under license agreements consisted of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.12%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Intangible asset - milestones </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21,100 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21,100 </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accumulated amortization </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (796) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (53) </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total intangible asset, net </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,304 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21,047 </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>    The estimated useful lives of these intangible assets are based on the estimated remaining patent life of Rubraca and extend through 2031.   We recorded amortization expense of $0.4 million and $0.8 million related to capitalized milestone payments during the three and six months ended June 30, 2017, respectively, included in cost of sales – intangible asset amortization at the Consolidated Statements of Operations and Comprehensive Loss. There was no amortization expense during the three and six months ended June 30, 2016.   Estimated future amortization expense associated with intangibles is expected to be as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2017 (remaining) </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 743 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,486 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,486 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,486 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,486 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Thereafter </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 13,617 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,304 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   The change in goodwill established as part of the purchase accounting of EOS in November 2013 consisted of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:84.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at December 31, 2016 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 57,192 </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change in foreign currency gains and losses </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,826 </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at June 30, 2017 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 62,018 </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

4826000

104517000

-245954000

-158373000

-235214000

-176667000

-33240000

-29059000

-1365000

-1281000

3608000

3202000

1023000

6478000

270000

3166000

-1260000

36855000

25000000

21047000

20304000

4210000

2106000

5178000

2598000

3594000

1797000

3594000

1797000

<div> <div> The following table sets forth total interest expense recognized during the three and six months ended June 30, 2017 and 2016 (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:44.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:26.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months ended June 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:23.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six months ended June 30,  </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Contractual interest expense </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,797 </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,797 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,594 </td> <td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,594 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accretion of interest on milestone liability </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 483 </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 949 </td> <td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Amortization of debt issuance costs </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 318 </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 309 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 635 </td> <td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 616 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total interest expense </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,598 </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,106 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,178 </td> <td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,210 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

3594000

2096000

2097000

<div> <div> 5. Inventories   We generally have two categories of inventory: work-in-process and finished goods. As of June 30, 2017, the carrying value of all of our product inventory, which consisted only of the Rubraca API, was categorized as work-in-process. The costs related to our finished goods on-hand as of June 30, 2017 were expensed as incurred prior to the commercialization of Rubraca on December 19, 2016. The carrying value of our inventory as of December 31, 2016 was zero.   At June 30, 2017, other assets on the Consolidated Balance Sheets includes a cash deposit of $31.8 million made to a manufacturer for the purchase of inventory which we do not expect to be commercially consumed within the next twelve months. <div /></div> </div>

6478000

<div> <div> Inventory   Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. We began capitalizing incurred inventory related costs upon the regulatory approval of Rubraca. Prior to the regulatory approval of Rubraca, we incurred costs for the manufacture of the drug that could potentially be available to support the commercial launch of Rubraca and all such costs were recognized as research and development expense. We periodically analyze our inventory levels, and write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and/or inventory in excess of expected sales requirements as cost of product revenues. Expired inventory would be disposed of and the related costs would be written off as cost of product revenues.    The active pharmaceutical ingredient (“API”) in Rubraca is currently produced by a single supplier. As the API has undergone significant manufacturing specific to its intended purpose at the point it is purchased by us, we classify the API as work-in-process inventory.        Our other significant accounting policies are described in Note 2, Summary of Significant Accounting Policies of the Notes to the Consolidated Financial Statements included in our 2016 Form 10-K.   From time to time, the Financial Accounting Standards Board (“FASB”) or other standards setting bodies issue new accounting pronouncements.  Updates to the FASB Accounting Standards Codification (“ASC”) are communicated through issuance of an Accounting Standards Update (“ASU”). <div /></div> </div>

<div> <div> 4. Available-for-Sale Securities   As of June 30, 2017, available-for-sale securities consisted of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:49.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gains </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Losses </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> U.S. treasury securities </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 179,758 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (14) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 179,744 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   As of December 31, 2016, available-for-sale securities consisted of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.16%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:49.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gains </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Losses </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> U.S. treasury securities </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 50,004 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (7) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 49,997 </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   As of June 30, 2017, the fair value and gross unrealized losses of available-for-sale securities that have been in a continuous unrealized loss position for less than 12 months were as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:72.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:00.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:00.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Losses </td> <td valign="bottom" style="width:00.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> U.S. treasury securities </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 179,744 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (14) </td> <td valign="bottom" style="width:00.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   We have concluded that decline in the market value of the available-for-sales securities is temporary. A decline in the market value of a security below its cost that is deemed to be other than temporary is charged to earnings and results in the establishment of a new cost basis for the security. Factors evaluated to determine if an investment is other-than-temporarily impaired include significant deterioration in earnings performance, credit rating, asset quality or business prospects of the issuer; adverse changes in the general market conditions in which the issuer operates; and our intent and ability to hold the security until an anticipated recovery in value occurs.   As of June 30, 2017, the amortized cost and fair value of available-for-sale securities by contractual maturity were (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Due in one year or less </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 179,758 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 179,744 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Due in one year to two years </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 179,758 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 179,744 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

368191000

506103000

364557000

849896000

85659000

219377000

142000000

<div> <div> 9. Convertible Senior Notes   On September 9, 2014, we completed a private placement of $287.5 million aggregate principal amount of 2.5% convertible senior notes due 2021 (the “Notes”) resulting in net proceeds of $278.3 million after deducting offering expenses. In accordance with the accounting guidance, the conversion feature did not meet the criteria for bifurcation, and the entire principal amount was recorded as a long-term liability on the Consolidated Balance Sheets.   The Notes are governed by the terms of the indenture between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee. The Notes are senior unsecured obligations and bear interest at a rate of 2.5% per year, payable semi-annually in arrears on March 15 and September 15 of each year. The Notes will mature on September 15, 2021, unless earlier converted, redeemed or repurchased.   Holders may convert all or any portion of the Notes at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the holders will receive shares of our common stock at an initial conversion rate of 16.1616 shares per $1,000 in principal amount of Notes, equivalent to a conversion price of approximately $61.88 per share. The conversion rate is subject to adjustment upon the occurrence of certain events described in the indenture, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date or upon our issuance of a notice of redemption, we will increase the conversion rate for holders who elect to convert the Notes in connection with such a corporate event or during the related redemption period in certain circumstances.   On or after September 15, 2018, we may redeem the Notes, at our option, in whole or in part, if the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending not more than two trading days preceding the date on which we provide written notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Notes.   If we undergo a fundamental change, as defined in the indenture, prior to the maturity date of the Notes, holders may require us to repurchase for cash all or any portion of the Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.   The Notes rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the Notes; equal in right of payment to all of our liabilities that are not so subordinated; effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries.   In connection with the issuance of the Notes, we incurred $9.2 million of debt issuance costs. The debt issuance costs are presented as a deduction from convertible senior notes on the Consolidated Balance Sheets and are amortized as interest expense over the expected life of the Notes using the effective interest method. We determined the expected life of the debt was equal to the seven-year term of the Notes. As of June 30, 2017 and December 31, 2016, the balance of unamortized debt issuance costs was $5.7 million and $6.4 million, respectively.   The following table sets forth total interest expense recognized during the three and six months ended June 30, 2017 and 2016 (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:44.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:26.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months ended June 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:23.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six months ended June 30,  </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Contractual interest expense </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,797 </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,797 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,594 </td> <td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,594 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accretion of interest on milestone liability </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 483 </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 949 </td> <td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Amortization of debt issuance costs </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 318 </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 309 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 635 </td> <td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 616 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total interest expense </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,598 </td> <td valign="bottom" style="width:02.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,106 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,178 </td> <td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,210 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

1943000

558440000

99244000

-133864000

-151670000

-149541000

-212714000

-129314000

-233849000

-175386000

<div> <div>   Recently Issued Accounting Standards   In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” and has subsequently issued several supplemental and/or clarifying ASUs (collectively, “ASC 606”). ASC 606 prescribes a single common revenue standard that replaces most existing U.S. GAAP revenue recognition guidance. ASC 606 is intended to provide a more consistent interpretation and application of the principles outlined in the standard across filers in multiple industries and within the same industries compared to current practices, which should improve comparability.  Adoption of ASC 606 is required for annual and interim periods beginning after December 15, 2017. Upon adoption, we must elect to adopt either retrospectively to each prior reporting period presented or use the modified retrospective transition method with the cumulative effect of initial adoption recognized at the date of initial application. We expect to apply the new standard using the modified retrospective method upon its adoption date on January 1, 2018.    We have begun a comprehensive scoping process to identify and disaggregate all revenue streams that may be impacted by the adoption of ASC 606. To date, we have examined our revenue recognition policy specific to revenue streams from representative contracts governing product sales from Rubraca and have come to preliminary conclusions on the impact of the new standard using the 5-step process prescribed by ASC 606. However, a detailed analysis of individual contracts representative of each of the revenue streams planned for the assessment phase of our implementation plan may impact these preliminary conclusions. We are continuing to assess ASC 606’s impact on our financial statements.   In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. ASU 2016-02 requires modified retrospective adoption for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures.   In January 2017, the FASB issued ASU No. 2017-01, “Clarifying the Definition of a Business,” which clarifies the definition of a business in ASC 805. The guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is permitted. Currently, there is no impact to our consolidated financial statements and related disclosures, but we will adopt on January 1, 2018 for any business combinations and will consider adopting early for any acquisitions prior to January 1, 2018.   In May 2017, the FASB issued ASU 2017-09, “Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting”, which amends the scope of modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which we would be required to apply modification accounting under ASC 718. Specifically, we would not apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. The guidance is effective for annual reporting periods, including interim period within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures should we have a modification to our share-based payment awards in the future. <div /></div> </div>

-4357000

-1727000

-121315000

-118928000

241597000

156646000

135564000

72359000

-241597000

-156646000

-113899000

-57739000

396000

2535000

6679000

6766000

90000

135000

2468000

47648000

3851000

441000

3410000

-2094000

76000

-2170000

5178000

-8000

5186000

4448000

-3000

4451000

2132000

-1381000

3279000

2812000

2410000

-1333000

3274000

2812000

-1441000

-163000

-1278000

761000

-28000

789000

-1904000

3000

-1907000

-1636000

3000

-1639000

278000

48000

-5000

<div> <div>   6. Other Current Assets   Other current assets were comprised of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Receivable from partners </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 52 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,882 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prepaid insurance </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 817 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,234 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Prepaid expenses - other </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,012 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,109 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Receivable - other </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,750 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 364 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Other </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 135 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 90 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,766 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,679 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

221000

196000

946000

594000

364000

2750000

180000000

756000

249000

0.001

10000000

2109000

3012000

6427000

4854000

1234000

817000

278300000

221200000

546170000

324900000

1943000

12270000

100000000

50000000

-212714000

-233849000

4440000

4155000

183600000

300000

142337000

6200000

67729000

2600000

65555000

900000

33108000

-1131043000

-1364893000

<div> <div> Revenue Recognition   Product revenue is derived from sales of our product, Rubraca, in the United States. We distribute our product in the U.S. principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers. Our customers subsequently resell our products to patients and healthcare providers. Separately, we have arrangements with certain payors and other third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and other discounts.   Revenues from product sales are recognized when persuasive evidence of an arrangement exists, delivery has occurred and title of the product and associated risk of loss has passed to the customer, the price is fixed or determinable, collection from the customer has been reasonably assured and all performance obligations have been met and returns and allowances can be reasonably estimated. Revenue is recorded net of estimated rebates, chargebacks, discounts and other deductions as well as estimated product returns (collectively, “sales deductions”). We only recognize revenue on product sales once the product is resold to the patient or healthcare provider by the specialty distributor or specialty pharmacy provider, therefore reducing the significance of estimates made for product returns. To date, we have not had any product returns and, we currently do not have an accrual for product returns. We will continue to assess our estimate for product returns as we gain additional historical experience. <div /></div> </div>

21665000

14620000

<div> <div> Other accrued expenses were comprised of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:73.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued personnel costs </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11,928 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 15,850 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued interest payable </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,097 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,096 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Income tax payable </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 662 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 556 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued corporate legal fees and professional services </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,072 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 589 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued royalties </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,551 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued sales deductions </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,003 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued expenses - other </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,535 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 396 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 21,848 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 19,487 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the three months ended June 30, 2017 and 2016 as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Foreign Currency </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:14.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total Accumulated </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Translation Adjustments </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:14.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Losses) Gains </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other Comprehensive Loss </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at April 1, </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (46,967) </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (43,564) </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (151) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (153) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (47,118) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (43,717) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other comprehensive income (loss) </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,451 </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,170) </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (3) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 76 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,448 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,094) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total before tax </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (42,516) </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (45,734) </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (154) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (77) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (42,670) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (45,811) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Tax effect </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,639) </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 789 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  3 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (28) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,636) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 761 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at June 30,  </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,155) </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,945) </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (151) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (105) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,306) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (45,050) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the six months ended June 30, 2017 and 2016 as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Foreign Currency </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:14.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total Accumulated </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Translation Adjustments </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:14.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Losses) Gains </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other Comprehensive Loss </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at December 31,  </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (47,434) </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (47,077) </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (146) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (383) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (47,580) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (47,460) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other comprehensive income (loss) </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,186 </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,410 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (8) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 441 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,178 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,851 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total before tax </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (42,248) </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (43,667) </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (154) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 58 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (42,402) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (43,609) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Tax effect </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,907) </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,278) </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  3 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (163) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,904) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,441) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at June 30,  </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,155) </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,945) </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (151) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (105) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,306) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (45,050) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:63.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:33.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three and Six months ended June 30,  </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:15.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Common shares under option </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,373 </td> <td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 455 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Convertible senior notes </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,646 </td> <td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,646 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:63.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total potential dilutive shares </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11,019 </td> <td valign="bottom" style="width:02.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,101 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> As of June 30, 2017, available-for-sale securities consisted of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:49.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gains </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Losses </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> U.S. treasury securities </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 179,758 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (14) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 179,744 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   As of December 31, 2016, available-for-sale securities consisted of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.16%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:49.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gains </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Losses </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> U.S. treasury securities </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 50,004 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (7) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 49,997 </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> Share-based compensation expense for all equity based programs, including stock options, restricted stock units and the employee stock purchase plan, for the three and six months ended June 30, 2017 and 2016 was recognized in the accompanying Consolidated Statements of Operations as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:26.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months ended June 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:23.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six months ended June 30,  </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,825 </td> <td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,615 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8,991 </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13,924 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Selling, general and administrative </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,792 </td> <td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,962 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 10,572 </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,618 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total share-based compensation expense </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10,617 </td> <td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 9,577 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 19,563 </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,542 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The following table identifies our assets and liabilities that were measured at fair value on a recurring basis (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 1 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 2 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:06.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Level 3 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> June 30, 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Assets: </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Money market </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 450,588 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 450,588 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> U.S. treasury securities </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 179,744 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 179,744 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total assets at fair value </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 630,332 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 450,588 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 179,744 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2016 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Assets: </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Money market </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 202,361 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 202,361 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> U.S. treasury securities </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 49,997 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 49,997 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total assets at fair value </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 252,358 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 202,361 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 49,997 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> Estimated future amortization expense associated with intangibles is expected to be as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2017 (remaining) </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 743 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,486 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,486 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,486 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,486 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Thereafter </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 13,617 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,304 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> Intangible assets related to capitalized milestones under license agreements consisted of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.12%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Intangible asset - milestones </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21,100 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21,100 </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accumulated amortization </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (796) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (53) </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total intangible asset, net </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,304 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21,047 </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The change in goodwill established as part of the purchase accounting of EOS in November 2013 consisted of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:84.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at December 31, 2016 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 57,192 </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change in foreign currency gains and losses </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,826 </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at June 30, 2017 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 62,018 </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div>   Other current assets were comprised of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:13.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Receivable from partners </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 52 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,882 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prepaid insurance </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 817 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,234 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Prepaid expenses - other </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,012 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,109 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Receivable - other </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,750 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 364 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Other </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 135 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 90 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,766 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,679 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Term (Years) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Thousands) </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at December 31, 2016 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,520,482 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 42.00 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 778,700 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (372,464) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (199,985) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at June 30, 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5,726,733 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 45.43 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.6 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 276,451 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested and expected to vest at June 30, 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,364,276 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 45.30 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 7.4 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 259,650 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Vested and exercisable at June 30, 2017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,935,211 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 44.63 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.2 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 143,983 </td> <td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

19379000

9552000

65373000

36149000

20542000

19563000

P3Y

P1Y

P2Y

0.50

0.25

0.50

27177

24.08

214984

61.67

562458

705822

24.70

36.32

44443

19.37

624925

578525

14284

4759

199985

778700

14.65

11.01

46.53

44.94

276451000

5520482

5726733

42.00

45.43

P7Y7M6D

143983000

2935211

44.63

P6Y2M12D

259650000

5364276

45.30

P7Y4M24D

41.00

88.00

<div> <div> 2. Summary of Significant Accounting Policies   Revenue Recognition   Product revenue is derived from sales of our product, Rubraca, in the United States. We distribute our product in the U.S. principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers. Our customers subsequently resell our products to patients and healthcare providers. Separately, we have arrangements with certain payors and other third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and other discounts.   Revenues from product sales are recognized when persuasive evidence of an arrangement exists, delivery has occurred and title of the product and associated risk of loss has passed to the customer, the price is fixed or determinable, collection from the customer has been reasonably assured and all performance obligations have been met and returns and allowances can be reasonably estimated. Revenue is recorded net of estimated rebates, chargebacks, discounts and other deductions as well as estimated product returns (collectively, “sales deductions”). We only recognize revenue on product sales once the product is resold to the patient or healthcare provider by the specialty distributor or specialty pharmacy provider, therefore reducing the significance of estimates made for product returns. To date, we have not had any product returns and, we currently do not have an accrual for product returns. We will continue to assess our estimate for product returns as we gain additional historical experience.   Cost of Sales – Product   Product cost of sales consists primarily of materials, third-party manufacturing costs as well as freight and royalties owed to our licensing partners for Rubraca sales. Based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, certain of the manufacturing costs of Rubraca units recognized as revenue during the three and six months ended June 30, 2017 were expensed prior to the December 19, 2016 FDA approval, and therefore are not included in costs of sales during the current period. We expect cost of sales to increase in relation to product revenues as we deplete these inventories and we expect to use the remaining pre-commercialization inventory for product sales through the third quarter of 2017.   Cost of Sales – Intangible Asset Amortization   Cost of sales for intangible asset amortization consists of the amortization of capitalized milestone payments made to our licensing partners upon FDA approval of Rubraca. Milestone payments are amortized on a straight-line basis over the estimated remaining patent life of Rubraca.    Inventory   Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. We began capitalizing incurred inventory related costs upon the regulatory approval of Rubraca. Prior to the regulatory approval of Rubraca, we incurred costs for the manufacture of the drug that could potentially be available to support the commercial launch of Rubraca and all such costs were recognized as research and development expense. We periodically analyze our inventory levels, and write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and/or inventory in excess of expected sales requirements as cost of product revenues. Expired inventory would be disposed of and the related costs would be written off as cost of product revenues.    The active pharmaceutical ingredient (“API”) in Rubraca is currently produced by a single supplier. As the API has undergone significant manufacturing specific to its intended purpose at the point it is purchased by us, we classify the API as work-in-process inventory.        Our other significant accounting policies are described in Note 2, Summary of Significant Accounting Policies of the Notes to the Consolidated Financial Statements included in our 2016 Form 10-K.   From time to time, the Financial Accounting Standards Board (“FASB”) or other standards setting bodies issue new accounting pronouncements.  Updates to the FASB Accounting Standards Codification (“ASC”) are communicated through issuance of an Accounting Standards Update (“ASU”).   Recently Issued Accounting Standards   In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” and has subsequently issued several supplemental and/or clarifying ASUs (collectively, “ASC 606”). ASC 606 prescribes a single common revenue standard that replaces most existing U.S. GAAP revenue recognition guidance. ASC 606 is intended to provide a more consistent interpretation and application of the principles outlined in the standard across filers in multiple industries and within the same industries compared to current practices, which should improve comparability.  Adoption of ASC 606 is required for annual and interim periods beginning after December 15, 2017. Upon adoption, we must elect to adopt either retrospectively to each prior reporting period presented or use the modified retrospective transition method with the cumulative effect of initial adoption recognized at the date of initial application. We expect to apply the new standard using the modified retrospective method upon its adoption date on January 1, 2018.    We have begun a comprehensive scoping process to identify and disaggregate all revenue streams that may be impacted by the adoption of ASC 606. To date, we have examined our revenue recognition policy specific to revenue streams from representative contracts governing product sales from Rubraca and have come to preliminary conclusions on the impact of the new standard using the 5-step process prescribed by ASC 606. However, a detailed analysis of individual contracts representative of each of the revenue streams planned for the assessment phase of our implementation plan may impact these preliminary conclusions. We are continuing to assess ASC 606’s impact on our financial statements.   In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. ASU 2016-02 requires modified retrospective adoption for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures.   In January 2017, the FASB issued ASU No. 2017-01, “Clarifying the Definition of a Business,” which clarifies the definition of a business in ASC 805. The guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is permitted. Currently, there is no impact to our consolidated financial statements and related disclosures, but we will adopt on January 1, 2018 for any business combinations and will consider adopting early for any acquisitions prior to January 1, 2018.   In May 2017, the FASB issued ASU 2017-09, “Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting”, which amends the scope of modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which we would be required to apply modification accounting under ASC 718. Specifically, we would not apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. The guidance is effective for annual reporting periods, including interim period within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures should we have a modification to our share-based payment awards in the future.   <div /></div> </div>

-3634000

343793000

<div> <div> 10. Stockholders’ Equity   Common Stock   In January 2017, we sold 5,750,000 shares of our common stock in a public offering at $41.00 per share. The net proceeds from the offering were $221.2 million, after deducting underwriting discounts and commissions and offering expenses. In June 2017, we sold 3,920,454 shares of our common stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.9 million, after deducting underwriting discounts and commissions and offering expenses.   The holders of common stock are entitled to one vote per share on all matters to be voted upon by our stockholders. Subject to the preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by our Board of Directors.   Accumulated Other Comprehensive Loss   Accumulated other comprehensive loss consists of changes in foreign currency translation adjustments, which includes changes in a subsidiary’s functional currency, and unrealized gains and losses on available-for-sale securities.   The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the three months ended June 30, 2017 and 2016 as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Foreign Currency </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:14.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total Accumulated </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Translation Adjustments </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:14.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Losses) Gains </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other Comprehensive Loss </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at April 1, </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (46,967) </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (43,564) </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (151) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (153) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (47,118) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (43,717) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other comprehensive income (loss) </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,451 </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,170) </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (3) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 76 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,448 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,094) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total before tax </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (42,516) </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (45,734) </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (154) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (77) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (42,670) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (45,811) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Tax effect </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,639) </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 789 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  3 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (28) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,636) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 761 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at June 30,  </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,155) </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,945) </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (151) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (105) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,306) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (45,050) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the six months ended June 30, 2017 and 2016 as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Foreign Currency </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:14.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total Accumulated </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Translation Adjustments </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:14.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Losses) Gains </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other Comprehensive Loss </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at December 31,  </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (47,434) </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (47,077) </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (146) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (383) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (47,580) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (47,460) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other comprehensive income (loss) </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,186 </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,410 </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (8) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 441 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,178 </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,851 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total before tax </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (42,248) </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (43,667) </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (154) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 58 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (42,402) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (43,609) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Tax effect </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,907) </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,278) </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  3 </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (163) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,904) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,441) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at June 30,  </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,155) </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,945) </td> <td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (151) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (105) </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (44,306) </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (45,050) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   The period change in each of the periods presented was primarily due to the currency translation of the goodwill and deferred income taxes associated with the acquisition of EOS in November 2013. There were no reclassifications out of accumulated other comprehensive loss in each of the three and six months ended June 30, 2017 and 2016. <div /></div> </div>

5750000

3920454

372464

556000

662000

6400000

5700000

38375000

38389000

44610000

45176000

EX-101.SCH 8 clvs-20170630.xsd EX-101.SCH 00100 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Available-for-Sale Securities - Summary of Available-for-Sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 40403 - Disclosure - Available-for-Sale Securities - Summary of Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40703 - Disclosure - Intangible Assets and Goodwill - Estimated Future Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Other Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Convertible Senior Notes - Schedule of Total Interest Expense Recognized Related to Notes (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00205 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Nature of Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Financial Instruments and Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Available-for-Sale Securities link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Other Current Assets link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Intangible Assets and Goodwill link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Other Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Convertible Senior Notes link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - License Agreements link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Net Loss Per Common Share link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Nature of Business and Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Financial Instruments and Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Available-for-Sale Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Intangible Assets and Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Other Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Convertible Senior Notes (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 31303 - Disclosure - Net Loss Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Nature of Business - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Financial Instruments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Financial Instruments and Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Available-for-Sale Securities - Summary of Fair Value and Gross Unrealized Losses of Available-for-Sale Securities in a Continuous Unrealized Loss Position (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Intangible Assets and Goodwill - Capitalized Milestones link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Intangible Assets and Goodwill - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40704 - Disclosure - Intangible Assets and Goodwill - Summary of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Convertible Senior Notes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Stockholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Stockholders' Equity - Component of Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Share-Based Compensation - Summary of Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 41103 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details) link:presentationLink link:calculationLink link:definitionLink 41104 - Disclosure - Share-Based Compensation - Summary of Activity Relating to Company's Unvested Restricted Stock Units (Detail) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - License Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Net Loss Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 clvs-20170630_cal.xml EX-101.CAL EX-101.DEF 10 clvs-20170630_def.xml EX-101.DEF EX-101.LAB 11 clvs-20170630_lab.xml EX-101.LAB Document and entity information. Document And Entity Information [Abstract] Statement [Table] Statement [Line Items] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Current Reporting Status Entity Current Reporting Status Entity Filer Category Entity Filer Category Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Consolidated Statements of Operations and Comprehensive Loss Revenues [Abstract] Revenues: Sales Revenue, Goods, Net Product revenue, net Operating Expenses [Abstract] Operating expenses: Cost of materials, third-party manufacturing costs as well as freight and royalties owed to our licensing partners related to product sales. Cost Of Goods Sold Product Cost of sales - product Cost of Goods Sold, Depreciation, Depletion and Amortization Cost of sales - intangible asset amortization Research And Development Expense Excluding Acquired In Process Cost Research and development General And Administrative Expense Selling, general and administrative Research And Development Asset Acquired Other Than Through Business Combination Written Off Acquired in-process research and development Impairment Of Intangible Assets Indefinitelived Excluding Goodwill Impairment of intangible asset Amount of the change in the fair value of contingent purchase consideration recognized in income (loss) in the period. Change In Fair Value of Contingent Purchase Consideration Change in fair value of contingent purchase consideration Operating Expenses Total expenses Operating Income Loss Operating loss Nonoperating Income Expense [Abstract] Other income (expense): Interest Expense Debt Interest expense Total interest expense Foreign Currency Transaction Gain Loss Before Tax Foreign currency gain (loss) Gain (Loss) Related to Litigation Settlement Legal settlement loss, net of insurance receivable Legal settlement loss, net of insurance receivable Other Nonoperating Income Expense Other income Nonoperating Income Expense Other income (expense), net Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Loss before income taxes Income Tax Expense Benefit Income tax benefit Net Income Loss Net loss Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Other comprehensive income Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Foreign currency translation adjustments, net of tax Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Net unrealized gain (loss) on available-for-sale securities, net of tax Other Comprehensive Income Loss Net Of Tax Other comprehensive income (loss) Comprehensive Income Net Of Tax Comprehensive loss Loss per basic and diluted common share: Earnings Per Share Basic And Diluted Basic and diluted net loss per common share Weighted Average Number Of Share Outstanding Basic And Diluted Basic and diluted weighted average common shares outstanding Consolidated Balance Sheets Assets [Abstract] ASSETS Assets Current [Abstract] Current assets: Cash And Cash Equivalents At Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Accounts Receivable, Net, Current Accounts receivable, net Insurance Settlements Receivable, Current Insurance receivable Inventory, Net Inventories Available For Sale Securities Current Available-for-sale securities Prepaid Expense Current Prepaid research and development expenses Other Assets Current Other current assets Total Assets Current Total current assets Property Plant And Equipment Net Property and equipment, net Intangible Assets Net Excluding Goodwill Intangible assets, net Goodwill Balance at end of period Balance at beginning of period Goodwill Other Assets Noncurrent Other assets Assets Total assets Liabilities And Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Liabilities Current [Abstract] Current liabilities: Accounts Payable Current Accounts payable Carrying value as of the balance sheet date of obligations incurred and payable for research and development activities which are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include contract research organizations, contract manufacturers and other research and development vendors. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Research And Development Expenses Accrued research and development expenses Deferred Long-term Liability Charges Milestone liability Estimated Litigation Liability, Current Accrued liability for legal settlement Accrued Liabilities Current Other accrued expenses Other accrued expenses Liabilities Current Total current liabilities Deferred Tax Liabilities Noncurrent Deferred income taxes, net Convertible Debt, Noncurrent Convertible senior notes Deferred Rent Credit Noncurrent Deferred rent, long-term Liabilities Total liabilities Commitments And Contingencies Commitments and contingencies (Note 14) Stockholders Equity [Abstract] Stockholders' equity (deficit): Preferred Stock Value Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at June 30, 2017 and December 31, 2016 Common Stock Value Common stock, $0.001 par value per share, 100,000,000 shares authorized at June 30, 2017 and December 31, 2016; 48,843,131 and 38,724,090 shares issued and outstanding at June 30, 2017 and December 31, 2016 respectively Additional Paid In Capital Common Stock Additional paid-in capital Accumulated Other Comprehensive Income Loss Net Of Tax Ending balance Beginning balance Accumulated other comprehensive loss Retained Earnings Accumulated Deficit Accumulated deficit Stockholders Equity Total stockholders' equity (deficit) Liabilities And Stockholders Equity Total liabilities and stockholders' equity (deficit) Preferred Stock Par Or Stated Value Per Share Preferred stock, par value Preferred Stock Shares Authorized Preferred stock, shares authorized Preferred Stock Shares Issued Preferred stock, shares issued Preferred Stock Shares Outstanding Preferred stock, shares outstanding Common Stock Par Or Stated Value Per Share Common stock, par value Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Operating activities Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Loss Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Share Based Compensation Share-based compensation expense Depreciation Depletion And Amortization Depreciation and amortization Accretion Amortization Of Discounts And Premiums Investments Amortization of premiums and discounts on available-for-sale securities Amortization Of Financing Costs Amortization of debt issuance costs Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 Change in fair value of contingent purchase consideration Gain Loss On Disposition Of Assets Loss on disposal of property and equipment Deferred Income Tax Expense Benefit Deferred income taxes Increase Decrease In Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Inventory The net increase (decrease) during the reporting period in the amount of outstanding money paid in advance for research and development goods and services that bring economic benefits for future periods or in the amount of other research and development expenses incurred but not yet paid. Increase (decrease) relates to amounts paid in advance, or incurred and not yet paid, to contract research organizations, contract manufacturers or other research and development vendors. Increase Decrease In Prepaid And Accrued Research And Development Expenses Prepaid and accrued research and development expenses Increase Decrease In Other Operating Assets Other operating assets Increase Decrease In Accounts Payable Accounts payable Increase Decrease In Other Accrued Liabilities Other accrued expenses Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Investing activities Payments To Acquire Property Plant And Equipment Purchases of property and equipment The cash outflow in the form of deposits associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. Payments to Acquire Property, Plant, and Equipment , Deposits Deposits for purchases of property and equipment Payments To Acquire Available For Sale Securities Debt Purchases of available-for-sale securities Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities Maturities of available-for-sale securities The amount of acquired In process research and development milestone paid Acquired In Process Research And Development Milestone Paid Acquired in-process research and development - milestone payment Net Cash Provided by (Used in) Investing Activities Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities Proceeds From Issuance Of Common Stock Proceeds from the sale of common stock, net of issuance costs Proceeds from offering Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options Proceeds from the exercise of stock options and employee stock purchases Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Effect Of Exchange Rate On Cash And Cash Equivalents Effect of exchange rate changes on cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease Increase (decrease) in cash and cash equivalents Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Interest Paid, Net Cash paid for interest Noncash Investing And Financing Items [Abstract] Non-cash investing and financing activities: The value of restricted stock units, that vested during the reporting period. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vesting of Restricted Stock Units, Value Vesting of restricted stock units Nature of Business and Basis of Presentation Business Description And Basis Of Presentation [Text Block] Nature of Business and Basis of Presentation Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Financial Instruments and Fair Value Measurements Fair Value Disclosures [Text Block] Financial Instruments and Fair Value Measurements Available-for-Sale Securities Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block] Available-for-Sale Securities Inventories Inventory Disclosure [Text Block] Inventories Other current assets. Other Current Assets [Abstract] Other Current Assets [Text Block] Other Current Assets Intangible Assets and Goodwill Goodwill And Intangible Assets Disclosure [Text Block] Intangible Assets and Goodwill Payables And Accruals [Abstract] Accounts Payable And Accrued Liabilities Disclosure [Text Block] Other Accrued Expenses Convertible Senior Notes, Long Term Debt [Text Block] Convertible Senior Notes Stockholders’ Equity Stockholders Equity Note Disclosure [Text Block] Stockholders' Equity Share-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Share-Based Compensation License Agreements License Agreements. License Agreements [Text Block] License Agreements Earnings Per Share [Text Block] Net Loss Per Common Share Commitments and Contingencies. Commitments And Contingencies Disclosure [Text Block] Commitments and Contingencies Basis Of Accounting Policy Policy [Text Block] Basis of Presentation Use Of Estimates Use of Estimates Revenue Recognition Policy [Text Block] Revenue Recognition Cost of Sales, Policy [Policy Text Block] Cost of Sales Inventory, Policy [Policy Text Block] Inventory New Accounting Pronouncements Policy Policy [Text Block] Recently Issued Accounting Standards Debt Policy [Text Block] Convertible Senior Notes Reimbursement. Reimbursement Policy [Text Block] Lucitanib Earnings Per Share Policy [Text Block] Net Loss Per Common Share Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule Of Available For Sale Securities Reconciliation Table [Text Block] Summary of Available-for-Sale Securities Available For Sale Securities Continuous Unrealized Loss Position Fair Value Table [Text Block] Summary of Fair Value and Gross Unrealized Losses of Available-for-Sale Securities in a Continuous Unrealized Loss Position Available For Sale Securities [Text Block] Summary of Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity Schedule Of Other Current Assets Table [Text Block] Other Current Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Intangible assets related to capitalized milestones under license agreements Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Estimated future amortization expense for intangible assets Schedule of Goodwill [Table Text Block] Summary of Goodwill Schedule Of Accrued Liabilities Table [Text Block] Other Accrued Expenses Interest Income And Interest Expense Disclosure Table [Text Block] Schedule of Total Interest Expense Recognized Related to Notes Schedule Of Accumulated Other Comprehensive Income Loss Table [Text Block] Component of Other Comprehensive Income (Loss) Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Share-Based Compensation Expense Recognized in Accompanying Statements of Operations Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Summary of Stock Options Activity Disclosure Of Share Based Compensation Arrangements By Share Based Payment Award [Text Block] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block] Summary of activity related to our unvested RSUs Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Shares Outstanding Excluded from Calculation of Diluted Net Loss Per Share Number Of Operating Segments Number of operating segments Stock Issued During Period Shares New Issues Issuance of stock (in shares) Common stock, shares issued Share Price Sale of stock, price per share Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Measurements Fair Value Hierarchy Fair Value Inputs Level1 [Member] Fair Value, Inputs, Level 1 Fair Value Inputs Level2 [Member] Fair Value, Inputs, Level 2 Fair Value Inputs Level3 [Member] Fair Value, Inputs, Level 3 Fair Value By Asset Class [Axis] Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class Money Market Funds [Member] Money Market U S Treasury Securities [Member] U.S. Treasury Securities Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Assets Fair Value Disclosure Recurring Assets at fair value Longterm Debt Type [Axis] EX-101.PRE 12 clvs-20170630_pre.xml EX-101.PRE XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Jul. 28, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Trading Symbol	CLVS
Entity Registrant Name	Clovis Oncology, Inc.
Entity Central Index Key	0001466301
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		48,879,354

XML 14 R2.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenues:
Product revenue, net	$ 14,620		$ 21,665	$ 0
Operating expenses:
Cost of sales - product	2,730		3,893	0
Cost of sales - intangible asset amortization	372		743	0
Research and development	33,108	$ 67,729	65,555	142,337
Selling, general and administrative	36,149	9,552	65,373	19,379
Acquired in-process research and development		300		300
Impairment of intangible asset		104,517		104,517
Change in fair value of contingent purchase consideration		(25,452)	0	(24,936)
Total expenses	72,359	156,646	135,564	241,597
Operating loss	(57,739)	(156,646)	(113,899)	(241,597)
Other income (expense):
Interest expense	(2,598)	(2,106)	(5,178)	(4,210)
Foreign currency gain (loss)	76	183	(83)	(368)
Legal settlement loss, net of insurance receivable	(117,000)		(117,000)
Other income	594	196	946	221
Other income (expense), net	(118,928)	(1,727)	(121,315)	(4,357)
Loss before income taxes	(176,667)	(158,373)	(235,214)	(245,954)
Income tax benefit	1,281	29,059	1,365	33,240
Net loss	(175,386)	(129,314)	(233,849)	(212,714)
Other comprehensive income
Foreign currency translation adjustments, net of tax	2,812	(1,381)	3,279	2,132
Net unrealized gain (loss) on available-for-sale securities, net of tax		48	(5)	278
Other comprehensive income (loss)	2,812	(1,333)	3,274	2,410
Comprehensive loss	$ (172,574)	$ (130,647)	$ (230,575)	$ (210,304)
Loss per basic and diluted common share:
Basic and diluted net loss per common share	$ (3.88)	$ (3.37)	$ (5.24)	$ (5.54)
Basic and diluted weighted average common shares outstanding	45,176	38,389	44,610	38,375

XML 15 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 491,786	$ 216,186
Accounts receivable, net	1,143	121
Insurance receivable	25,000
Inventories	6,478	0
Available-for-sale securities	179,744	49,997
Prepaid research and development expenses	4,854	6,427
Other current assets	6,766	6,679
Total current assets	715,771	279,410
Property and equipment, net	4,155	4,440
Intangible assets, net	20,304	21,047
Goodwill	62,018	57,192
Other assets	47,648	2,468
Total assets	849,896	364,557
Current liabilities:
Accounts payable	13,360	10,912
Accrued research and development expenses	21,158	35,198
Milestone liability	21,011	20,062
Accrued liability for legal settlement	142,000
Other accrued expenses	21,848	19,487
Total current liabilities	219,377	85,659
Deferred income taxes, net	632	0
Convertible senior notes	281,761	281,126
Deferred rent, long-term	4,333	1,406
Total liabilities	506,103	368,191
Commitments and contingencies (Note 14)
Stockholders' equity (deficit):
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at June 30, 2017 and December 31, 2016
Common stock, $0.001 par value per share, 100,000,000 shares authorized at June 30, 2017 and December 31, 2016; 48,843,131 and 38,724,090 shares issued and outstanding at June 30, 2017 and December 31, 2016 respectively	49	39
Additional paid-in capital	1,752,943	1,174,950
Accumulated other comprehensive loss	(44,306)	(47,580)
Accumulated deficit	(1,364,893)	(1,131,043)
Total stockholders' equity (deficit)	343,793	(3,634)
Total liabilities and stockholders' equity (deficit)	$ 849,896	$ 364,557

XML 16 R4.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Consolidated Balance Sheets
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	48,843,131	38,724,090
Common stock, shares outstanding	48,843,131	38,724,090

XML 17 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Operating activities
Net Loss	$ (233,849)	$ (212,714)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	19,563	20,542
Depreciation and amortization	1,281	550
Amortization of premiums and discounts on available-for-sale securities	245	151
Amortization of debt issuance costs	635	616
Legal settlement loss, net of insurance receivable	117,000
Impairment of intangible asset		104,517
Change in fair value of contingent purchase consideration	0	(24,661)
Loss on disposal of property and equipment	0	170
Deferred income taxes	(1,266)	(33,207)
Changes in operating assets and liabilities:
Accounts receivable	(1,023)	0
Inventory	(6,478)	0
Prepaid and accrued research and development expenses	(15,162)	(12,772)
Other operating assets	(36,855)	1,260
Accounts payable	3,202	3,608
Other accrued expenses	3,166	270
Net cash used in operating activities	(149,541)	(151,670)
Investing activities
Purchases of property and equipment	(249)	(756)
Deposits for purchases of property and equipment	(2,515)	0
Purchases of available-for-sale securities	(180,000)	0
Maturities of available-for-sale securities	50,000	100,000
Acquired in-process research and development - milestone payment	(1,100)	0
Net cash (used in) provided by investing activities	(133,864)	99,244
Financing activities
Proceeds from the sale of common stock, net of issuance costs	546,170	0
Proceeds from the exercise of stock options and employee stock purchases	12,270	1,943
Net cash provided by financing activities	558,440	1,943
Effect of exchange rate changes on cash and cash equivalents	565	106
Increase (decrease) in cash and cash equivalents	275,600	(50,377)
Cash and cash equivalents at beginning of period	216,186	278,756
Cash and cash equivalents at end of period	491,786	228,379
Supplemental disclosure of cash flow information:
Cash paid for interest	3,594	3,594
Non-cash investing and financing activities:
Vesting of restricted stock units	$ 2,627	$ 34

XML 18 R6.htm IDEA: XBRL DOCUMENT

Nature of Business and Basis of Presentation	6 Months Ended
Nature of Business and Basis of Presentation	Jun. 30, 2017
Nature of Business and Basis of Presentation
Nature of Business and Basis of Presentation	1. Nature of Business and Basis of Presentation Clovis Oncology, Inc. (together with its consolidated subsidiaries, the “Company”, “Clovis”, “we”, “our”, “us”) is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and other international markets. We have and intend to continue to license or acquire rights to oncology compounds in all stages of development. In exchange for the right to develop and commercialize these compounds, we generally expect to provide the licensor with a combination of upfront payments, milestone payments and royalties on future sales. In addition, we generally expect to assume the responsibility for future drug development and commercialization costs. We currently operate in one segment. Since inception, our operations have consisted primarily of developing in-licensed compounds, evaluating new product acquisition candidates and general corporate activities. During the second quarter of 2016, we completed the submission of our New Drug Application (“NDA”) with the U.S. Food and Drug Administration (“FDA”) for approval of rucaparib in the U.S. On December 19, 2016, the FDA approved Rubraca® (rucaparib) tablets as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. We began selling Rubraca in the U.S. in the fourth quarter of 2016. Our Marketing Authorization Application (MAA) for rucaparib that was submitted to the European Medicines Agency (“EMA”) for an ovarian cancer treatment indication comparable to what was approved by the FDA is currently under review. We anticipate an opinion from the Committee for Medicinal Products for Human Use (CHMP) in late 2017, and, pending a favorable opinion from the CHMP, a potential approval would follow during the first quarter of 2018. Following a potential approval for the treatment indication, we intend to submit a supplemental application for the second-line or later maintenance treatment indication, for which we anticipate a potential approval during the third quarter of 2018. Basis of Presentation All financial information presented includes the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments, consisting only of normal recurring adjustments that, in the opinion of management, are necessary to fairly state our financial position, results of operations and cash flows for the periods presented herein. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2016 (“2016 Form 10-K”) for a broader discussion of our business and the opportunities and risks inherent in such business. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates, including estimates related to revenue deductions, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. Liquidity We have incurred significant net losses since inception and have relied on our ability to fund our operations through debt and equity financings. We expect operating losses and negative cash flows to continue for the foreseeable future. As we continue to incur losses, transition to profitability is dependent upon achieving a level of revenues from Rubraca adequate to support our cost structure. We may never achieve profitability, and unless or until we do, we will continue to need to raise additional cash. In January 2017, we sold 5,750,000 shares of our common stock in a public offering at $41.00 per share. The net proceeds from the offering were $221.2 million, after deducting underwriting discounts and commissions and offering expenses. In June 2017, we sold 3,920,454 shares of our common stock in a public offering at $88.00 per share. The net proceeds from the offering were $324.9 million, after deducting underwriting discounts and commissions and offering expenses. We intend to use the net proceeds of the offerings for general corporate purposes, including sales and marketing expenses associated with Rubraca in the United States and, if approved by the EMA, in Europe, funding of our development programs, selling, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. Based on current estimates, we believe that our existing cash, cash equivalents and available-for-sale securities will allow us to fund our operating plan through at least the next 12 months.

XML 19 R7.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies	6 Months Ended
Summary of Significant Accounting Policies	Jun. 30, 2017
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Revenue Recognition Product revenue is derived from sales of our product, Rubraca, in the United States. We distribute our product in the U.S. principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers. Our customers subsequently resell our products to patients and healthcare providers. Separately, we have arrangements with certain payors and other third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and other discounts. Revenues from product sales are recognized when persuasive evidence of an arrangement exists, delivery has occurred and title of the product and associated risk of loss has passed to the customer, the price is fixed or determinable, collection from the customer has been reasonably assured and all performance obligations have been met and returns and allowances can be reasonably estimated. Revenue is recorded net of estimated rebates, chargebacks, discounts and other deductions as well as estimated product returns (collectively, “sales deductions”). We only recognize revenue on product sales once the product is resold to the patient or healthcare provider by the specialty distributor or specialty pharmacy provider, therefore reducing the significance of estimates made for product returns. To date, we have not had any product returns and, we currently do not have an accrual for product returns. We will continue to assess our estimate for product returns as we gain additional historical experience. Cost of Sales – Product Product cost of sales consists primarily of materials, third-party manufacturing costs as well as freight and royalties owed to our licensing partners for Rubraca sales. Based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, certain of the manufacturing costs of Rubraca units recognized as revenue during the three and six months ended June 30, 2017 were expensed prior to the December 19, 2016 FDA approval, and therefore are not included in costs of sales during the current period. We expect cost of sales to increase in relation to product revenues as we deplete these inventories and we expect to use the remaining pre-commercialization inventory for product sales through the third quarter of 2017. Cost of Sales – Intangible Asset Amortization Cost of sales for intangible asset amortization consists of the amortization of capitalized milestone payments made to our licensing partners upon FDA approval of Rubraca. Milestone payments are amortized on a straight-line basis over the estimated remaining patent life of Rubraca. Inventory Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. We began capitalizing incurred inventory related costs upon the regulatory approval of Rubraca. Prior to the regulatory approval of Rubraca, we incurred costs for the manufacture of the drug that could potentially be available to support the commercial launch of Rubraca and all such costs were recognized as research and development expense. We periodically analyze our inventory levels, and write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and/or inventory in excess of expected sales requirements as cost of product revenues. Expired inventory would be disposed of and the related costs would be written off as cost of product revenues. The active pharmaceutical ingredient (“API”) in Rubraca is currently produced by a single supplier. As the API has undergone significant manufacturing specific to its intended purpose at the point it is purchased by us, we classify the API as work-in-process inventory. Our other significant accounting policies are described in Note 2, Summary of Significant Accounting Policies of the Notes to the Consolidated Financial Statements included in our 2016 Form 10-K. From time to time, the Financial Accounting Standards Board (“FASB”) or other standards setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification (“ASC”) are communicated through issuance of an Accounting Standards Update (“ASU”). Recently Issued Accounting Standards In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” and has subsequently issued several supplemental and/or clarifying ASUs (collectively, “ASC 606”). ASC 606 prescribes a single common revenue standard that replaces most existing U.S. GAAP revenue recognition guidance. ASC 606 is intended to provide a more consistent interpretation and application of the principles outlined in the standard across filers in multiple industries and within the same industries compared to current practices, which should improve comparability. Adoption of ASC 606 is required for annual and interim periods beginning after December 15, 2017. Upon adoption, we must elect to adopt either retrospectively to each prior reporting period presented or use the modified retrospective transition method with the cumulative effect of initial adoption recognized at the date of initial application. We expect to apply the new standard using the modified retrospective method upon its adoption date on January 1, 2018. We have begun a comprehensive scoping process to identify and disaggregate all revenue streams that may be impacted by the adoption of ASC 606. To date, we have examined our revenue recognition policy specific to revenue streams from representative contracts governing product sales from Rubraca and have come to preliminary conclusions on the impact of the new standard using the 5-step process prescribed by ASC 606. However, a detailed analysis of individual contracts representative of each of the revenue streams planned for the assessment phase of our implementation plan may impact these preliminary conclusions. We are continuing to assess ASC 606’s impact on our financial statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. ASU 2016-02 requires modified retrospective adoption for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures. In January 2017, the FASB issued ASU No. 2017-01, “Clarifying the Definition of a Business,” which clarifies the definition of a business in ASC 805. The guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is permitted. Currently, there is no impact to our consolidated financial statements and related disclosures, but we will adopt on January 1, 2018 for any business combinations and will consider adopting early for any acquisitions prior to January 1, 2018. In May 2017, the FASB issued ASU 2017-09, “Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting”, which amends the scope of modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which we would be required to apply modification accounting under ASC 718. Specifically, we would not apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. The guidance is effective for annual reporting periods, including interim period within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures should we have a modification to our share-based payment awards in the future.

XML 20 R8.htm IDEA: XBRL DOCUMENT

Financial Instruments and Fair Value Measurements

6 Months Ended

Jun. 30, 2017

Financial Instruments and Fair Value Measurements

Financial Instruments and Fair Value Measurements

3. Financial Instruments and Fair Value Measurements

The three levels of inputs that may be used to measure fair value include:

Level 1:	Quoted prices in active markets for identical assets or liabilities. Our Level 1 assets consist of money market investments. We do not have Level 1 liabilities.

Level 2:	Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Our Level 2 assets consist of U.S. treasury securities. We do not have Level 2 liabilities.

Level 3:	Unobservable inputs that are supported by little or no market activity. We do not have Level 3 assets or liabilities that are measured at fair value on a recurring basis.

The following table identifies our assets and liabilities that were measured at fair value on a recurring basis (in thousands):


	Balance		Level 1		Level 2		Level 3
June 30, 2017
Assets:
Money market	$	450,588	$	450,588	$	—	$	—
U.S. treasury securities		179,744		—		179,744		—
Total assets at fair value	$	630,332	$	450,588	$	179,744	$	—
December 31, 2016
Assets:
Money market	$	202,361	$	202,361	$	—	$	—
U.S. treasury securities		49,997		—		49,997		—
Total assets at fair value	$	252,358	$	202,361	$	49,997	$	—

There were no transfers between the Level 1 and Level 2 categories or into or out of the Level 3 category during the three and six months ended June 30, 2017.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 21 R9.htm IDEA: XBRL DOCUMENT

Available-for-Sale Securities

6 Months Ended

Jun. 30, 2017

Available-for-Sale Securities

Available-for-Sale Securities

4. Available-for-Sale Securities

As of June 30, 2017, available-for-sale securities consisted of the following (in thousands):


			Gross		Gross		Aggregate
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. treasury securities	$	179,758	$	—	$	(14)	$	179,744

As of December 31, 2016, available-for-sale securities consisted of the following (in thousands):


			Gross		Gross		Aggregate
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. treasury securities	$	50,004	$	—	$	(7)	$	49,997


	Aggregate		Gross
	Fair		Unrealized
	Value		Losses
U.S. treasury securities	$	179,744	$	(14)

As of June 30, 2017, the amortized cost and fair value of available-for-sale securities by contractual maturity were (in thousands):


	Amortized		Fair
	Cost		Value
Due in one year or less	$	179,758	$	179,744
Due in one year to two years		—		—
Total	$	179,758	$	179,744

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

XML 22 R10.htm IDEA: XBRL DOCUMENT

Inventories	6 Months Ended
Inventories	Jun. 30, 2017
Inventories
Inventories	5. Inventories We generally have two categories of inventory: work-in-process and finished goods. As of June 30, 2017, the carrying value of all of our product inventory, which consisted only of the Rubraca API, was categorized as work-in-process. The costs related to our finished goods on-hand as of June 30, 2017 were expensed as incurred prior to the commercialization of Rubraca on December 19, 2016. The carrying value of our inventory as of December 31, 2016 was zero. At June 30, 2017, other assets on the Consolidated Balance Sheets includes a cash deposit of $31.8 million made to a manufacturer for the purchase of inventory which we do not expect to be commercially consumed within the next twelve months.

XML 23 R11.htm IDEA: XBRL DOCUMENT

Other Current Assets

6 Months Ended

Jun. 30, 2017

Other Current Assets [Abstract]

Other Current Assets

6. Other Current Assets

Other current assets were comprised of the following (in thousands):


	June 30,		December 31,
	2017		2016
Receivable from partners	$	52	$	2,882
Prepaid insurance		817		1,234
Prepaid expenses - other		3,012		2,109
Receivable - other		2,750		364
Other		135		90
Total	$	6,766	$	6,679

XML 24 R12.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill

6 Months Ended

Jun. 30, 2017

Intangible Assets and Goodwill

Intangible Assets and Goodwill

7. Intangible Assets and Goodwill

Intangible assets related to capitalized milestones under license agreements consisted of the following (in thousands):


	June 30,		December 31,
	2017		2016
Intangible asset - milestones	$	21,100	$	21,100
Accumulated amortization		(796)		(53)
Total intangible asset, net	$	20,304	$	21,047

The estimated useful lives of these intangible assets are based on the estimated remaining patent life of Rubraca and extend through 2031.

Estimated future amortization expense associated with intangibles is expected to be as follows (in thousands):


2017 (remaining)	$	743
2018		1,486
2019		1,486
2020		1,486
2021		1,486
Thereafter		13,617
	$	20,304

The change in goodwill established as part of the purchase accounting of EOS in November 2013 consisted of the following (in thousands):


Balance at December 31, 2016	$	57,192
Change in foreign currency gains and losses		4,826
Balance at June 30, 2017	$	62,018

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

XML 25 R13.htm IDEA: XBRL DOCUMENT

Other Accrued Expenses

6 Months Ended

Jun. 30, 2017

Payables And Accruals [Abstract]

Other Accrued Expenses

8. Other Accrued Expenses

Other accrued expenses were comprised of the following (in thousands):


	June 30,		December 31,
	2017		2016
Accrued personnel costs	$	11,928	$	15,850
Accrued interest payable		2,097		2,096
Income tax payable		662		556
Accrued corporate legal fees and professional services		1,072		589
Accrued royalties		2,551		—
Accrued sales deductions		1,003		—
Accrued expenses - other		2,535		396
Total	$	21,848	$	19,487

XML 26 R14.htm IDEA: XBRL DOCUMENT

Convertible Senior Notes

6 Months Ended

Jun. 30, 2017

Convertible Senior Notes,

Convertible Senior Notes

9. Convertible Senior Notes

In connection with the issuance of the Notes, we incurred $9.2 million of debt issuance costs. The debt issuance costs are presented as a deduction from convertible senior notes on the Consolidated Balance Sheets and are amortized as interest expense over the expected life of the Notes using the effective interest method. We determined the expected life of the debt was equal to the seven-year term of the Notes. As of June 30, 2017 and December 31, 2016, the balance of unamortized debt issuance costs was $5.7 million and $6.4 million, respectively.

The following table sets forth total interest expense recognized during the three and six months ended June 30, 2017 and 2016 (in thousands):


	Three months ended June 30,				Six months ended June 30,
	2017		2016		2017		2016
Contractual interest expense	$	1,797	$	1,797	$	3,594	$	3,594
Accretion of interest on milestone liability		483		—		949		—
Amortization of debt issuance costs		318		309		635		616
Total interest expense	$	2,598	$	2,106	$	5,178	$	4,210

XML 27 R15.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

6 Months Ended

Jun. 30, 2017

Stockholders’ Equity

Stockholders' Equity

10. Stockholders’ Equity

Common Stock

Accumulated Other Comprehensive Loss

The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the three months ended June 30, 2017 and 2016 as follows (in thousands):


	Foreign Currency				Unrealized				Total Accumulated
	Translation Adjustments				(Losses) Gains				Other Comprehensive Loss
	2017		2016		2017		2016		2017		2016
Balance at April 1,	$	(46,967)	$	(43,564)	$	(151)	$	(153)	$	(47,118)	$	(43,717)
Other comprehensive income (loss)		4,451		(2,170)		(3)		76		4,448		(2,094)
Total before tax		(42,516)		(45,734)		(154)		(77)		(42,670)		(45,811)
Tax effect		(1,639)		789		3		(28)		(1,636)		761
Balance at June 30,	$	(44,155)	$	(44,945)	$	(151)	$	(105)	$	(44,306)	$	(45,050)

The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the six months ended June 30, 2017 and 2016 as follows (in thousands):


	Foreign Currency				Unrealized				Total Accumulated
	Translation Adjustments				(Losses) Gains				Other Comprehensive Loss
	2017		2016		2017		2016		2017		2016
Balance at December 31,	$	(47,434)	$	(47,077)	$	(146)	$	(383)	$	(47,580)	$	(47,460)
Other comprehensive income (loss)		5,186		3,410		(8)		441		5,178		3,851
Total before tax		(42,248)		(43,667)		(154)		58		(42,402)		(43,609)
Tax effect		(1,907)		(1,278)		3		(163)		(1,904)		(1,441)
Balance at June 30,	$	(44,155)	$	(44,945)	$	(151)	$	(105)	$	(44,306)	$	(45,050)

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 28 R16.htm IDEA: XBRL DOCUMENT

Share-Based Compensation

6 Months Ended

Jun. 30, 2017

Share-Based Compensation

Share-Based Compensation

11. Share-Based Compensation


	Three months ended June 30,				Six months ended June 30,
	2017		2016		2017		2016
Research and development	$	4,825	$	6,615	$	8,991	$	13,924
Selling, general and administrative		5,792		2,962		10,572		6,618
Total share-based compensation expense	$	10,617	$	9,577	$	19,563	$	20,542

Stock Options

The following table summarizes the activity relating to our options to purchase common stock for the six months ended June 30, 2017:


				Weighted
		Weighted		Average	Aggregate
		Average		Remaining	Intrinsic
	Number of	Exercise		Contractual	Value
	Options	Price		Term (Years)	(Thousands)
Outstanding at December 31, 2016	5,520,482	$	42.00
Granted	778,700
Exercised	(372,464)
Forfeited	(199,985)
Outstanding at June 30, 2017	5,726,733	$	45.43	7.6	$	276,451
Vested and expected to vest at June 30, 2017	5,364,276	$	45.30	7.4	$	259,650
Vested and exercisable at June 30, 2017	2,935,211	$	44.63	6.2	$	143,983

The following table summarizes information about our stock options as of and for the three and six months ended June 30, 2017 and 2016 (in thousands):


	Three months ended June 30,				Six months ended June 30,
	2017		2016		2017		2016
Weighted-average grant date fair value per share	$	44.94	$	11.01	$	46.53	$	14.65
Intrinsic value of options exercised	$	4,759	$	578,525	$	14,284	$	624,925
Cash received from stock option exercises	$	5,439	$	352,423	$	11,113	$	407,523

Restricted Stock

The following table summarizes the activity relating to our unvested RSUs for the six months ended June 30, 2017:



		Weighted
		Average
	Number of	Grant Date
	Units	Fair Value
Unvested at December 31, 2016	562,458	$	24.70
Granted	214,984		61.67
Vested	(44,443)		19.37
Forfeited	(27,177)		24.08
Unvested as of June 30, 2017	705,822	$	36.32
Expected to vest after June 30, 2017	604,394	$	35.81

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 29 R17.htm IDEA: XBRL DOCUMENT

License Agreements	6 Months Ended
License Agreements	Jun. 30, 2017
License Agreements
License Agreements	12. License Agreements In June 2011, we entered into a worldwide license agreement with Pfizer, Inc. to obtain exclusive global rights to develop and commercialize rucaparib, a small molecule inhibitor of poly (ADP-ribose) polymerase (“PARP”), used for the treatment of selected solid tumors. The exclusive rights are exclusive even as to Pfizer and include the right to grant sublicenses. Pursuant to the terms of the license agreement, we made a $7.0 million upfront payment to Pfizer and are required to make additional payments to Pfizer for the achievement of certain development and regulatory and sales milestones and royalties on sales as required by the license agreement. Prior to the FDA approval of rucaparib, discussed below, we made milestone payments of $1.4 million, which were recognized as acquired in-process research and development expense. On August 30, 2016, we entered into a first amendment to the worldwide license agreement with Pfizer, which amends the June 2011 existing worldwide license agreement to permit us to defer payment of the milestone payments payable upon (i) FDA approval of an NDA for 1st Indication in US and (ii) EMA approval of an MAA for 1st Indication in EU, to a date that is 18 months after the date of achievement of such milestones. In the event that we defer such milestone payments, we have agreed to certain higher payments related to the achievement of such milestones. On December 19, 2016, the FDA approved Rubraca (rucaparib) tablets as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. The FDA approval resulted in a $0.75 million milestone payment to Pfizer as required by the license agreement, which was made in the first quarter of 2017. The FDA approval also resulted in the obligation to pay a $20.0 million milestone payment, for which we have exercised the option to defer payment by agreeing to pay $23.0 million within 18 months after the date of the FDA approval. These payments were recognized as intangible assets and will be amortized over the estimated remaining useful life of Rubraca. We are obligated under the license agreement to use commercially reasonable efforts to develop and commercialize rucaparib and we are responsible for all remaining development and commercialization costs for rucaparib. We are required to make regulatory milestone payments to Pfizer of up to an additional $69.75 million in aggregate if specified clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are obligated to make sales milestone payments to Pfizer if specified annual sales targets for rucaparib are met, the majority of which relate to annual sales targets of $500.0 million and above, which, in the aggregate, could amount to total milestone payments of $170.0 million, and tiered royalty payments at a mid-teen percentage rate on our net sales, with standard provisions for royalty offsets to the extent we need to obtain any rights from third parties to commercialize rucaparib. In April 2012, we entered into a license agreement with AstraZeneca UK Limited to acquire exclusive rights associated with rucaparib under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of rucaparib for the uses claimed by these patents. The FDA approval of rucaparib on December 19, 2016 resulted in a $0.35 million milestone obligation to AstraZeneca as required by the license agreement, which was paid in the first quarter of 2017. This payment was recognized in intangible assets and will be amortized over the estimated remaining useful life of rucaparib. AstraZeneca will also receive royalties on any net sales of rucaparib. We are party to other product license agreements for our other drug candidates, lucitanib and rociletinib (see our 2016 Form 10-K for additional details). We and Les Laboratories Servier (“Servier”) are developing lucitanib pursuant to a global development plan agreed to between the parties. Servier is responsible for all of the global development costs for lucitanib up to €80.0 million. Cumulative global development costs in excess of €80.0 million, if any, will be shared equally between us and Servier. We recorded a $0.1 million and $1.3 million receivable at June 30, 2017 and December 31, 2016, respectively, for the reimbursable development costs incurred under the global development plan, which is included in other current assets on the Consolidated Balance Sheets. For the three months ending June 30, 2017 and 2016, we incurred $0.0 million and $2.6 million, respectively, in research and development costs and recorded reductions in research and development expense of $0.1 million and $2.8 million, respectively, for reimbursable development costs due from Servier. For the six months ending June 30, 2017 and 2016, we incurred $0.9 million and $6.2 million, respectively, in research and development costs and recorded reductions in research and development expense of $1.0 million and $6.4 million, respectively, for reimbursable development costs due from Servier. During the second quarter of 2016, we and Servier agreed to discontinue the development of lucitanib for breast cancer and lung cancer and are continuing to evaluate, what, if any, further development of lucitanib will be pursued. Based on current estimates, we expect to complete the committed on-going development activities in 2017 and expect full reimbursement of our development costs from Servier. Reimbursements are recorded as a reduction to research and development expense on the Consolidated Statements of Operations.

XML 30 R18.htm IDEA: XBRL DOCUMENT

Net Loss Per Common Share

6 Months Ended

Jun. 30, 2017

Loss per basic and diluted common share:

Net Loss Per Common Share

13. Net Loss Per Common Share


	Three and Six months ended June 30,
	2017	2016
Common shares under option	6,373	455
Convertible senior notes	4,646	4,646
Total potential dilutive shares	11,019	5,101

XML 31 R19.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2017
Commitments and Contingencies.
Commitments and Contingencies	14. Commitments and Contingencies Royalty and License Fee Commitments We have entered into certain license agreements, as identified in Note 12, License Agreements, with third parties that include the payment of development and regulatory milestones, as well as royalty payments, upon the achievement of pre-established development, regulatory and commercial targets. Our payment obligation related to these license agreements is contingent upon the successful development, regulatory approval and commercialization of the licensed products. Due to the nature of these arrangements, the future potential payments are inherently uncertain, and accordingly, we only recognize payment obligations which are probable and estimable as of the balance sheet date. Milestone liabilities of $21.0 million and $20.1 million are recorded on our Consolidated Balance Sheets at June 30, 2017 and December 31, 2016, respectively, and relate to milestone payments for the licensing of our rucaparib product, which was approved by the FDA on December 19, 2016. Manufacture and Services Agreement Commitments On October 3, 2016, we entered into a Manufacturing and Services Agreement (the “Agreement”) with a non-exclusive third-party supplier for the production of the active ingredient for Rubraca. Under the terms of the Agreement, we will provide the third-party supplier a rolling forecast for the supply of the active ingredient in Rubraca that will be updated by us on a quarterly basis. We are obligated to order material sufficient to satisfy an initial quantity specified in any forecast. In addition, the third-party supplier will construct, in its existing facility, a production train that will be exclusively dedicated to the manufacture of the Rubraca active ingredient. We are obligated to make scheduled capital program fee payments toward capital equipment and other costs associated with the construction of the dedicated production train. Further, once the facility is operational, we are obligated to pay a fixed facility fee each quarter for the duration of the Agreement, which expires on December 31, 2025, unless extended by mutual consent of the parties. As of June 30, 2017, $183.6 million of purchase commitments exist under the Agreement. Legal Proceedings We and certain of our officers were named as defendants in several lawsuits, as described below. We cannot reasonably predict the outcome of these legal proceedings, nor can we estimate the amount of loss or range of loss, if any, that may result. An adverse outcome in these proceedings could have a material adverse effect on our results of operations, cash flows or financial condition. On November 19, 2015, Sonny P. Medina, a purported Clovis shareholder, filed a purported shareholder class action complaint in the United States District Court for the District of Colorado (the “Medina Complaint”). The Medina Complaint purported to be asserted on behalf of a class of persons who purchased Clovis stock between May 20, 2014 and November 13, 2015, and it generally alleged that Clovis and certain of its officers violated federal securities laws by making allegedly false and misleading statements regarding the progress toward FDA approval and the potential for market success of rociletinib. Throughout November and December 2015, three other purported shareholders filed similar purported class actions concerning alleged misstatements about rociletinib. On January 19, 2016, a number of motions were filed seeking to consolidate the shareholder class actions into one matter and for appointment of a lead plaintiff. On February 18, 2016, the Medina Court consolidated the various actions into a single proceeding and appointed M. Arkin (1999) LTD and Arkin Communications LTD (the “Arkin Plaintiffs”) as the lead plaintiffs and Bernstein Litowitz Berger & Grossmann LLP as lead counsel for the putative class. The Arkin Plaintiffs filed a consolidated complaint on May 6, 2016 (the “Consolidated Complaint”). The Consolidated Complaint named as defendants the Company and certain of its current and former officers (the “Clovis Defendants”), certain underwriters (the “Underwriter Defendants”) for a Company follow-on offering conducted in July 2015 (the “July 2015 Offering”), and certain Company venture capital investors (the “Venture Capital Defendants”). The Consolidated Complaint alleged that defendants violated particular sections of the Securities Exchange Act of 1934 (the “Exchange Act”) and the Securities Act of 1933 (the “Securities Act”). The purported misrepresentations and omissions concerned allegedly misleading statements about rociletinib. The consolidated action was purportedly brought on behalf of investors who purchased the Company’s securities between May 31, 2014 and April 7, 2016 (with respect to the Exchange Act claims) and investors who purchased the Company’s securities pursuant or traceable to the July 2015 Offering (with respect to the Securities Act claims). The Consolidated Complaint sought unspecified compensatory and recessionary damages. The Clovis Defendants, the Underwriter Defendants and the Venture Capital Defendants filed motions to dismiss on July 27, 2016. On February 9, 2017, the Medina Court issued an opinion and order granting in part and denying in part the Clovis Defendants’ motion to dismiss, granting in part and denying in part the Underwriter Defendants’ motion to dismiss, and granting the Venture Capital Defendants’ motion to dismiss. On February 22, 2017, the Arkin Plaintiffs filed an amended consolidated class action complaint, directed solely at repleading its Section 12(a) claims against the Underwriter Defendants. On March 14, 2017, the Clovis Defendants and the Arkin Plaintiffs participated in a mediation, which did not result in a settlement. On June 18, 2017, the Clovis Defendants entered into a stipulation and agreement of settlement with the Arkin Plaintiffs whereby Clovis will issue to the plaintiffs and participating class members a total consideration comprised of $25.0 million in cash and the issuance of a to be determined number of shares of Clovis common stock (the “Settlement Shares”) equal to $117.0 million divided by the volume weighted average price of Clovis common stock over the 10 trading days immediately preceding the date of the hearing set by the Medina Court to consider the final approval of the settlement. The cash portion of the consideration is expected to be funded by Clovis’ insurance carriers. At June 30, 2017, the liability for the issuance of the shares and cash, including the amount to be reimbursed through insurance proceeds, was recorded to accrued liability for legal settlement on the Consolidated Balance Sheets in the amount of approximately $142.0 million and a receivable of approximately $25.0 million from the insurance carriers on the Consolidated Balance Sheets. Clovis will issue the Settlement Shares no later than 5 business days after the date the judgment is entered by the Medina Court approving the settlement whereby the issuance of the shares will be recorded in common stock and additional paid-in capital and the accrued liability for legal settlement will be cleared. As the settlement agreement is in response to the alleged violation of securities laws by certain of our officers, we have determined that the resulting loss does not relate to activities that are in the normal course of our operations and therefore, should not be recognized in operating losses for the period. Accordingly, we have recognized the entire expense associated to the settlement agreement in legal settlement loss within the other income (expense), net of insurance receivable on the Consolidated Statements of Operations and Comprehensive Loss. On July 14, 2017, the Medina Court issued an order preliminarily approving the settlement. A final hearing to determine whether the settlement should be approved is scheduled for October 26, 2017. On January 22, 2016, the Electrical Workers Local #357 Pension and Health & Welfare Trusts, a purported shareholder of Clovis, filed a purported class action complaint (the “Electrical Workers Complaint”) against Clovis and certain of its officers, directors, investors and underwriters in the Superior Court of the State of California, County of San Mateo. The Electrical Workers Complaint purports to be asserted on behalf of a class of persons who purchased stock in the July 2015 Offering. The Electrical Workers Complaint generally alleges that the defendants violated the Securities Act because the offering documents for the July 2015 Offering contained allegedly false and misleading statements regarding the progress toward FDA approval and the potential for market success of rociletinib. The Electrical Workers Complaint seeks unspecified damages. On June 30, 2016, the Electrical Workers Plaintiffs filed an amended complaint asserting substantially similar claims (the “Electrical Workers Amended Complaint”). On September 23, 2016, following briefing and after hearing oral argument, the Electrical Workers Court granted defendants’ motion to stay proceedings pending resolution of the Medina action. Per the order to stay proceedings, the parties’ first status report as to the progress of the Medina action was filed on March 23, 2017. The parties’ second status report is due on September 21, 2017. The Company intends to vigorously defend against the allegations in the Electrical Workers Amended Complaint, but there can be no assurance that the defense will be successful. On November 10, 2016, Antipodean Domestic Partners (“Antipodean”) filed a complaint (the “Antipodean Complaint”) against Clovis and certain of its officers, directors and underwriters in New York Supreme Court, County of New York. The Antipodean Complaint alleges that the defendants violated certain sections of the Securities Act by making allegedly false statements to Antipodean and in the Offering Materials for the July 2015 Offering relating to the efficacy of rociletinib, its safety profile, and its prospects for market success. In addition to the Securities Act claims, the Antipodean Complaint also asserts Colorado state law claims and common law claims. Both the state law and common law claims are based on allegedly false and misleading statements regarding rociletinib’s progress toward FDA approval. The Antipodean Complaint seeks compensatory, recessionary, and punitive damages. On December 15, 2016, the Antipodean Plaintiffs filed an amended complaint (the “Antipodean Amended Complaint”) asserting substantially the same claims against the same defendants and purporting to correct certain details in the original Antipodean Complaint. On January 31, 2017, Defendants filed a motion to stay the Antipodean action pending resolution of the Medina action in the District of Colorado. Defendants also filed a motion to dismiss the Antipodean Amended Complaint on March 29, 2017. A hearing on both motions is scheduled for August 8, 2017. On March 14, 2017, the Clovis Defendants and Antipodean participated in a mediation, which did not result in a settlement. The Company intends to vigorously defend against the allegations in the Antipodean Amended Complaint. However, there can be no assurance that the defense will be successful. Clovis received a letter dated May 31, 2016 from an alleged owner of its common stock, which purports to set forth a demand for inspection of certain of our books and records pursuant to 8 Del. C. § 220 (the “Macalinao Demand Letter”). Clovis also received a letter dated December 15, 2016 from a second alleged owner of Clovis common stock, which purports to set forth a similar demand for inspection of the Company’s books and records pursuant to 8 Del. C. § 220 (the “McKenry Demand Letter”). Both the Macalinao and McKenry Demand Letters were purportedly made for the purposes of investigating alleged misconduct at the Company relating to rociletinib. Clovis submitted a response to the Macalinao Demand Letter on June 24, 2016, and likewise submitted a response to the McKenry Demand Letter on January 4, 2017. The Company produced certain books and records in response to the Macalinao and McKenry Demand Letters in January and February 2017, respectively. In March 2017, Macalinao and McKenry (the “Derivative Plaintiffs”) filed shareholder derivative complaints against certain directors and officers of the Company in the Court of Chancery of the State of Delaware. On May 4, 2017, the Macalinao and McKenry actions were consolidated for all purposes in a single proceeding under the caption In re Clovis Oncology, Inc. Derivative Litigation, Case No, 2017-0222 (the “Consolidated Derivative Action”). On May 18, 2017, the Derivative Plaintiffs filed the Consolidated Verified Shareholder Derivative Complaint (the “Consolidated Derivative Complaint”). The Consolidated Derivative Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by allegedly causing or allowing misrepresentations of the Company’s business operations and prospects, failing to ensure that the TIGER-X clinical trial was being conducted in accordance with applicable rules, regulations and protocols, and engaging in insider trading. The Consolidated Derivative Complaint purported to rely on documents produced by the Company in response to the Macalinao and McKenry Demand Letters. The Consolidated Derivative Complaint sought, among other things, an award of money damages. On July 13, 2017, the court ordered the following briefing schedule with respect to the defendants’ forthcoming motion to dismiss the Consolidated Derivative Complaint: Defendants’ motion to dismiss was due, and was filed, on July 31, 2017; Plaintiffs’ opposition is due on August 30, 2017; and Defendants’ reply is due on September 14, 2017. The Company intends to vigorously defend against the allegations in the Consolidated Derivative Complaint, but there can be no assurance that the defense will be successful. On May 10, 2017, John Solak, a purported shareholder of the Company, filed a shareholder derivative complaint in the Court of Chancery of the State of Delaware (the “Solak Complaint”) against certain directors and an officer of the Company. The Solak Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by adopting a compensation plan that overcompensated the non-employee director defendants, in relation to companies of comparable market capitalization and size. The Solak Complaint also alleged claims of waste of corporate assets and unjust enrichment due to this allegedly wrongful compensation plan. The Solak Complaint sought, among other things, an award of money damages and the imposition of corporate governance reforms. On June 12, 2017, the parties in the Solak action entered into a stipulation extending the defendants’ time to respond to the Solak Complaint until August 11, 2017, which was entered by the Court on June 20, 2017. The Company intends to vigorously defend against the allegations in the Solak Complaint, but there can be no assurance that the defense will be successful. On March 20, 2017, a purported shareholder of the Company, filed a shareholder derivative complaint (the “Guo Complaint”) against certain officers and directors of the Company in the United States District Court for the District of Colorado. The Guo Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by either recklessly or with gross negligence approving or permitting misrepresentations of the Company’s business operations and prospects. The Guo Complaint also alleged claims for waste of corporate assets and unjust enrichment. Finally, the Guo Complaint alleged that certain of the individual defendants violated Section 14(a) of the Securities Exchange Act, by allegedly negligently issuing, causing to be issued, and participating in the issuance of materially misleading statements to stockholders in the Company’s Proxy Statement on Schedule DEF 14A in connection with the 2015 Annual Meeting of Stockholders, held on June 11, 2015. The Guo Complaint sought, among other things, an award of money damages. On June 19, 2017, the parties filed a joint motion to stay the Guo action pending resolution of the motion to dismiss the Consolidated Derivative Complaint. On June 20, 2017, the court granted the motion to stay. The Company intends to vigorously defend against the allegations in the Guo Complaint, but there can be no assurance that the defense will be successful. In addition, the Company has received inquiries and requests for information from governmental agencies, including the U.S. Securities and Exchange Commission and the U.S. Department of Justice, relating to the Company’s regulatory update announcement in November 2015 that the FDA requested additional clinical data on the efficacy and safety of rociletinib. The Company is continuing to cooperate with these agencies with respect to their investigations. The proposed settlement of the Medina action does not resolve these inquiries and the Company cannot predict their timing or outcome.

XML 32 R20.htm IDEA: XBRL DOCUMENT

Nature of Business and Basis of Presentation (Policies)	6 Months Ended
Nature of Business and Basis of Presentation (Policies)	Jun. 30, 2017
Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation All financial information presented includes the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments, consisting only of normal recurring adjustments that, in the opinion of management, are necessary to fairly state our financial position, results of operations and cash flows for the periods presented herein. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2016 (“2016 Form 10-K”) for a broader discussion of our business and the opportunities and risks inherent in such business.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates, including estimates related to revenue deductions, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.
Revenue Recognition	Revenue Recognition Product revenue is derived from sales of our product, Rubraca, in the United States. We distribute our product in the U.S. principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers. Our customers subsequently resell our products to patients and healthcare providers. Separately, we have arrangements with certain payors and other third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and other discounts. Revenues from product sales are recognized when persuasive evidence of an arrangement exists, delivery has occurred and title of the product and associated risk of loss has passed to the customer, the price is fixed or determinable, collection from the customer has been reasonably assured and all performance obligations have been met and returns and allowances can be reasonably estimated. Revenue is recorded net of estimated rebates, chargebacks, discounts and other deductions as well as estimated product returns (collectively, “sales deductions”). We only recognize revenue on product sales once the product is resold to the patient or healthcare provider by the specialty distributor or specialty pharmacy provider, therefore reducing the significance of estimates made for product returns. To date, we have not had any product returns and, we currently do not have an accrual for product returns. We will continue to assess our estimate for product returns as we gain additional historical experience.
Cost of Sales	Cost of Sales – Product Product cost of sales consists primarily of materials, third-party manufacturing costs as well as freight and royalties owed to our licensing partners for Rubraca sales. Based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, certain of the manufacturing costs of Rubraca units recognized as revenue during the three and six months ended June 30, 2017 were expensed prior to the December 19, 2016 FDA approval, and therefore are not included in costs of sales during the current period. We expect cost of sales to increase in relation to product revenues as we deplete these inventories and we expect to use the remaining pre-commercialization inventory for product sales through the third quarter of 2017. Cost of Sales – Intangible Asset Amortization Cost of sales for intangible asset amortization consists of the amortization of capitalized milestone payments made to our licensing partners upon FDA approval of Rubraca. Milestone payments are amortized on a straight-line basis over the estimated remaining patent life of Rubraca.
Inventory	Inventory Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. We began capitalizing incurred inventory related costs upon the regulatory approval of Rubraca. Prior to the regulatory approval of Rubraca, we incurred costs for the manufacture of the drug that could potentially be available to support the commercial launch of Rubraca and all such costs were recognized as research and development expense. We periodically analyze our inventory levels, and write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and/or inventory in excess of expected sales requirements as cost of product revenues. Expired inventory would be disposed of and the related costs would be written off as cost of product revenues. The active pharmaceutical ingredient (“API”) in Rubraca is currently produced by a single supplier. As the API has undergone significant manufacturing specific to its intended purpose at the point it is purchased by us, we classify the API as work-in-process inventory. Our other significant accounting policies are described in Note 2, Summary of Significant Accounting Policies of the Notes to the Consolidated Financial Statements included in our 2016 Form 10-K. From time to time, the Financial Accounting Standards Board (“FASB”) or other standards setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification (“ASC”) are communicated through issuance of an Accounting Standards Update (“ASU”).
Recently Issued Accounting Standards	Recently Issued Accounting Standards In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” and has subsequently issued several supplemental and/or clarifying ASUs (collectively, “ASC 606”). ASC 606 prescribes a single common revenue standard that replaces most existing U.S. GAAP revenue recognition guidance. ASC 606 is intended to provide a more consistent interpretation and application of the principles outlined in the standard across filers in multiple industries and within the same industries compared to current practices, which should improve comparability. Adoption of ASC 606 is required for annual and interim periods beginning after December 15, 2017. Upon adoption, we must elect to adopt either retrospectively to each prior reporting period presented or use the modified retrospective transition method with the cumulative effect of initial adoption recognized at the date of initial application. We expect to apply the new standard using the modified retrospective method upon its adoption date on January 1, 2018. We have begun a comprehensive scoping process to identify and disaggregate all revenue streams that may be impacted by the adoption of ASC 606. To date, we have examined our revenue recognition policy specific to revenue streams from representative contracts governing product sales from Rubraca and have come to preliminary conclusions on the impact of the new standard using the 5-step process prescribed by ASC 606. However, a detailed analysis of individual contracts representative of each of the revenue streams planned for the assessment phase of our implementation plan may impact these preliminary conclusions. We are continuing to assess ASC 606’s impact on our financial statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. ASU 2016-02 requires modified retrospective adoption for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures. In January 2017, the FASB issued ASU No. 2017-01, “Clarifying the Definition of a Business,” which clarifies the definition of a business in ASC 805. The guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is permitted. Currently, there is no impact to our consolidated financial statements and related disclosures, but we will adopt on January 1, 2018 for any business combinations and will consider adopting early for any acquisitions prior to January 1, 2018. In May 2017, the FASB issued ASU 2017-09, “Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting”, which amends the scope of modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which we would be required to apply modification accounting under ASC 718. Specifically, we would not apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. The guidance is effective for annual reporting periods, including interim period within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period. We are currently evaluating the impact the standard may have on our consolidated financial statements and related disclosures should we have a modification to our share-based payment awards in the future.
Convertible Senior Notes	The debt issuance costs are presented as a deduction from convertible senior notes on the Consolidated Balance Sheets and are amortized as interest expense over the expected life of the Notes using the effective interest method. We determined the expected life of the debt was equal to the seven-year term of the Notes.
Lucitanib	Reimbursements are recorded as a reduction to research and development expense on the Consolidated Statements of Operations.
Net Loss Per Common Share	Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury-stock method for the stock options and RSUs and the if-converted method for the Notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share.

XML 33 R21.htm IDEA: XBRL DOCUMENT

Financial Instruments and Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2017

Financial Instruments and Fair Value Measurements

Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table identifies our assets and liabilities that were measured at fair value on a recurring basis (in thousands):


	Balance		Level 1		Level 2		Level 3
June 30, 2017
Assets:
Money market	$	450,588	$	450,588	$	—	$	—
U.S. treasury securities		179,744		—		179,744		—
Total assets at fair value	$	630,332	$	450,588	$	179,744	$	—
December 31, 2016
Assets:
Money market	$	202,361	$	202,361	$	—	$	—
U.S. treasury securities		49,997		—		49,997		—
Total assets at fair value	$	252,358	$	202,361	$	49,997	$	—

XML 34 R22.htm IDEA: XBRL DOCUMENT

Available-for-Sale Securities (Tables)

6 Months Ended

Jun. 30, 2017

Available-for-Sale Securities

Summary of Available-for-Sale Securities

As of June 30, 2017, available-for-sale securities consisted of the following (in thousands):


			Gross		Gross		Aggregate
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. treasury securities	$	179,758	$	—	$	(14)	$	179,744

As of December 31, 2016, available-for-sale securities consisted of the following (in thousands):


			Gross		Gross		Aggregate
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
U.S. treasury securities	$	50,004	$	—	$	(7)	$	49,997

Summary of Fair Value and Gross Unrealized Losses of Available-for-Sale Securities in a Continuous Unrealized Loss Position


	Aggregate		Gross
	Fair		Unrealized
	Value		Losses
U.S. treasury securities	$	179,744	$	(14)

Summary of Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity

As of June 30, 2017, the amortized cost and fair value of available-for-sale securities by contractual maturity were (in thousands):


	Amortized		Fair
	Cost		Value
Due in one year or less	$	179,758	$	179,744
Due in one year to two years		—		—
Total	$	179,758	$	179,744

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

XML 35 R23.htm IDEA: XBRL DOCUMENT

Other Current Assets (Tables)

6 Months Ended

Jun. 30, 2017

Other Current Assets [Abstract]

Other Current Assets

Other current assets were comprised of the following (in thousands):


	June 30,		December 31,
	2017		2016
Receivable from partners	$	52	$	2,882
Prepaid insurance		817		1,234
Prepaid expenses - other		3,012		2,109
Receivable - other		2,750		364
Other		135		90
Total	$	6,766	$	6,679

XML 36 R24.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill (Tables)

6 Months Ended

Jun. 30, 2017

Intangible Assets and Goodwill

Intangible assets related to capitalized milestones under license agreements

Intangible assets related to capitalized milestones under license agreements consisted of the following (in thousands):


	June 30,		December 31,
	2017		2016
Intangible asset - milestones	$	21,100	$	21,100
Accumulated amortization		(796)		(53)
Total intangible asset, net	$	20,304	$	21,047

Estimated future amortization expense for intangible assets

Estimated future amortization expense associated with intangibles is expected to be as follows (in thousands):


2017 (remaining)	$	743
2018		1,486
2019		1,486
2020		1,486
2021		1,486
Thereafter		13,617
	$	20,304

Summary of Goodwill

The change in goodwill established as part of the purchase accounting of EOS in November 2013 consisted of the following (in thousands):


Balance at December 31, 2016	$	57,192
Change in foreign currency gains and losses		4,826
Balance at June 30, 2017	$	62,018

XML 37 R25.htm IDEA: XBRL DOCUMENT

Other Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2017

Payables And Accruals [Abstract]

Other Accrued Expenses

Other accrued expenses were comprised of the following (in thousands):


	June 30,		December 31,
	2017		2016
Accrued personnel costs	$	11,928	$	15,850
Accrued interest payable		2,097		2,096
Income tax payable		662		556
Accrued corporate legal fees and professional services		1,072		589
Accrued royalties		2,551		—
Accrued sales deductions		1,003		—
Accrued expenses - other		2,535		396
Total	$	21,848	$	19,487

XML 38 R26.htm IDEA: XBRL DOCUMENT

Convertible Senior Notes (Tables)

6 Months Ended

Jun. 30, 2017

Convertible Senior Notes,

Schedule of Total Interest Expense Recognized Related to Notes

The following table sets forth total interest expense recognized during the three and six months ended June 30, 2017 and 2016 (in thousands):


	Three months ended June 30,				Six months ended June 30,
	2017		2016		2017		2016
Contractual interest expense	$	1,797	$	1,797	$	3,594	$	3,594
Accretion of interest on milestone liability		483		—		949		—
Amortization of debt issuance costs		318		309		635		616
Total interest expense	$	2,598	$	2,106	$	5,178	$	4,210

XML 39 R27.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2017

Stockholders’ Equity

Component of Other Comprehensive Income (Loss)

The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the three months ended June 30, 2017 and 2016 as follows (in thousands):


	Foreign Currency				Unrealized				Total Accumulated
	Translation Adjustments				(Losses) Gains				Other Comprehensive Loss
	2017		2016		2017		2016		2017		2016
Balance at April 1,	$	(46,967)	$	(43,564)	$	(151)	$	(153)	$	(47,118)	$	(43,717)
Other comprehensive income (loss)		4,451		(2,170)		(3)		76		4,448		(2,094)
Total before tax		(42,516)		(45,734)		(154)		(77)		(42,670)		(45,811)
Tax effect		(1,639)		789		3		(28)		(1,636)		761
Balance at June 30,	$	(44,155)	$	(44,945)	$	(151)	$	(105)	$	(44,306)	$	(45,050)

The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the six months ended June 30, 2017 and 2016 as follows (in thousands):


	Foreign Currency				Unrealized				Total Accumulated
	Translation Adjustments				(Losses) Gains				Other Comprehensive Loss
	2017		2016		2017		2016		2017		2016
Balance at December 31,	$	(47,434)	$	(47,077)	$	(146)	$	(383)	$	(47,580)	$	(47,460)
Other comprehensive income (loss)		5,186		3,410		(8)		441		5,178		3,851
Total before tax		(42,248)		(43,667)		(154)		58		(42,402)		(43,609)
Tax effect		(1,907)		(1,278)		3		(163)		(1,904)		(1,441)
Balance at June 30,	$	(44,155)	$	(44,945)	$	(151)	$	(105)	$	(44,306)	$	(45,050)

XML 40 R28.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2017

Share-Based Compensation

Share-Based Compensation Expense Recognized in Accompanying Statements of Operations


	Three months ended June 30,				Six months ended June 30,
	2017		2016		2017		2016
Research and development	$	4,825	$	6,615	$	8,991	$	13,924
Selling, general and administrative		5,792		2,962		10,572		6,618
Total share-based compensation expense	$	10,617	$	9,577	$	19,563	$	20,542

Summary of Stock Options Activity


				Weighted
		Weighted		Average	Aggregate
		Average		Remaining	Intrinsic
	Number of	Exercise		Contractual	Value
	Options	Price		Term (Years)	(Thousands)
Outstanding at December 31, 2016	5,520,482	$	42.00
Granted	778,700
Exercised	(372,464)
Forfeited	(199,985)
Outstanding at June 30, 2017	5,726,733	$	45.43	7.6	$	276,451
Vested and expected to vest at June 30, 2017	5,364,276	$	45.30	7.4	$	259,650
Vested and exercisable at June 30, 2017	2,935,211	$	44.63	6.2	$	143,983

Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award

The following table summarizes information about our stock options as of and for the three and six months ended June 30, 2017 and 2016 (in thousands):


	Three months ended June 30,				Six months ended June 30,
	2017		2016		2017		2016
Weighted-average grant date fair value per share	$	44.94	$	11.01	$	46.53	$	14.65
Intrinsic value of options exercised	$	4,759	$	578,525	$	14,284	$	624,925
Cash received from stock option exercises	$	5,439	$	352,423	$	11,113	$	407,523

Summary of activity related to our unvested RSUs



		Weighted
		Average
	Number of	Grant Date
	Units	Fair Value
Unvested at December 31, 2016	562,458	$	24.70
Granted	214,984		61.67
Vested	(44,443)		19.37
Forfeited	(27,177)		24.08
Unvested as of June 30, 2017	705,822	$	36.32
Expected to vest after June 30, 2017	604,394	$	35.81

XML 41 R29.htm IDEA: XBRL DOCUMENT

Net Loss Per Common Share (Tables)

6 Months Ended

Jun. 30, 2017

Loss per basic and diluted common share:

Shares Outstanding Excluded from Calculation of Diluted Net Loss Per Share


	Three and Six months ended June 30,
	2017	2016
Common shares under option	6,373	455
Convertible senior notes	4,646	4,646
Total potential dilutive shares	11,019	5,101

XML 42 R30.htm IDEA: XBRL DOCUMENT

Nature of Business - Additional Information (Details) $ / shares in Units, $ in Thousands	1 Months Ended		6 Months Ended
	Jun. 30, 2017 USD ($) $ / shares shares	Jan. 31, 2017 USD ($) $ / shares shares	Jun. 30, 2017 USD ($) segment $ / shares shares	Jun. 30, 2016 USD ($)
Nature of Business and Basis of Presentation
Number of operating segments \| segment			1
Issuance of stock (in shares) \| shares	3,920,454	5,750,000	3,920,454
Sale of stock, price per share \| $ / shares	$ 88.00	$ 41.00	$ 88.00
Proceeds from offering \| $	$ 324,900	$ 221,200	$ 546,170	$ 0

XML 43 R31.htm IDEA: XBRL DOCUMENT

Financial Instruments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets at fair value	$ 630,332	$ 252,358
Money Market
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets at fair value	450,588	202,361
U.S. Treasury Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets at fair value	179,744	49,997
Fair Value, Inputs, Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets at fair value	450,588	202,361
Fair Value, Inputs, Level 1 \| Money Market
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets at fair value	450,588	202,361
Fair Value, Inputs, Level 1 \| U.S. Treasury Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets at fair value	0	0
Fair Value, Inputs, Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets at fair value	179,744	49,997
Fair Value, Inputs, Level 2 \| Money Market
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets at fair value	0	0
Fair Value, Inputs, Level 2 \| U.S. Treasury Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets at fair value	179,744	49,997
Fair Value, Inputs, Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets at fair value	0	0
Fair Value, Inputs, Level 3 \| Money Market
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets at fair value	0	0
Fair Value, Inputs, Level 3 \| U.S. Treasury Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets at fair value	$ 0	$ 0

XML 44 R32.htm IDEA: XBRL DOCUMENT

Financial Instruments and Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Dec. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Transfers between level 1 and level 2, assets	$ 0	$ 0
Transfers between level 2 and level 1, assets	0	0
Transfers between level 1 and level 2, liabilities	0	0
Transfers between level 2 and level 1, liabilities	0	0
Transfer of assets into level 3	0	0
Transfer of assets out of level 3	0	0
Transfer of liabilities into level 3	0	0
Transfer of liabilities out of level 3	0	0
Convertible senior notes	281,761	281,761	$ 281,126
Convertible Senior Notes.
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Convertible senior notes	281,800	281,800
Convertible Senior Notes. \| Fair Value, Inputs, Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Convertible senior notes, fair value	$ 487,000	$ 487,000

XML 45 R33.htm IDEA: XBRL DOCUMENT

Available-for-Sale Securities - Summary of Available-for-Sale Securities (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 179,758
Aggregate Fair Value	179,744
U.S. Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	179,758	$ 50,004
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(14)	(7)
Aggregate Fair Value	$ 179,744	$ 49,997

XML 46 R34.htm IDEA: XBRL DOCUMENT

Available-for-Sale Securities - Summary of Fair Value and Gross Unrealized Losses of Available-for-Sale Securities in a Continuous Unrealized Loss Position (Details) - U.S. Treasury Securities $ in Thousands	6 Months Ended
	Jun. 30, 2017 USD ($)
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Fair Value	$ 179,744
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Gross Unrealized Losses	$ (14)

XML 47 R35.htm IDEA: XBRL DOCUMENT

Available-for-Sale Securities - Summary of Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Details) $ in Thousands	Jun. 30, 2017 USD ($)
Available-for-Sale Securities
Amortized Cost, Due in one year or less	$ 179,758
Amortized Cost, Due in one year to two years	0
Amortized Cost	179,758
Fair Value, Due in one year or less	179,744
Fair Value, Due in one year to two years	0
Aggregate Fair Value	$ 179,744

XML 48 R36.htm IDEA: XBRL DOCUMENT

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Inventories
Inventory, Net	$ 6,478	$ 0
Cash deposit for inventory	$ 31,800

XML 49 R37.htm IDEA: XBRL DOCUMENT

Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Other Current Assets [Abstract]
Receivable from partners	$ 52	$ 2,882
Prepaid Insurance	817	1,234
Prepaid expenses - other	3,012	2,109
Receivable - other	2,750	364
Other	135	90
Total	$ 6,766	$ 6,679

XML 50 R38.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill - Capitalized Milestones - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Intangible Assets and Goodwill
Intangible asset - milestones	$ 21,100	$ 21,100
Accumulated amortization	(796)	(53)
Total intangible asset, net	$ 20,304	$ 21,047

XML 51 R39.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Intangible Assets and Goodwill
Amortization of Intangible Assets	$ 400	$ 0	$ 800	$ 0

XML 52 R40.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill - Estimated Future Amortization (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Intangible Assets and Goodwill
2017 (remaining)	$ 743
2018	1,486
2019	1,486
2020	1,486
2021	1,486
Thereafter	13,617
Total intangible asset, net	$ 20,304	$ 21,047

XML 53 R41.htm IDEA: XBRL DOCUMENT

Intangible Assets and Goodwill - Summary of Goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2017 USD ($)
Goodwill:
Balance at beginning of period	$ 57,192
Change in foreign currency gains and losses	4,826
Balance at end of period	$ 62,018

XML 54 R42.htm IDEA: XBRL DOCUMENT

Other Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Payables And Accruals [Abstract]
Accrued personnel costs	$ 11,928	$ 15,850
Accrued interest payable	2,097	2,096
Income tax payable	662	556
Accrued corporate legal fees and professional services	1,072	589
Accrued royalties	2,551
Accrued sales deductions	1,003
Accrued expenses - other	2,535	396
Other accrued expenses	$ 21,848	$ 19,487

XML 55 R43.htm IDEA: XBRL DOCUMENT

Convertible Senior Notes - Additional Information (Details) - Convertible Senior Notes. $ / shares in Units, $ in Millions		6 Months Ended
	Sep. 09, 2014 USD ($) item $ / shares	Jun. 30, 2017 USD ($) item	Dec. 31, 2016 USD ($)
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 287.5
Convertible senior notes, interest rate	2.50%
Net proceeds from convertible senior notes	$ 278.3
Convertible senior notes, maturity date		Sep. 15, 2021
Common stock initial conversion rate per $1,000 in principal amount	16.1616
Convertible senior notes, initial conversion price per share \| $ / shares	$ 61.88
Debt instrument, redemption period start date		Sep. 15, 2018
Last reported sale price of common stock	150.00%
Debt instrument, conversion in effect for number of trading days \| item	20
Debt instrument conversion, consecutive trading day period	30 days
Debt instrument, trading days preceding redemption notice, maximum \| item		2
Debt instrument redemption price percentage to principal amount	100.00%
Debt instrument repurchase percentage		100.00%
Debt issuance costs	$ 9.2
Debt instrument term		7 years
Unamortized debt issuance costs		$ 5.7	$ 6.4
Semi Annual Payment, First payment date
Debt Instrument [Line Items]
Interest payment date on senior notes		--03-15
Semi Annual Payment, Second payment date
Debt Instrument [Line Items]
Interest payment date on senior notes		--09-15

XML 56 R44.htm IDEA: XBRL DOCUMENT

Convertible Senior Notes - Schedule of Total Interest Expense Recognized Related to Notes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Convertible Senior Notes,
Contractual interest expense	$ 1,797	$ 1,797	$ 3,594	$ 3,594
Accretion of interest on milestone liability	483		949	0
Amortization of debt issuance costs	318	309	635	616
Total interest expense	$ 2,598	$ 2,106	$ 5,178	$ 4,210

XML 57 R45.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Additional Information (Details) $ / shares in Units, $ in Thousands	1 Months Ended		6 Months Ended
	Jun. 30, 2017 USD ($) $ / shares shares	Jan. 31, 2017 USD ($) $ / shares shares	Jun. 30, 2017 USD ($) Vote $ / shares shares	Jun. 30, 2016 USD ($)
Stockholders’ Equity
Common stock, shares issued \| shares	3,920,454	5,750,000	3,920,454
Sale of stock, price per share \| $ / shares	$ 88.00	$ 41.00	$ 88.00
Proceeds from the sale of common stock, net of issuance costs \| $	$ 324,900	$ 221,200	$ 546,170	$ 0
Number Of Vote Per Common Stock \| Vote			1

XML 58 R46.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Component of Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	$ (47,118)	$ (43,717)	$ (47,580)	$ (47,460)
Other comprehensive income (loss)	4,448	(2,094)	5,178	3,851
Total before tax	(42,670)	(45,811)	(42,402)	(43,609)
Tax effect	(1,636)	761	(1,904)	(1,441)
Ending balance	(44,306)	(45,050)	(44,306)	(45,050)
Reclassifications out of accumulated other comprehensive loss	0	0	0	0
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(46,967)	(43,564)	(47,434)	(47,077)
Other comprehensive income (loss)	4,451	(2,170)	5,186	3,410
Total before tax	(42,516)	(45,734)	(42,248)	(43,667)
Tax effect	(1,639)	789	(1,907)	(1,278)
Ending balance	(44,155)	(44,945)	(44,155)	(44,945)
Unrealized (Losses) Gains
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(151)	(153)	(146)	(383)
Other comprehensive income (loss)	(3)	76	(8)	441
Total before tax	(154)	(77)	(154)	58
Tax effect	3	(28)	3	(163)
Ending balance	$ (151)	$ (105)	$ (151)	$ (105)

XML 59 R47.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 10,617	$ 9,577	$ 19,563	$ 20,542
Employee Service Share Based Compensation Tax Benefit From Compensation Expense	$ 0	0	$ 0	0
Closing Stock Price	$ 93.63		$ 93.63
Research and development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 4,825	6,615	$ 8,991	13,924
Selling, general and administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	5,792	$ 2,962	10,572	$ 6,618
Common shares under option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to non-vested options	83,400		$ 83,400
Unrecognized stock-based compensation expense related to non-vested options and RSUs, weighted-average remaining vesting period			2 years 7 months 6 days
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to unvested RSUs	$ 18,500		$ 18,500
Unrecognized stock-based compensation expense related to non-vested options and RSUs, weighted-average remaining vesting period			3 years 4 months 24 days
2011 Stock Incentive Plan \| Vesting after year one
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options vesting period			1 year
Stock options vesting percentage			50.00%
2011 Stock Incentive Plan \| Vesting after year two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options vesting period			2 years
Stock options vesting percentage			50.00%
2011 Stock Incentive Plan \| One year from date of grant
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options vesting period			1 year
Stock options vesting percentage			25.00%
2011 Stock Incentive Plan \| End of the vesting period
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options vesting period			3 years

XML 60 R48.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Summary of Stock Options Activity (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2017 USD ($) $ / shares shares
Share-Based Compensation
Beginning Balance, Number of Options Outstanding	5,520,482
Number of Options, Granted	778,700
Number of Options, Exercised	(372,464)
Number of Options, Forfeited	(199,985)
Ending Balance, Number of Options Outstanding	5,726,733
Number of Options, Vested and expected to vest at June 30, 2017	5,364,276
Number of Options, Vested and exercisable at June 30, 2017	2,935,211
Beginning Balance, Weighted Average Exercise Price \| $ / shares	$ 42.00
Ending Balance, Weighted Average Exercise Price \| $ / shares	45.43
Vested and expected to vest, Weighted Average Exercise Price \| $ / shares	45.30
Vested and exercisable, Weighted Average Exercise Price \| $ / shares	$ 44.63
Outstanding, Weighted Average Remaining Contractual Term (Years)	7 years 7 months 6 days
Vested and expected to vest, Weighted Average Remaining Contractual Term (Years)	7 years 4 months 24 days
Exercisable, Weighted Average Remaining Contractual Term (Years)	6 years 2 months 12 days
Outstanding, Aggregate Intrinsic Value \| $	$ 276,451
Vested and expected to vest, Aggregate Intrinsic Value \| $	259,650
Vested and exercisable, Aggregate Intrinsic Value \| $	$ 143,983

XML 61 R49.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Share-Based Compensation
Weighted-average grant date fair value per share	$ 44.94	$ 11.01	$ 46.53	$ 14.65
Intrinsic value of options exercised	$ 4,759	$ 578,525	$ 14,284	$ 624,925
Cash received from stock option exercises	$ 5,439	$ 352,423	$ 11,113	$ 407,523

XML 62 R50.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Summary of Activity Relating to Company's Unvested Restricted Stock Units (Detail) - Restricted Stock Units (RSUs)	6 Months Ended
	Jun. 30, 2017 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested at the beginning of the period \| shares	562,458
Number of Units, Granted \| shares	214,984
Number of Units, Vested \| shares	(44,443)
Number of Units, Forfeited \| shares	(27,177)
Unvested at the end of the period \| shares	705,822
Number of Units, Expected to vest after June 30,2017 \| shares	604,394
Weighted Average Grant Date Fair Value, Beginning Balance \| $ / shares	$ 24.70
Weighted Average Grant Date Fair Value, Granted \| $ / shares	61.67
weighted-average estimated grant date fair value of purchase awards under Purchase Plan \| $ / shares	19.37
Weighted Average Grant Date Fair Value, Forfeited \| $ / shares	24.08
Weighted Average Grant Date Fair Value, Ending Balance \| $ / shares	36.32
Weighted Average Grant Date Fair Value, Expected To Vest After June 30, 2017 \| $ / shares	$ 35.81

XML 63 R51.htm IDEA: XBRL DOCUMENT

License Agreements - Additional Information (Details) $ in Thousands, € in Millions		1 Months Ended		3 Months Ended		6 Months Ended
	Dec. 19, 2016 USD ($)	Sep. 30, 2012 EUR (€)	Jun. 30, 2011 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research and development				$ 33,108	$ 67,729	$ 65,555	$ 142,337
License Agreements Lucitanib
Research And Development Arrangement Contract To Perform For Others [Line Items]
Initial global development costs reimbursable \| €		€ 80.0
Development cost receivable				100		100		$ 1,300
Research and development				0	2,600	900	6,200
Reduction in research and development expense for reimbursable development costs due from Servier				100	$ 2,800	1,000	$ 6,400
License Agreements Licensor Pfizer \| Rucaparib
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments	$ 750
Milestone payment due prior to deferment of milestone payment						20,000
Deferred milestone payment						23,000
Maximum potential future development, regulatory milestone payments						69,750
Additional maximum payments payable on attaining the sales target				$ 170,000		170,000
License Agreements Licensor Pfizer \| Rucaparib \| Minimum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Annual sales target for sales milestone payments						500,000
License Agreements Licensor Astra Zeneca U K Ltd \| Rucaparib
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments	$ 350
License Agreement Terms \| License Agreements Licensor Pfizer \| Rucaparib
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront payment			$ 7,000
Milestones paid to Pfizer prior to FDA approval						$ 1,400

XML 64 R52.htm IDEA: XBRL DOCUMENT

Net Loss Per Common Share (Details) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	11,019	5,101
Common shares under option
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	6,373	455
Convertible senior notes
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	4,646	4,646

XML 65 R53.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Details) $ in Thousands		2 Months Ended	6 Months Ended
	Jun. 18, 2017 USD ($)	Dec. 31, 2015 shareholder	Jun. 30, 2017 USD ($)	Dec. 31, 2016 USD ($)
Commitments and Contingencies.
Milestone liability			$ 21,011	$ 20,062
Purchase commitment			$ 183,600
Cash paid	$ 25,000
Amount of common stock issued	$ 117,000
Number of trading days	10 days
Number of business days			5 days
Number of purported shareholders \| shareholder		3

EXCEL 66 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 68 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 70 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 104 267 1 false 28 0 false 9 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.clovisoncology.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.clovisoncology.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 2 false false R3.htm 00200 - Statement - Consolidated Balance Sheets Sheet http://www.clovisoncology.com/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 3 false false R4.htm 00205 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.clovisoncology.com/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 4 false false R5.htm 00300 - Statement - Consolidated Statements of Cash Flows Sheet http://www.clovisoncology.com/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 5 false false R6.htm 10101 - Disclosure - Nature of Business and Basis of Presentation Sheet http://www.clovisoncology.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation Nature of Business and Basis of Presentation Notes 6 false false R7.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.clovisoncology.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 10301 - Disclosure - Financial Instruments and Fair Value Measurements Sheet http://www.clovisoncology.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements Financial Instruments and Fair Value Measurements Notes 8 false false R9.htm 10401 - Disclosure - Available-for-Sale Securities Sheet http://www.clovisoncology.com/role/DisclosureAvailableForSaleSecurities Available-for-Sale Securities Notes 9 false false R10.htm 10501 - Disclosure - Inventories Sheet http://www.clovisoncology.com/role/DisclosureInventories Inventories Notes 10 false false R11.htm 10601 - Disclosure - Other Current Assets Sheet http://www.clovisoncology.com/role/DisclosureOtherCurrentAssets Other Current Assets Notes 11 false false R12.htm 10701 - Disclosure - Intangible Assets and Goodwill Sheet http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwill Intangible Assets and Goodwill Notes 12 false false R13.htm 10801 - Disclosure - Other Accrued Expenses Sheet http://www.clovisoncology.com/role/DisclosureOtherAccruedExpenses Other Accrued Expenses Notes 13 false false R14.htm 10901 - Disclosure - Convertible Senior Notes Notes http://www.clovisoncology.com/role/DisclosureConvertibleSeniorNotes Convertible Senior Notes Notes 14 false false R15.htm 11001 - Disclosure - Stockholders' Equity Sheet http://www.clovisoncology.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 11101 - Disclosure - Share-Based Compensation Sheet http://www.clovisoncology.com/role/DisclosureShareBasedCompensation Share-Based Compensation Notes 16 false false R17.htm 11201 - Disclosure - License Agreements Sheet http://www.clovisoncology.com/role/DisclosureLicenseAgreements License Agreements Notes 17 false false R18.htm 11301 - Disclosure - Net Loss Per Common Share Sheet http://www.clovisoncology.com/role/DisclosureNetLossPerCommonShare Net Loss Per Common Share Notes 18 false false R19.htm 11401 - Disclosure - Commitments and Contingencies Sheet http://www.clovisoncology.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 19 false false R20.htm 20202 - Disclosure - Nature of Business and Basis of Presentation (Policies) Sheet http://www.clovisoncology.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPolicies Nature of Business and Basis of Presentation (Policies) Policies http://www.clovisoncology.com/role/DisclosureSummaryOfSignificantAccountingPolicies 20 false false R21.htm 30303 - Disclosure - Financial Instruments and Fair Value Measurements (Tables) Sheet http://www.clovisoncology.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables Financial Instruments and Fair Value Measurements (Tables) Tables http://www.clovisoncology.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements 21 false false R22.htm 30403 - Disclosure - Available-for-Sale Securities (Tables) Sheet http://www.clovisoncology.com/role/DisclosureAvailableForSaleSecuritiesTables Available-for-Sale Securities (Tables) Tables http://www.clovisoncology.com/role/DisclosureAvailableForSaleSecurities 22 false false R23.htm 30603 - Disclosure - Other Current Assets (Tables) Sheet http://www.clovisoncology.com/role/DisclosureOtherCurrentAssetsTables Other Current Assets (Tables) Tables http://www.clovisoncology.com/role/DisclosureOtherCurrentAssets 23 false false R24.htm 30703 - Disclosure - Intangible Assets and Goodwill (Tables) Sheet http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwillTables Intangible Assets and Goodwill (Tables) Tables http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwill 24 false false R25.htm 30803 - Disclosure - Other Accrued Expenses (Tables) Sheet http://www.clovisoncology.com/role/DisclosureOtherAccruedExpensesTables Other Accrued Expenses (Tables) Tables http://www.clovisoncology.com/role/DisclosureOtherAccruedExpenses 25 false false R26.htm 30903 - Disclosure - Convertible Senior Notes (Tables) Notes http://www.clovisoncology.com/role/DisclosureConvertibleSeniorNotesTables Convertible Senior Notes (Tables) Tables http://www.clovisoncology.com/role/DisclosureConvertibleSeniorNotes 26 false false R27.htm 31003 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.clovisoncology.com/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.clovisoncology.com/role/DisclosureStockholdersEquity 27 false false R28.htm 31103 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.clovisoncology.com/role/DisclosureShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.clovisoncology.com/role/DisclosureShareBasedCompensation 28 false false R29.htm 31303 - Disclosure - Net Loss Per Common Share (Tables) Sheet http://www.clovisoncology.com/role/DisclosureNetLossPerCommonShareTables Net Loss Per Common Share (Tables) Tables http://www.clovisoncology.com/role/DisclosureNetLossPerCommonShare 29 false false R30.htm 40101 - Disclosure - Nature of Business - Additional Information (Details) Sheet http://www.clovisoncology.com/role/DisclosureNatureOfBusinessAdditionalInformationDetails Nature of Business - Additional Information (Details) Details 30 false false R31.htm 40301 - Disclosure - Financial Instruments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://www.clovisoncology.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Financial Instruments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 31 false false R32.htm 40302 - Disclosure - Financial Instruments and Fair Value Measurements - Additional Information (Details) Sheet http://www.clovisoncology.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAdditionalInformationDetails Financial Instruments and Fair Value Measurements - Additional Information (Details) Details 32 false false R33.htm 40401 - Disclosure - Available-for-Sale Securities - Summary of Available-for-Sale Securities (Details) Sheet http://www.clovisoncology.com/role/DisclosureAvailableForSaleSecuritiesSummaryOfAvailableForSaleSecuritiesDetails Available-for-Sale Securities - Summary of Available-for-Sale Securities (Details) Details 33 false false R34.htm 40402 - Disclosure - Available-for-Sale Securities - Summary of Fair Value and Gross Unrealized Losses of Available-for-Sale Securities in a Continuous Unrealized Loss Position (Details) Sheet http://www.clovisoncology.com/role/DisclosureAvailableForSaleSecuritiesSummaryOfFairValueAndGrossUnrealizedLossesOfAvailableForSaleSecuritiesInContinuousUnrealizedLossPositionDetails Available-for-Sale Securities - Summary of Fair Value and Gross Unrealized Losses of Available-for-Sale Securities in a Continuous Unrealized Loss Position (Details) Details 34 false false R35.htm 40403 - Disclosure - Available-for-Sale Securities - Summary of Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Details) Sheet http://www.clovisoncology.com/role/DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndFairValueOfAvailableForSaleSecuritiesByContractualMaturityDetails Available-for-Sale Securities - Summary of Amortized Cost and Fair Value of Available-for-Sale Securities by Contractual Maturity (Details) Details 35 false false R36.htm 40501 - Disclosure - Inventories (Details) Sheet http://www.clovisoncology.com/role/DisclosureInventoriesDetails Inventories (Details) Details http://www.clovisoncology.com/role/DisclosureInventories 36 false false R37.htm 40601 - Disclosure - Other Current Assets (Details) Sheet http://www.clovisoncology.com/role/DisclosureOtherCurrentAssetsDetails Other Current Assets (Details) Details http://www.clovisoncology.com/role/DisclosureOtherCurrentAssetsTables 37 false false R38.htm 40701 - Disclosure - Intangible Assets and Goodwill - Capitalized Milestones Sheet http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwillCapitalizedMilestones Intangible Assets and Goodwill - Capitalized Milestones Uncategorized 38 false false R39.htm 40702 - Disclosure - Intangible Assets and Goodwill - Additional Information (Details) Sheet http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails Intangible Assets and Goodwill - Additional Information (Details) Uncategorized 39 false false R40.htm 40703 - Disclosure - Intangible Assets and Goodwill - Estimated Future Amortization (Details) Sheet http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwillEstimatedFutureAmortizationDetails Intangible Assets and Goodwill - Estimated Future Amortization (Details) Uncategorized 40 false false R41.htm 40704 - Disclosure - Intangible Assets and Goodwill - Summary of Goodwill (Details) Sheet http://www.clovisoncology.com/role/DisclosureIntangibleAssetsAndGoodwillSummaryOfGoodwillDetails Intangible Assets and Goodwill - Summary of Goodwill (Details) Uncategorized 41 false false R42.htm 40801 - Disclosure - Other Accrued Expenses (Details) Sheet http://www.clovisoncology.com/role/DisclosureOtherAccruedExpensesDetails Other Accrued Expenses (Details) Uncategorized 42 false false R43.htm 40901 - Disclosure - Convertible Senior Notes - Additional Information (Details) Notes http://www.clovisoncology.com/role/DisclosureConvertibleSeniorNotesAdditionalInformationDetails Convertible Senior Notes - Additional Information (Details) Uncategorized 43 false false R44.htm 40902 - Disclosure - Convertible Senior Notes - Schedule of Total Interest Expense Recognized Related to Notes (Details) Notes http://www.clovisoncology.com/role/DisclosureConvertibleSeniorNotesScheduleOfTotalInterestExpenseRecognizedRelatedToNotesDetails Convertible Senior Notes - Schedule of Total Interest Expense Recognized Related to Notes (Details) Uncategorized 44 false false R45.htm 41001 - Disclosure - Stockholders' Equity - Additional Information (Details) Sheet http://www.clovisoncology.com/role/DisclosureStockholdersEquityAdditionalInformationDetails Stockholders' Equity - Additional Information (Details) Uncategorized 45 false false R46.htm 41002 - Disclosure - Stockholders' Equity - Component of Other Comprehensive Income (Loss) (Details) Sheet http://www.clovisoncology.com/role/DisclosureStockholdersEquityComponentOfOtherComprehensiveIncomeLossDetails Stockholders' Equity - Component of Other Comprehensive Income (Loss) (Details) Uncategorized 46 false false R47.htm 41101 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Details) Sheet http://www.clovisoncology.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseRecognizedInAccompanyingStatementsOfOperationsDetails Share-Based Compensation - Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Details) Uncategorized 47 false false R48.htm 41102 - Disclosure - Share-Based Compensation - Summary of Stock Options Activity (Details) Sheet http://www.clovisoncology.com/role/DisclosureShareBasedCompensationSummaryOfStockOptionsActivityDetails Share-Based Compensation - Summary of Stock Options Activity (Details) Uncategorized 48 false false R49.htm 41103 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details) Sheet http://www.clovisoncology.com/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails Share-Based Compensation - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details) Uncategorized 49 false false R50.htm 41104 - Disclosure - Share-Based Compensation - Summary of Activity Relating to Company's Unvested Restricted Stock Units (Detail) Sheet http://www.clovisoncology.com/role/DisclosureShareBasedCompensationSummaryOfActivityRelatingToCompanySUnvestedRestrictedStockUnitsDetail Share-Based Compensation - Summary of Activity Relating to Company's Unvested Restricted Stock Units (Detail) Uncategorized 50 false false R51.htm 41201 - Disclosure - License Agreements - Additional Information (Details) Sheet http://www.clovisoncology.com/role/DisclosureLicenseAgreementsAdditionalInformationDetails License Agreements - Additional Information (Details) Uncategorized 51 false false R52.htm 41301 - Disclosure - Net Loss Per Common Share (Details) Sheet http://www.clovisoncology.com/role/DisclosureNetLossPerCommonShareDetails Net Loss Per Common Share (Details) Uncategorized 52 false false R53.htm 41401 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.clovisoncology.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Uncategorized 53 false false All Reports Book All Reports clvs-20170630.xml clvs-20170630.xsd clvs-20170630_cal.xml clvs-20170630_def.xml clvs-20170630_lab.xml clvs-20170630_pre.xml true true ZIP 72 0001558370-17-005797-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-17-005797-xbrl.zip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
J0$ 8VQV&UL4$L%!@ & 8 *B@$ +_C 0 $! end